var title_f0_52_832="Ultrasound image of normal bowel";
var content_f0_52_832=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal bowel",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 403px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this longitudinal image, the echotexture of the fetal bowel is homogenous, and is considerably less echodense than fetal bone at low gain settings.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Chasen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_52_832=[""].join("\n");
var outline_f0_52_832=null;
var title_f0_52_833="TEE coronary sinus";
var content_f0_52_833=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Coronary sinus and mitral valve on transesophageal echocardiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 234px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADqAg4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKK6Xxt4I1/wTNYxeJLH7I97B9ohG9XyuehwTgjuD61zVABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFenfEf4P6n4F0q6vrzVtNultbmO0njiEqMHdN67S6BXG3k7Scd+hwAeY0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFbnge80nTvF2kXviKK5m0q2uEmuIrdVZ5FU7goDFRgkAHkcE1h0UAetfEr4n6V498Gi0u9JuLHW7bU5by1kjlM0RjmyZVJZty5bBAAI4HSvJaKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK9j+Jfxr/wCEz0fXbGHQ57T+2JbeSY3OpG6jg8kDb5EflqIy2PmPOcmvHKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoqdbaUxCQxuEJwHKHafxpghk2k7GxQBHRT/Kk/uN+VMoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorc8LaIdX1KJLmVbWxVgZ7hx8qJ3PucdB3NADYfDl+2jw6rPDJDp0zmOO4ZflZh2zn2P5VmXluba4aJiSVwckYzkA/wBa+tdEn+H0nh+38HRxw3UUUbMkzxsXLE/fyACDlu2PTpXk/wC0/YaSnjmDUtBmtZbe6tY0nW3DYWRBtBPGzBQIBtP8LZAPJAPG6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiitzwh4W1Xxbqb2OiwJJJFE1xNJLIscUES/ed3YgKoyOTQBh0V3S/DDXmnvP3+j/2faRRzTamNRhNoFkYqn70NgkspGBzx0rlNb0ufRtUnsLt7d5oSMvbzLNGwIDBldSQwIIOQaAKFFFFABRRRQAV0Hgfw1ceK/ENtpltJBD5odmmuGKxxhVLEsQCR6dOpFZkWmzyaZLfh7YW8cgjYNcxrJk46RFt7DnqFI/Ku80Px7/wjugjTPDs0tnm6Fw88gWQuNmMEYPfHbtQB7f4n+H2k/wDCsNN0TTriaFopI2aSe+lEO8nLSFOVGcsMherD3p/izwp8OrS8TQtUbRdJtHii+w3NpdKtzn5i7yO+cjIUDOevWvB9d+KOsatM5ad41lEJkZV+Zmj5U/e6Ak//AK64/VdWm1RI2vpHmuI/lVzxhfQ+tAH0F8S/C/gnSfhXrUmjNpV7NZzww2d7BdJJOzMF3q5QgNgMe34cV81UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRUkMZkkC9u/wBKAH28PmHJ4XOKv210bYr5eG4UYLsM+xxioxEI4yqMwz05GSaqjBBTgk4IBfPP4UAa91qgubz7RtVbhSWd1yM4xjGPTnnkmpjrd7caRLprXDtp0kglMG47NwGAce1ZGzYoB+VzwGxkk/X06U50LEEtkg8HYeDQBVuIvKkKhgy8EMOh4zUNb9rdJb6ZdWrWdrNJPsC3DIfMgw2TswcDOcHIPHpWG6gAYDA9wR09KAGUUU+KN5ZUjiRnkchVVRksT0AHrQAyvTfE3gjStM8U/DjT7drkweINK029vCzgsJJ3KvsOOBgcA5/GuG12O3tZYrC3EbPagrPMpz5kp+9g/wB1fujHB27v4q6GX4o+LptJ0/TZdSge109LeO1zYW5eJYGVogJPL34BRe/POc5OZhLnjzIHodT4a+Hmjaj8fdU8HT/bH0m2mu0jCShZWESsVG7aRnKjtW3c/C3wxc6lNo+nvf23iK60BtTtdNku47hre6Qkm3dlUBiyDIGARgk9QK4G7+LPjO61i31WbVIP7RtxKEnTT7ZG/eLtfdtjG7I9c47YrlfD2taj4d1q01bRblrXULV98MygMVOMdCCCMEjBGOaoDoviZ4bsPCd3o+kwGc6sunw3GqCRuI55Rv8ALAxxtQpn3NcZV/XdWvte1i71XVrhrm/u5DLNKwALMfYYAHsAAO1UKACiiigAooooAKKKKACiiigAooooAK7j4X+LdO8ONrthr9tdz6Nrdi1lctZlRPFyGV03fKcEdDjOfbB4eigD13wX438MeDb+/Hh7VPFtnY3CRLIJLO0uVusFiwkhdto6gKQxI+brmuK+IOpWviTxTq2v6LpCaXpNxcAR28QG2I7R1A4BbazY6Z3YziuXq3p19JYzM6KkkbrslhkGUlTurD04ByOQQCCCAamXNb3QKlFaWo2Mawre6ezSWDtt+Y5eB+ux8d+DhujAHoQyrm0Rkpq6AKK7DwN4Gu/FEd7cyTNYadaLukupIWZCePlBHGcHOM1zGoRCC+niVGQI5UK2c8fWqArU52LsWY5JptFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFbPhbw9e+I9Vgs7OGdldwryRxFwn/1/bIzQBL4T8Lap4ovGh0q3Mqx7TK+4AICevJ/lW54w8NJ4deyjFncW88gcSGSVXV2UgfKAMgfUnOfavpz4WeDNK0fStumyRyLKixSSCEJIJEB3ZzyDkng9K1vEXww0rV9HnQQxi72OUuHh37WOeQOxz1NAHxYyFJMSqwI6joelR7Rxy3Hua9j8X/CTU9J0mO/b7XeXTMEaBIWYjI9VyMf/AKq8x1HR7vT5mhvITbzKBmN0ZWx64NAGWseSSgwRycAc01YxtIcggnrtFWRA5zxz/ut/hV/SdHu9TvY7ewt7i4kbjbFAXJ/D6UAWrDwpeT+GrzXJkkttLtduZvKyGLHAA5A6kAnPGe9Y+mSaQIL9tct79pZrZvsTW7RqqzZwC+4cp9MHj8vqjRfhpHbfDK5smnktbq7WORpHtlVkIIbY6sSCB09utfKfifSpdG1+902VdzwSMGCqB34wR26c0AY7oyNhhg+ma2dLH9mac+qtxcyFoLIdw2Pnl/4CCAD/AHmyPuGvQPhX8Mn+IFsym7Fj5cxUzm18wMdmcZyO+OM1wXja3urHxFc6feWktkbE/Zo7eTqiLnHPQ5yWJHBLE96xqe/L2fTr6dvn+VxrTUwaKKK2EFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAW9OvpLGZnRUkjddksMgykqd1YenAORyCAQQQDXrejfBK51HwbL4rmvXs9NMQu4bSSIvOYAMsSRgdB8pA+YYJ25xXPfCP4b3PjfVUa7S4g0dTtkuI8Alj0AyD3xnjpXo3iXxrr/wx8TzeH9Nze+HrUC3W3vlMqSDYu4B+COSeBwM9K8vM6eM5YzwLXMmrp/aS6eTff8AEuDjtI9J8EHRtS8L6hZ+HbIWMNmWt5bSPBdpCBgkZIPUc98V8h+Lbaa08QXcNwsSurkBYl2qACRgDHbBFe5fCJ72z8b3umWMf2WzMizrGrCUDeMAM/8AFwQM4HTtXCftA6ZFpPxAvLVn3OsalNicAEk4JznoetemndXIPMKKKKYBRRRQAU+WN4ZCkqMjjqrDBH4UyvpLx9o+gaz+0A3iu+8UeGJvCzXEE8gh1WGSVlhtlJXyw2fmaLZx/eHrQB84zRSQuUmjeNx1Vhg/lUde1fH/AFTRvGlloHinR9Xtb/U2WSxv4gggm+Ri8chhyWC7WKlunyjnsPGChyR0IGSG4oAZRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFdz4W1qTQtKguLG8KRm5BliBTejqPvgYJxjHPqDXD4/Sp7QOk4wp98igD7q+HviS11vTrS4sbctJOAZ5MAAMByT2JPtXodsNqqrdHXIBOf0/Gvmr4HeItRg02O3is4/L3o88mU3Bc4B2Y4BHfn8a+h7K/M8AnRvNGdn0/lQBfe3AZWhADA9+c1xvijwLpHiK++069p8dy6oqRyFmVgAScZUj1PvXavKVjVtoyexYD9aqvfAzyRQj54sFgx9elAHmSfBTwm90sy2AEAJzEZ5BuJ7Z3Z4Fdrovgrw/pQkOn6fBDvdWJiJH3elayTzEyIVUgkjb3FYszamIrmV51htA4CpgAj1JagDR128gSzCAI6bwjsWGEUnBJz1FfG3xu07S7PXoL7S54Jpbu4uEmjSZHKKrKEJCnjIyefT61774QlnXXruwvTdzMzC6lvI2UwOTkBOpIGByAB7+/G+BotHsvi3441/U7yybRLS1ZJJDGqwRmSQfIBzuwIyM/xEnArizHGfUsNPEcvNbp3bdkvvZUI8zsdB+zrYpofhuWa9lb9+RMAZ/kUFflG3s5GGPsVryf4tnRfHXi9bk65pWk6llbPZLKzwhVLfM8ipweevPYe9ejeE/G/hfULnxDeWcEtjo/mM7RSyIQ5KjMoTqufQZ/oPlvWGP2uQK7NDI3mJkAHHQcdvpWuEcpUlOcWpS1ae6fb5bClvYg1G2FnqF1arcQ3KwStGJ4G3RybSRuUnGVOMg+lW/DGiXfiTxDp2jaaEN5fTrBHvOFBJ6k+g6n6VBpVjeavqVtp9jG891cyLHHGDyzE4HWujtYPEPwx8ZaVql9pc9tdWVwJoRcxFY5tuCyhujDDYJU8ZroETePPAM3hXTrLUoNUtNV026uJ7Tz7dXTZNC210IYA+4I6iuLRGkdURSzMcADqTXvWseG/GvxR8FaO/g3wV9k8N/arq+jZtVgkeaaSQhz85QqqlWUDb07nrXNxfAD4oxSJJH4a2uhDKft9rwR/20oAz/G3wov/AAto2o3r6pYXs+lTQW+qWsAfdaPMgZPmIAccgEg8H8a4LSrF9S1G3s4praB5m2CS5mWGJfdnYgKPcmvePiTc+PNbsNd0tfhnrdjqGrXUE2rXUEUt1FO8ChV8ram1VJG7IZ89jXmOl/D3xZDqEEmpeBPFN1Zq2ZYYrGaF3HoHMbbfrg0AaifCTVj8Ub7wQ99ZC9soPtE06B3Up5SykIoXc7YcDaBknPbmrNz8H7qy1PWE1HXtOttI0q0tru51BkkOxbg4iRotu9XJ6qQMDn0rZ8S/FA2Xxc1TxHf+DL3TNTvLFrK+srq8ZJ4t8SIskLmJWhfYq4ODwxx1qrqXxnj1e81iLWPDoutE1OwtLGe2F8VuJPszl4pXuNh3vliGJXkY6YoA878b+Gb7wd4q1HQNVMZvLJwjtGSVYFQysM84KsDz61hV0XxB8VXXjbxlqfiG+ijhnvXDeVGchFVQirnvhVAz3rnaACiiigAooqaO2nkiaWOGR41zudVJAxzyaAIaKk8mXYj+W+xzhW2nDH0FK9vMm/fDIojID5Ujbnpn0oAiooooAK7n4Y+B5fFOt2IvRLb6VJMYjP5bEOwXdsXA64H4Zpfhh4CvfGF+7riKygUu0jDIZhj5RwQTznB9K+gbTQtJ0KeHSLq2TdKsdw+xpFinb7u5QMBWBxwABQB6P4eNt4UvtM8O/wBnRx2lzCfKMNu5iYDsW6bvXv3rmfiZ8HbPWriTUdAS0guLiIxzQ3COVY/3o9p+VgO2MV6hbW23TrOOdolWIKO/IA4GTzVYX0Nq0sNxPGzROZArNtK5PuenvQBwPwt8CL4OIt544J8OZY5ntwsuCMbRn8e9eT/tVeF5U1v+1AI4ovLUIqIcyMWO4k9vpzX1PHq+m30STLLbOQ+VKSKc/iDUHjDSdA8T+H57XXVtzbOFLF3CMhBBGGyCPTg0Afms8ToMspAqOvsLWPBnw2s7Ey23hlNXW3neO4ez1J1ERGMqxD7c4I+XOR+Ncr47+EfhbW7Wa68DXA0+ZBuW0nkln3gLzgBWYc98kcdB2SkpXs9gPmeitLU9E1DSiV1S0nspNoZY7iJo2cE4yAR0/wAKoBlCEeWCx/iJPH0pgMpy4yMkDnv0oGCQOnPWlZlIGECkdSCeaAG8AngHtSUU4jAByDnt6UANooooA3PBHh+XxX4u0nQoJlge/uFg81hkICeWx3wMnHeun+I3gXTvD+g6freg6jdXmn3F5c6fIt3CsciSwtjI2kgqw5HcVxmgaveaBrdjq2mSeVe2UyzwuRkBlORkdx6iva7/AMPeIfif4Q0O+udb8BeHNLke5u7fT3u5LV2d5nSSVlYOSS0bYw2AOAByKAPCIYmmmjijGXdgqj3NesfEH4U2PhvQ9en07WLi8v8Aw7c21tqSSwCOJzOgYNEQxJAJxhh7/WVfgXfqwZfHfgAMDkEaw2R/5Dq/8QL7xlr1rqOj3l34EIuLiOS+vrHW7OJ9QeJdiO/mTggYAOAic9RQB41pVvb3eo28F5exWFvI217mVHdYh6lUBY/gDXqa/CK3X416j4Ek1iRorK3+0CdYVWS4PkJL5agttUncQCzY4z7Vy2l+DdUsdQguZf8AhEr1I23G3ufEdj5cns225VsfQium8XfEnxNp/wARtQ1bVtF8PQ6te6eLTUIYN09vfW00UZXcyzMCDH5eDGw4/GgC9q/wg0nQ9S8TT6vrGox6LoVnZXNwqWi/alkum2pEQW2ErySwJHYd8ee/EvwnJ4H8c6t4dmuRdGydQswXbvVkV1JHODtYZGetdHJ8Ydenvrp7yw0e6024soNPbSpoHNqIYGLxKAHD5VixBLE8nOa4zxb4h1DxX4jvtb1mRZL+8ffIVXaowAAAOwAAA9hQBkUUUUAFFFFABRRRQAUUUUAFFFKAT0oASintGQ+0YY/7PNSQ20swzGF2jqSwAH1JPFAEPQ9jV7TrWOdxufHzYAK8fiR0/I1HYWT3k/lK8ceeN8jYUfzrbs/Dt/Hqlvby27SvIC+YsFse2cA8DNAHrvwh05LSPVbS6nk0+62xtDcyxuiSI2cMpbHXBxxzmvaPCcWswX9zDdWzXGnx58q4aMgtz12knI9xj6CvnG3s/E0WlmO9ntLSwTY5aSLYCVPA3hchu3B54Fd34F+J9xZWxWKS9leOF2mi8uSYLtOd+7suPoKTaSuwPczJLPeMt2zxoG3oijG5QPT61zl9rOm6d4ktVdLxPtEi7ZpVYLz1A4+vSpNF+IEGo2CajfQWaSIpyDcqpK4656AE9vatS31fQfFUMSTzWsoyrwbtzhG68PjAI9jxTAn1fXdP0oW8EBZpLkMyKgJPHLHjt3qWDUV1I4wUti26MSwMshwOu1h908/hWZeeFvDNvBKZHQomZXBuZWG4knf971rJgkt7V7ma7uZrtUjG2KHzFAUd+D949PftQBy3xY8Jxtd/2zpswWby8Th41aJsHKqQwxkngV86eOJdQS4FveWjWW/EzxpCIYpDztJUAAkbmGfc19UeNo47nQ7Ce7kgsLKSONxHqEmBE24Mpdc8kEjOeuK82+JngWbVrCTxB9rtrqys7aWVp1uS32lQM8LjbHjHABOfak1fcD58s72azkZovLJOfvKCAcYyKrMWJ+ckn3q/amFrkNOLmRTj5YWAPTgZK46+1P1nSr/TzG+ohVaRQQvnI7KCMgEAkjjscY74pgZ6HAGz7/05+gpMvIcfMxH400dRxmnxSvDIkkbbXQhlYdQQcg0Ad7pkd34p8IWOl6TNMniHRRKkdkrlWvLZnaX92P4pEdpCV6lWGM7SK4uS+1CKRo5Lq7R1JVlaRgQR1BGaS71C7vdRa+uLh2vHYOZix3bh0OfwFdGfHmp3SKmv2el68VwBLqNsHmIHGDOhWVhx3c0Ack7tI7O7FmY5JJySa3vCnhe61+WSZnWy0e1w17qUwIht19z/ABOeioOWP5i4vi2xhO6z8GeGbeUchyt1P/47NO6/pWb4g8T6v4gESapeF7aHPk2sSLDBDn+5EgCL+AFADvGmrwa54lu72zheCyxHBaxOcskEUaxRA+4RFz71h0UUAFFFFABRRRQAV7/8I/Huk+Cvg/DPd6ldreweKTc/2dp9yiTXMf2VRiVSc+QWGCcHkDvXgFFAH0ho3xG8MWPw+8KjVbW0mu11DUNUtrS2dD9hu1nBtxIuQViIlc89dgx7XvGN3pHil/i5p2neI/D8cupX+nS2ktzqUMUU6xoC5Ry2GxjHGea+YaKALjKunajNFNHa3ohdoziRmicg43KyMMjjgg4NX47qFJITNoNkqOQRk3HzA46fvKx4QrSqHJCk4JHJFdJa2GpR39rcTW815bBRvSUMd0S9V5xgY6YxjIxUSpqTu7/ewufQ/wADzph0oX+hQW9nKS8d3bGSYFtpGHUM7DgY/OvTLa8W41BjJYI9wx/e+USwYDoQDjmvCPhfbwW0V1qFhLOmnTZjWCaMjZJkcBgfYjr6V79oViLfSvPF3ypMiTMgCsD0yxPpxU+yj5/e/wDMdyfxzrNvZ+GrmUNHJOIy0cRkAZlBB4XPJA9K840DxQ/iG8uLmyWOTT3QIu9CsrE/ewSeQp4wAe3TFYHiHUdW1HxJctp0mpQXjbEEEkcL2ptwTvZOcMwGScAHGKqeG9a1LQL2ZLJ5Es4gzhjaRQxRtn7xQ5DDrllxR7KPn97/AMwudPeahFbatqWlWln5MthFHIot9SKm4OMnkEYHOOfTntXNfEPxnqlj4Llkuru0hmmSMxWTahNJM4ZlJ3bWUHAzz04681yXxF+J002qzxwWVg6thkKtDNETtHJQqcHIPp15Gea8l1vW9R125E+q3k1y6LtjDsSsa5+6o6KvsOKPZR8/vf8AmFz2T4a/G+w8H+Eb+zm0NrjUrm9e4CxSssJDIi5dnZ2zlTwBjFT+E/i+p8QS6xqMGm6dDsK+TZLLGvzYGGAB3MOT6c+teO+GtXvtN+3Q2Vxcxx3du8MqwNjcCMc+1Y5DRSYIKsp5HSuLD5ThcPXniqcfflu7t/qU6kmuV7H2J4w0PQPilodre208VzfxIqQySM6q4POzg8HPJwM8V8w6n4H1+y1SewGk3rTR7iCkLkSqGxlOMlc9DXR/CTx9L4O1OBp2D6cxz5LDOHzjPqBXs/xN+L93p2maZcadqrwvOjSeXbWUbmQcHDs5yq89cHPtXpEHytfWVzY3b297bTW0yNhopVKMp9DnpVdsZOBx9c1734R1TT/ibfT2Pjk3F9qF7KDBd2sEEMpVUzsyVGFXHUHJz+FcL4t+E/izwxZS3upWEEFieFeW9gLdeABvyTgdhQB55RTg2M4AwfUZpCKAA0lKPerMUG4LkYIzkFTQBVrttGFr4r8M2mgzXMFnrenPIdNkuHCRXUbnc1uznhGD7mQkgEuwOODUPhnwbq+tr52naddS2iPtkuVjJjQ4zjPTODnGaj1/wbqGmRS3It5XslbaLpVzET9QSMdsg4oAwdY0nUNFvpLLV7K4srtPvRTxlG+uD1Hv0NUa6ew8YeJdJsY7GLU5ZNPQ/Ja3KrcwL9I5Ayj8qlX4ga9Gd1qdJs5ByJLPRrO3cfR44lYfnQA7w94PkktYtY8TPJpPhwHcbiRcS3WP4LdDzIx6ZHyr1J4wcjxXrLeIPEN7qbQpbpMwEUCHKwxKoWOMHuFRVX8Kqatql/rF695q17c3t2/3priVpHP4k5qnQAUUUUAFFFFABRRRQAUUUUAFFFFABWz4ensoHm+32xuFddpAbawHcr71U01LWUyR3ZdSwGxkGSD9MgH6fypt7YXOnyKLy2mjVwTGzptDj1GeCKAPQH8O6Pbb7zw3d6hM4YCAAI0yk9nQH7nbeu4c8gdD3uhaTDObCXxVpklxcoPMjhdkDMM/Mp2rlh7AHHU4rx7whbaU7ma9univUIMMPlqySH3JYbf1/wAfXB8bLmHT/s+raTZJe2rpFFcrABLEmB96PdycZzgge3agDM8bPo8VhPaJ4eu7G1luCGeG9QpuB4ZAByecdDgDtWn8FbXUtPmmeW4tZtNtbhk2SE5B28NggN+PseK4nxt4sl1mwZLO9tbmCaVp5FQGB0yOhDN8wxxwOwq3Zaxf65HaR6aIoPswEnmTSltq4ALEnr1wBgHsATilKSirsD6I0DxRpupz3Au9Em8rcEkkeFSsXucE5U56n07V2Q0XQtS0GTTVtIl0u4XBht18rdgjsMHrXg+meLZruyZNAS3jyii6a+TY8gXgHIbAPUgFvxPNa2kaZqP9oxa3p91/Z1w0Z+1+TCk3njI5KyOAuMdeM15eIy2GNr08TVb9x3Ub6Ps2u6eq/Hy0U+VNLqeh3Pwr0KbSpLDTZp7dCSHHyOxXHQEjjnBzzXneqfCvxPosLweHL+8ttNG13zdBskHsq4Pp2r0yx1rUbO5AurSQwyZIZIVDDjrkMVqpP4kvTdm50x45rJXWOfewYxtnGCM989q9UzPna98OeNRqk1rcRagsu1s7pC6yBuTgjOc46Vd8EeHviFp96Dp+nXcYVvNxKiKo9OXHP+NfRU3iyCJGkuWMcuSCXQrGuDySf6irus+IYrrSZfItVnCOFJuQAjHp8vfPPpQByWm6HPq9hFp3ijF5cFBNI7RLsBznbnHO01BbeGdctDc2q3wbQY1JjjeCNmOTyAFVcAAnv+HevNtP1ubwx4njtdd06C4vLfZPD5KK+5C+PlDup3fj29663xZ8XdNtbVp5LK/tZHjkRI7iNB5rL1V4w5IGcckj696API/HOi69rb3OpWdoY9Ns7p4/K8yCAooAyzNu3Zznk568V5ZevI3lwOZw6cOksm4b/UDAxwB6/Wun8W+ONT16d7e3+zafpvm+alrZgQxk44LYIyfrXIwyhblZXXcA24gHFAGunhTWZI98NmZfu8RsrH5hkcA9xWRc281rO9vcRNHNGcMjDBH1r1az+LVxbeHl0jRdPitrlozEJmUuRyCMZY9ec/yrhU8Ka/ewvfDTbyaN2ZjMke4Oc4JH97nrjvQBgRuFkDMoYdwR1q7rd9DqF81xbWMNjERgQwszKPf5iT+tSazp1xoupGzvLSSC4jUMyXC4bkZ5GcVmjBPzHGT6UAIRgkUlaGsrpaTxDRpbyWHyl8xrqNUPmY+baFJ+X0zzWfQAUUUUAFFFFABRRRQAUUUUAT2VtJeXcNtAAZZXCLk4AJ7k9h711HjTwRceFtL0u+mv7S7jvzIEEJPGzHIJ+8Oeo6Hg1yFOZmYAMxIHAyelAApIPAB+ozXU6dew3Xhu4snjWLbMkiukO5kYkBmVs5UEdR09q5YuxRVLEqucD0rV0qOGWwu43khjkfaB5jlQcHPrj+dAHv8A8LI0s9HiiWKCezjjfzrmG0DuuTuIlB5AIOQQTnt0rp/Ety3hnR7y1gklgsbgieO5ghjba2P4V6MD3AIrwz4f+IB4ajureaR5FuYtpEDryu7BHX5vpXsHibXND1TwrYONSswkRIMCzwqzqRj1xx3HvQB53PLCsWp3ljdNGJ0jaS6hjWCWLc3IEY++G4Gd2Vye2c640+8m8CyfZ2ufP2SI0LXALOhGQQ3Yck4I9qp6RoFtPf2kVnv+zuysss80U0JQHIi3DJU+hweT0r0Px7oYbQ7C6k/sewu4YJFYTX+15FXBCxkKFkPHQ4wSPegD5V1KKSG7dZgRJ3BHSq3auk8d6np+rav9p0y0a2VlG8OBvJwOpBwe/O1fx61zjjG3jGRnrmgCW0heZn2QSTBELME7D1PtUFFFADmYsADjj0AFKCzlVZjgcDJ6CmglTkEg+opKANrQ/Ed/otzFcadItvPESVliUK/I6Fhg4/GvUvB/jbW/HHim0t9dhi1uKQqn2WVD5Nt1G8FsqDg9T6V4nUkU0kLKY3ZSCGGCRyKAPovxB+zu893IdC1mHzJI2kWAxnaOehkB5GT2WuS1b4AeLtOsbe4SKC9llm8tre3Ylo12ltzHpjIx1649a4O08d+Kba5glj8Q6wgi+6iXjqoHoBnGPwr1XVP2iNe1C2t7Sxs4LIjAmmjcs8g9iwwufoTn0rzMSsw+sQ9g4+zv71783y6Fx5La7nnk/wAPtdt5Ao0q8lY9EFpNu6kYIK4z+nua6PwR8Ktc1rVBBd2F7ZW8YJld7VsLj+HnAz7V614D8Z2viS8bSdI0dbS8uER5L4zvcN5mME/OPmIHcn8q+iPDWnW+m6VHbxrygO9m5JPc/jk13Wqd193/AASdDkW8L2Z0C002G0tdO01ZFle2hgRS4xj5yOpPGeMnHOaXxj4N0bW9HGnTx+RZIgAhtkC7vQ4A69PpXU6zDJPdWz7olt0bLGVgAeDyMjt61YRLeVHlLCbYMl9wOSPQ0Wqd193/AAQ0Pgrx98PdY8N67Parp15NaOzNBIsW7cmeM7c4PtXO6n4G8Q2SRyXOjX8BlXcsZgbd+I6r+IFfXnxc0+y1fw/qUJs7K41FInkikupNwhYfxDjA6Djoe9fLvj/xtq3iFzBrtxp13JFID9rtrRI2YhcY3BAxHbnjj6UWqd193/BDQ5Xwn4fuvEfizTdBtlZLq8uVt/mXmPJwzEf7IyT9K9L/AOFOWR+KGl+Ho/EPmaFqWntqVtq6wDDRqjM2V3cYKEHngYrzvwV4rv8AwbrUmq6Qls2ofZ5beKaZWYwGRSpkTBGHAJwTkcnINdSvxm8TvHpRvk0+/utNjuoYbq4ibzTHcIUdWKsAQByOOCB1HFaiNzUfgfc6P4c0+91nU/I1C61yPSXtEiDeXG8jIJc55zsLAY5Uqc815t450NfDPjHWdEjnNwun3UlsJiu0uFbGcZOK27T4m+IYdHh0+5kivli1O31RZ7svJL5kChI03bvuYUcYz7iqfj7xrJ40vftt3omi6devK808+nxSI87NjJffI2enbHU0AcnRRRQAUUUUAFFFFABRRRQAqkggjqOa6G28STyW0VnqAt5LaOJ4wWtldjnpnkcjs3UVztLnjpQBfeU3VvDBneY242xDcAfcYz9T/hVSZBGcLIrggEFemPeoq1NM05HgN9qTtBpyNjK/fnYYykfGM88seFB5ySqtM5qCuwLvhmzt7qC5Oo7YLAYSS7KZMLHldoxlmOD8o6jPIAJGwTdamJrfQ7SE2VtIJUswXBkAGPMbpliM+mOQAB15u4vBqtzDDI8VlZQgrDGAdkQJ5zgZLHjLck4HYADrdHs7JLy3udN1lrO/CMitYM7F3C/wiMB0yM8lTnms4wcnzz+S7f8AB/Lp3b9C74XsNM1e1cltF0m9+VYvJN0JM56EOWBJ4HGfzxXTfCyy0Vtcv4ru6vnv2VwzQxkRsVPK5yXOcA9B+FM8Kt4mis5NRstdtrmHJN0JZZ9ykckkOAd/uOvrT9e+IUul6/C1vqf2uyliaIi3kdzA4AGdrgH8ye/SthHRT66ul35vtSN0ukGf7Pbysv76CQpxgsucY3cljwfwq9b+MoNPhudRtJJLhmjGbWSL58nADeYDtAOc4xXkfiWbS1+02zSNczQy7xLu+8GX7wXOCc9RgDH5Vz8MbzOq3N2k9nGsW6WWZfMjU9Qg3ZbHPAzQB9AnxjNZaPNrWo2joksXyQTO0rlgewAwCfesTxd4qk1LSZUjaRNSu0QiweFopCRzvUuNrHpxk/QVx+k+IND8LxI9s15ewzRPC2+Z4wBnIJUBGU9uGrKfxJPrFndacLRr+RmZ4HubpnaEex+Vjj0LHryDQBj6jrUl6jXckslzeyqgDC2+ZZFJxySSvr8vXoRVvTdK1C4tIV1bSpPs8W+fc8SwSOCecnbl/YHPXiuWMkcTxldkjFBu2hmCE8YO7v8AT/61dL4aS1RLi41HUJGBRvLtIz80j4IClz/qwTjnnigDnfEMMQu2eyUm2HykiHYFb0PvjmssocnghfXHaugv7ljZNZSQ2ayo/KpOCG4zvLA4Zh0+97YqK20dotOW8vNqQMygbbld7cgcIMnv1NAHd/A7w1b6p4mgGp20c9so3DeuUJDA9fXjoeOxr3rx1YWyeH768k1eLTbCFCiGGNIxEVJztbqWI4wPoOtfNnhjx1/wjcyjT9IgN1ESqXJnmLFc8FhuCn8h9Kd4u8TXHiK3Ed5qHnOu+aSSWfhiSMoI/ur7Y9M+tAHN+Lo4ZdcuZ7E3MsMhMimSMjKDjdksSen4VhZ+UjA+ta2rXE968l0sn7jiMZCRMwwP4AefcjNZFACkcdQa1Nc06xsBaGw1i21MyxB5RDFInkv3Q71GfqOKyySTk8mgkk5PJoASir+o6Rf6bbWU99bPDDexedbs2MSJnGRVCgAooooAKKKKACtbQ9Fm1gslod9xkgRKOemc/TtWTUttPJbTpNCdsiHIOM0ANkRopHjkUq6EqykYII6im9SSf0FdP4l8Sw+JLCB76yit9VtlWNZ7dMCdP9vLcEdcgH04rnoZ2iWSNVjdZBt+ZA2PcZ6H3oAWztLi7k2W0Rkf0GOa0tGspLmK4SGRV2gecskKll56qx6fXg/hmrng3U49H1CQ31lb3EJX5454kLDI6gsMjt+dFskcmsrLbwbEOJS0+AEUnGck8igDdj0Af2PDc6VHeXUsZbLxorFGz0IBJVeh3hj64ro/CMct/bXFpf6fcSwzMVb97EJEYL1VQAxx32jBrNhgtI/D+qvFNFBOhMZ8uKOQSbj8vKgbfTvXQaP4dubHQZL6/tUhnMwRQqJJEygZP3Pu59SaANz4UWd9p3iyW0028v8AyFKs0MEypHk5+YxkMAPau8+KoUf2eJri/wBNntlkaO4trvykDcEZULhs+gANVPh/DFq8hu7CyO+MAfas4lRvUnA3D2rM8ZeKLkaidL1O9028WPcG86OVXjkHcKcEnPTGaAPnvxxqGs3HiufVNVvftGoswBuBgE7RgZwAOgHaucvLj7TN5nlRREgAiMEAn15J5Ne3fE7UfBiahol/daLazvu/0uG0Wa3aZNuM8qFwCOgbOcds15v46fwXO8M/gxdXty4zLbXoRlQ/7LA59OuaAOSooooAKKKKAF7YoGM89KSlIweCD9KADjPcD861/D+jXeqavBaWUEss8pIjjRdzvwegrIAycDrXQ+CtTm0fX7a/tzGJIXJIZTk5BBHH1PegD7B+HPg6bwh4at5JLVjr8kCLIY4oz5I5O0E9+Tk8/lXY6PrUmi2c7eJr8RrK5aFZRHG7LxgZB+Y/5xXJ+CvEd54i8LCSK2ihnAA8xEU5GeoBOR07msP4jWt7LZ2LoPtRi4lnaJMRYOMhz346DHTrQB3dxr+oeKPEMdtpEBXToCd8sm0Atjrzzgen8q2L7U10fTGgtPNvZ41XzWLfxH3/AD4qr4ZtjpPhqJreMtJNjkJtLcevbp1NW5NOhjuIZfLaabaCBkhUJOSePvE+vpQB4x8R9U1qUma9klg0+4VljsVk/wBYw5DPxnbyB1/xrzm78HQeJb+Ty7h/sst0UYo6szyqnLLnHygcV6F8Z9C1bVLCe91KFIBAZTbrFvZ2XHAOQRjoAAMknrXK/Dzw/qU11Zyy2dzAYS6m5ns2IjJU/dGcMecYP19qAPEPEmgXOi6pcWF0EFxAdpVGDA++R7evNYhBU4IIPoa+/R8LfDeu+A5NLutNtrWV0Hl3otVE0ZyDuVj82TgZ5GelfGHxO8IXvgvxNcaZepIUR2EM7R7ROgPyuPqO2TigDkKKKKACiiigAooooAKKKKACiiigArp7zwD4sstHt9VuvDupxafcMixTNbthi5ATjr8xIx65GOtYGn3C2t/bXDxLMsUqyGNujgEHafY9K9p8X+IvDeo/EE+N9G8eXVrdXV1bTrZSabLJJa7WTIkyQjqm3IUE54HvQB5/feB9V8M2K6n4v0u8s7Nn8qKJl2tNLt3bGP8AAAOTnnsB1K81qV/PqNwJJtqqo2RRRjCRL2VR2HP4kknJJNeo/GLxJ4T1zQbd9MGmTeJ5r5ri8utHtri1tZItp5eObBMpZicgHAzzzXkgwevHHbvWap+9zS1f5DuBBHBGPwq1p+oXVlMklnMYZFOVZcAg49f85qqAOrEgfTNTxRMzhEGBnlnThf51oI3H18ANcibUF1M7DvWcbCQc5OBmuq+H9nbazcane3U17c33ktJmJwJWOeTliNx9Oa4TUJHijW1EtpcrIqsJI413D2zjOfrzRpV7PaSSRwxQyHaysHB6d8HIoA6wak9jPe6hDcFyJtphuVj87IAGShB6VVm8X6xf2MthJevHZzEFvLtY42znPykcqPoeawrd472+AtyLXcc7VVmPA7FQzVak0+f5H1K8W0dsFEvIp2Y+4Owjv60AZlxdO6yRu0kihj8zvyff69Kbb3AhRmL3CyBv3bI4+Ujrz1/Km3x23Mi77ZwM/PFHtVvoMDH5CqvUDJ9s5oAv2V3Ml9HdTXFwsiyCXfs3nI5zyea6Sxvl+z3Aubi6muL5iGKKmF+bOdvJBPXjFchhA21vbnGf61v6TqyW1q9ulkk0jqQDKvyrz1AHf8SOeQaAFvJVhE1pa2yC1eTD3ZgVpG9l3/6v3AIPuaTTdbvPDkM32K5mhvpVXZJG6HYMnPIyQfoQR3q7fWlw15b21/FDp13LiWQX0Atl244YDAUKe2FGfWsu5geRrmSIxuCqu37nYucdAMD8D+NAGROZpppJrh3kldi8kjksSSfvE98k9afCoDLGxfBwWVVBx+f4VYlt3a0MjmLEQyY1DEgFgM8DHcDrVWNcYYxnJzgbc5/WgC5q08M+ozNZIwiYgJ5qxhuBg/KowOfT/wCvWZnjjPvUxkJlBJVSOM+WBj8B3qE8jPFACUoHX2oH0pyAbuhKgZPFACZ/EjpVqbTL6DT4b+a0mSymdo452QhHZeoB6EiqdTNcztAsDTSmFWLCMudoJ6nHTNAENFFFABU8M0ccE8b20UryABZHLBosHquGA59wfwqCigAor2H9l+wuNR+IMsA02C/0/wCxzNcrNZxzqhCMYzllO358dMZ6c133gLS9E1Lwv4a0nxlplpaa7qfiC7YXbWscTR3UEqN9ndQoAR90kewcAlQB0wAfMFSREb13IHH93OM19QC58OeFvCnjTUdRso4APHl7YQy22lWt26J5e5Yws2FVBtJ4PHpgmvnUvozLvlnvnmOSQlqkYyfcSHp9KmUlECx5cEwjR5mERBaSYRNvgOOhA5dR6+/Wuw+HK2F6NQttVvUdTEtvA7Hywy/3Q2OBwOp4rB0280W31uAXMV95YB3yR3abJeM4KiMjHtk10VtNotlqqyafo63OlzgM0Z1DCMcnAAxgNn+EknjgCo9pL+V/h/mOx058OXaNb2GmyXclmWkVxbz7QvcLJwRKMZ+bp247+2aF4b03yTZzXN9Gsox5LGQxh8cEAgY/MYrgPDXiaC00+GfT9Mi+zurbo49QZ5ISGxtKAkk45GM17J4a1C5vLC2ure4gmtz9+GSRy2McYY4ZTyOMUc8ntH8v+CFjhW0vW/BMTxuXuoHkjD3kSSyZXPPmKnIAHc8VzHiHTG+IwN5bXspt7QvHuR3Kg+q/N8pxzghvoK90m1GBZNjzRoWAILSdPxI7fSuG8UQacs5ij1JbW91HcYrrzsq5HB6IQevTaPqK4cFWx1SpNYmkoxTfK07tq+mlu3mvQqSikrM+RfiXp0Gi+IZdLtL2e9gtwoEs3JztBIzn39F/rXI17v8AtJeFtO0xbDVrK0ihvbuXbPLDcSSLMdvHytnGMDofWvCSMEj04r0yBKKK9N8T+FPDnhzxL8Po75rz+yNY0aw1HUm80b0MxYSFDjgAAEA56UAeZUV6x8RfhraeBNC1+bVWuTfNrH2HRlLBRJbqvmPMwx8wKvGvB4YmvKASOnFACUUUUAFdp8O7JX1eMTaTJfSupMcTHYp/2sk8jt0xXL6ZatczHaUUJyS+cfoK9A06G3uPGVvCytbL5XLXCeW6nbk8A9+1AH0NpK3Hm2Wi6MsentIkTXTQ4fYueUz0B6jr74r0vWpNMs7S101zA80gI2uOOOvAGO/euI+Gej406OfTSJYeodmBEpyfmZwSTzn1xXYi1cTSXGstZwxQrneh5468n/PtQBt3F0jwCCOYYYd84x68Vl2mrJHCzyb3O3IOxiT+J4H6U6DU21Szj+zRLDCWG52ck7cdAAPp1rM1izNze+cjTzeWiqsRnZYkwfvNgZJ+npQB5/4r8MXev3lxrJF01rE0jGKWJ2809FCjeCoBzycfQ8V33w38NTf2aj6tbxQIrZS2WPbgds8k/nWhY2Sy26tfwriIl0QAhfooJyfxzW1NdGzsFdYA8zttCbsBFxyT/nrQBfvLy3hAg3KBtGPm6V85/HLwvP4/upEtLxXm05XFvEg3lmYjcGPAUDao5/rXrPiWWRI49r5knYJhZArYzyc/5xXFa34hHh/T5BY2duZ7yQxK/wBtwxB+85ODQB8U3ltLZ3U1tcpsmiYo65zgioa97+KnhrStX0yXULYxxa00gdZXnkka5ULjbgrx2wTj7vpXgrKVYqwwQcEUAJRRRQAUUUUAFFFFABRRRQAUUUUAFOOMDB+tNpQceuO9AAeg6U6KRopFdduR/eUMPyPBplXLSdrG6VnRXH8SE9fyNAFYMMNlQWPQ+n4UbyQA/wAwUEAelTXUyTXBeKGOJTgBVzgfmTUtjYXWpSLDaIHk5IUlUz9CSMn2oAhjleJgVdgw6Ykxjj2pskheTfIfMZh3JOPzqa+truzumtr2Ka3uozgxSJsZePSq+5v4ssvfn8aABgoyDgEf3ec/rSxu2SBkA8nbxTV5GAB0xn8akiXevQk/7IHp3PagBFYIwwTg8nDfz4q1G7RzJJG0YPTIky30pkcbbASGJx22gEenuKnsnWCeLzWaKNTkEEZP+c0AaVvDPqIaW5IkhjZS5lPyrxgAnsO3UVq3FmdPitWnlupoWykkmTDHgdFWTkMMnrg49Oa7m0uNP8SaTbNqjaI92jmGI391IpIAHaMjr71s638MNQ1zw9YWdldz6rcWRUBIo4LeDafvASbdxPTBORxyBnNAHg0kGLyRIN0lruJAD5VVz0L4A/4EOOKpyhUBGIzhiNu8t+ORxXquqjw54Yg+waoHvtSgdz9isJ4xFauDtxJLhmZvULjHPSvMdUvpL+9luJYoYC2QI41Khf6k+5JJ7k0AUWOTkAD6Uq84Xgc9TQcZPp7U6QYyTkZwR8oGf8KAFCr5h+5t543cUw45Hynvu5ocsT82cjj6Uh7YGKAAgjqKSnL19+1JnIA449qAL/8Aakw0Q6WI4Ps5nFxv8lPM3bduN+N2Mds4/Gr/AIKu9Ista83xDJqsdj5TKTpgj87JwMfPwBjPvWBRQBb1M2Q1G5/sr7T9g3nyftOPMKZ437eM/SqlFFADjjAwST3yKI1LuFGMnpk4pDRnjGBn1oAk8vy5zHcLIjA7WG35lP0P8qHiZJSrq6gNg7htP/1qaIpCAQjEHABx61q6HpP9p3sVtJJJCzAlQIyzMM/wjIzQBdtrGBtYtrCOCS8hkkLbGdIDL8vVX5C857kH2PFdpbabp00UcdlcXEME/lQshCRSx/8AXUZAkAP8YAYVj+KPCUfhUR3Vlq0F/GsoVoZrYK6EqSN0ZY8EA4z+FZVr9rF7Ff6XBNE0TIcRqZI2O7ktuJx24OaAPoTwp4bTVtJbTdeskupLYMsV2FRN6k/ejcpwenIY5xXrFjpU2kWn7q9ubuNAT/pToZVOOzBRxkd815b8NfF9+mppaatpv2KwMO4XcNqzxNIW5DKF2p35OOnvXpPjHVoINKmnl82CNVz58IYn8FGSPrQBy/iO8vdT/suO5F3p+oI6GRo7hCRHn5iCueCeMDn2rQRdNiuYbmVjNLCGAYtkIWxnAxuBP9K8u0GC5CSapb+K45UlHm/Z40MbpznKpyWb1wMmsfxJJeXcn24iyFtKHxey20yShgQCZMDr6ZA4HegDD/aN1621DxHHp9pPcmK22sYWz5aZXqoPfk15BIQXYqWYdi3WtjxW8k2qs0s0U7njfC25W9MHr+dYo4NACV12rfETxPq/hmDQNRvoJ9Lgt4rWJDZQB0iiIKKJQm/A2j+LnnOcmuSPJpKAOg8VeMde8VxabH4g1GS9TTYBb2odFXy044+UDceBljknHJrn6KKAHFiVC8YHsM/nTaKfEhllRAVBYhQWOAM+poA7H4c2XiG5v5I/DwkRiMSOSFVfxPX8jXR2fh2ztPFLQ+KtWEBIYzCBlMpOMgfOABn8as+D/Cun6baLqOsmWe3eFsyWFvJJEB3LORtOOehqPw7omharrypYWt5JaSPhLu6gyXOMEELIgXB789uKAPfvh3qFpB4ahn8Nw3b6fCVVln25YDggHLZPsDge1dhqthc+JrC2DW8sFq77mjEqqSAQOQAc/jx7Gqfhfw7Fo/hq3tJPssSRoAXityGY/ixxWz4XRYdQljtGmaHljI5LDOR3JJzQB0WoWbJpphhd7YdA0bgP+BxwKqWCG4tI4FYm1j2hnPO7GDknvyM1cmQ3TPFGjO5PzM54xj/9VX0gS1sEijVQsagY6DigCndJFFsmIYgKS2VycdsD86zNUuUExRLWdtuB5jqAjHGcD/8AVVvUbl41eUOgxkvlS2PyrkdYv/LvIniMDytl1C27SSHA6gZ/U0AXb+zM8c8KpL+8ALcIu4/7xzxXEaZp0Ok3V5JJO8rKzb5JpY/LjOedh25J555JPtWtBPqItJrq4jvZ7i5KAo0RhCJ2UDcdvucnJ4qj8RtTOn6HYWunaOLrVb0ELDGBtt+m52OMYGQcnA96AKs9xpLat/wkF9LPJMG8iAFwyRKwC5wB95uc+1c58fPA+l+LvDza9pAuJvEVrCIoooRkXCI2XG0jnaCxzntjniua8ZeOrbwn4cTT54/tOrtIGFvI7ZAx95sDgdOMgnPHFeI6v431/U9aOqG/ltLnyhAgtGMSpGOiAA9BQBzjKVYqwIYHBB4INNp8kjyyPJK7PI5LMzHJYnqSaZQAUUUUAFFFFABRRRQAUUUUAFO4I5PP0ptL60AA71aFy81sLbyo3JbIfb8/Tpn0qCELuG51U/7S5FW3gLRtI1pIsQP+tRWA/I5oAe+mqkkSS3C2zOMn7Qjrj3GAcipih0yUc2jOwIUqqXCt26Ekr19M1rfZNOttNVoLhZopdoaSeBl8vnnBGc9eo/Kuhh0Lw9DZpLPrGkOskZIF8s2/Pcgoq5IPYk0AeehZLq7y6uztwFihB5xwNvGK3rDwtC1tLNq9++neWVBDW+489Dtzn9K1/D9j4WWRxfalaH5zzLaXCbV9VKhs844OO/NZ+rXOh296FsbR76MrkXEUzIDyeCGXnp1PrQB0Hhv4cWmq2c1wt5c3kUalo0jhaFn+gYGtjwn8KrDVbxYbvUo7W4b7ljcwypKFAJ+Y7MZ+hrm/DXiaGxkjd7DSVSXcA91EZS2D0O05q/qN/pNxeQamJNPN6r/NpljDcqX4wCCcD8moA9Svfh74Z0KGC206402bWQB8kkrNk8AjYrZ9cZNV4vAfhazi1C7bT59T1WSKRhZIVKox6BTt+X0yfXmubtdWg123mAsJ9kIXKWluZnU843HOF/Pt7Vb0X4jaULC50SaSW0tlDRSzGMSTsrZyQ2cgjtwSPwoA5+NV0y1urlPDeoaXHE5y8lwMDgjDMVCkE+nP4VzVpqd3qN1NJq32nUcD5rK3WQJjP8ZHGMk88/T1X4k+JdL1K+todHt7hrS3QIslzMWWTHRtoUEYye9crLqEsj222QypGuAjxnaAD0wD834igDt9av8ARZNKQrdaXYeUGCWVlpSSSMc4xK7Nnj17+lebTyNO7PsA9cCp71xLJ5zsFdmJMaQhFX02qOMfhVYEbstjbz2A7UABO7L7R+v+f/10FgAcbRkdAM/zpFXeQAcH05NCDClweR7UANOMnHSjp1HX1oooAAeDwDnv6UE55pSCMEjFIRjHvQAlFFFABRRRQAUrKVOD1pKKAJoX2pJ8pJx749OfzrW8N2yzXnnLd28DQkMI5WKh/oaj0F9NxKmpRynOCrwLmQY5OMsAfpVOGGW4uWhsI5pGBYoqr8xH+7k849M0Aa3jG7nuL/N1b+TIp428owHcEgZ59qs+E9TvINVg8i3W5hODLANn73HUdOKzre62wvaak9xlXG6J03flkgg+1dHoHhLX5Ybe88OxzTQzYKsHWMk54Jyf0PFAH0L4L1df+EakJ0CW2bDL9mMqcj1D7f0xxViw8QXv9q29j4lsZ7axmDYn89ZVU84Vjt54HtVDwFda1B4dez8QpeWt/bqwZbqyTyJxklVWVBjuMnJxzV2712S3uGs7/Tri3lcFojBeQTKFx94ZGO/pketAHE+KPD+k6ZqiXGhXNtqFxBMrlba7RfJy38cRJ3L/ALrJ7CsXx/rOtaZbeZpWpXaNMC88UNzJHbqoA/gK/Kx55EjfhV6DUtR0+8udY1NLryonyHjeGG4UZwF+Q4lHPcH6VznxB8baL4i0iZW01lvgCBdSRqkm7tuYJkn2zQB5NqEy3F1LII9jO25v3hfnvz/+v61VoooAKKKKACiilAycDrQA+NVYY/iJwOvH4AV1fhXS7ZNXRbyza+Q7WUK5i7/7YX+tdb8DdU8V215Jp/h+3gNvM2ZXkjUFePUYbt0zjnpXtNp4S8Q2eoy3NtvkgvSHvhLIqnIHGxiMjn3NJu2rAdLMLT4aSyalBDp+nLESiC9mIbk/KdpByfQV4DYX9vqusibVZ4ZoFk+WAtIscSYwCMsMfiT+te4eLPh74v8AEoEKPY2Wmxj93Gs5Lv6E4BWvOfA2hnXbSK3NpdXRE+XnMZMe0D1DZzk+mK5cNjsNi3JYeopcu9nexUouO6O98Cw3GlTzWs+pWk7XYQm4aflR2VUIxnBxivdfDFrBp+kQxRALHgld3yk5OSe/c15x4J8DWfh6dr3WIpZrhnU2qKrOwAPHy9Mjj1+tek2b3Uk8hWGdiW2JESo8oepO456V1km3pMEqNI85yxOeHyAfyHrVm/dRCUbHzY706OFkiCtK2AOcYFYt3fosuNhdTgEgjn/GgDI8WXNvHZ4kcOSrFYzI6qT6sVPQV55qV8dE05Z72Wa6ijl+aSGJiWyOIoxxxnuTn3rsvE2pWj3UcepwSMgOYYU+dpT7gdMe5Fc/4u8Q6Xo+knV9emeC3dtkEWwkkYJ+UZ69aAIIoLn+yjqd/M6SGNJU0+E73DEZw4456fTmvLfiD8RLDRIba6hAvdYuY5ozDHfAm2IPymUKDkAnhOM468ccz8SvjHdajEdN8JyXOm6UyASOY1WaY56lskqPo1eLSO0sjySMWdyWZickk9TQBY1XUbvVr+W91G4luLqU5aSRixPoMnsKqUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUueMUlADwwCkbFJ9ec/zpfNk2FPMfYf4cnFR0UAX9Pu/sTOS90pI4+zXIj/AD4OaI75cubq3humOTmVnzn1JUjJ+tUhj0+vNBI5GOO1ACsxJ5OR6c8ZpY3KtwxUd8UypIZJIWWROxz8wyD+B+lAFi3vJbUmSGWSOcggNFJtx78D+tBupo5PPErmUkZYzEt+Ywa17zxNcXOnC2+y2AUqQ7fZYNx+jbA4+oNYtpLFFdI06FoR1VQpOPxHNAGpc6689nHDDbxxThstOskrO/ucsR+lWtN8Naze2bXlrEwiz9/GNxPoT1/P1rWsvE+meW1m9jNPZMFwFUq8ZB6gIwBx17dK3tV8V3mkWFp5KawYNpSNtT00bCOCNhaRlP4qaAPOtS0a+0t2OoRiBwQNpuELjjOcAknrVZLeaW1ecMiQoRuYyZPoOOvp2ro/FHi9NVnU2ts8aADdK4hEzMOhDJGu0dOB1rk5JpJCDI5YjuetAASzZZuAw/PkdM0wYwfX60oBwG+YAdDj/PelO5MBlwPoM0ANBxn3FIDweB9fSnyHPBA3DuCMfpTB1GelAAMd6cdu7AGP+Bf1plSEnLA7M/hQAjHDDbjjuM00/nSUvbPagBKKKKACiiigAooooAKmSSPy9jwq3P3wSG+np+lQ0UAbckdqt5Bc6ZKtygxvinjAcf8AAGLBuBngn8K6jw9BYWeu28Ud5eQaddCMzqyIu1s8ZyzKw7155XWeG/Hmq6HbtbNDY6nattHk6lALhVVeirk5Uew9BQB9QaTb6dDoy2On38tzFIHCrcoqHng7ZV+U8ngGvNr2+/4RbXp4oZzqig7Gs7yX5ogQCMNggfhTND+KuhjRb9Fu5tMuGgxHa3FuZolkOd3lFclB7Ed6wdCZtdnk1W/t7zULGKVl+1WxGQyqDgg/N3HbFAEcsdj4q8+w0vUb+xuG2k2V4zTh2Bz8jggAcDgj0rhvFj3Nuy2N2YopYCytFGWJ7D5j0PTitCCzh8R+KibCO8uLVnGfstvtbliRvBbBPPJyM9q9A+Jui6NF4XtlSHT7S7iicK9xb3FvM7L0VWIKN+JH15oA8KpQcHPH4jNKASDhScdSKUuSFBC4X2A/OgBlFFS20L3E6RRo0jscBV6mgCKu58AfDvV/F8Uk1hJbRQofvu6E5+m7Ir1PwF8B7HVNKt73Xr64sJWjRxGUHGeefWvQ4rLwP4UVtMtPIuNUji3hxalSfQkgY9O9AHE+DPBmv+Flu/smqsNSRdyWsRVIzwBuZskH6CvVodW1DSfBgv8AxGyLiFHnmEnyxk4HU+5FT6FrSzWxN3bqY3zsSKzkckY9BmvMPiPr+oazqzeGkttOsrOaJG82+tpUkRd3UK2B/CecGgCNPiNeWj3kHhWY6jDcb2ZJ1eURsx6oVI2jrkV33w/8K3N8IdV8QxWsNxCSII4YjGEGMY+/tJ+o49e1ec/DzwTZ2mpSzozRRpmN72ePck3zDPlqCc/Xjp0r6AEMaCL7NNsHAWNYAOMe/OK5YYKhCcqkIJSlu1o39xXM2rGpaWNvC7bUjdsDGFHHpmr+lpbRPJKgSMknIwMk96o6fZGFo2uJC4HLKRnNUPGfj7w/4QiQ6xew2hlDFFKM7MB1IVQTxkVryTj8Mvv/AKX43Fc6pbiG4yyglEOCWTH8+a5PXbhYbiSeef7PBCm55T8ojUck+1eCeL/2i50vfK8K2sMsC8Ga8jcBvcBWBx9QDXL+H9AvvjPe6nquras+nOgSzso3/eRz3JWSRYVJxtUBSeSTz1NOMpN2kv6/B/gB0XjL41aXpk9zbeELM3M4mcSXNwP3cpyfmUq+WBPPbIrwPxT4i1HXdVm1DU5TNcynliuFAxgAAdOAK7/wr8KJvE/gN9atNQxqKX72zaa0GHaJCnmupLDLIH3FcdFNS6f8LfDMuq+MtPvfEmpw3Phn7RNceVp6urwRuF3KTIPmOen61oI8aJyc8fgMUlWNRS2j1C5TT5ZZrNZWEEkqBHePJ2sygnBIwSMnHrVegAooooAKKKKACiiigAooooAKKKKACiiigAooooAKdkemfrTaKAClzmkooAWge9JRQA5WKnIx+IzSE5PHSkooAt29/c2y4t5WiPXKcGoJJC5JY7nY5ZjySc+tR0UALnBBUmgksckkn3pKKAHMQeigcUbjjHHp0FNooAduO7dxn6DFAI6Ede/pTaKAHDG3nrTaKKAClJ59KSigAooooAKKKKACiiigAooooAKKKKACp7O7uLG6jubKeW3uIzlJYXKOp9QRyKgooA2PDev3Wga5Z6pbpDNNbyiXbMgYPzkgnrz6g5r2e1/aGinhmi1rwhZ3IkUr+6u5IwAeudwfOfwrwCigDt/iLrHhTWFtZ/DGiLpdy53XKB3YA46DLbSM85CiuQAmVkjEifOAR+8XAB6ZOcD6HHvVeigDoPD+iTa7fCxt4w9z1yJIwoGepYkA/nmvpf4f/CPRPC11HrGu3VluUfJEt0SqHj5t2Rn6Y718kVKs8qjhz+PNAH3V4t8UWsFkuy2XVNN+XfFbXhLEbuo+ULx15auW1LxF4Znto5bS4fRpSCsbzX3lqSMZX5uOM9AK+Oy7HOWY59TQWYjBYkdMZoA+gZviJeRa3/ZT6jp96h+7ctdNFCeM/fRh/Kugs38IQyyeIvEesaJdzRwhTaW12LgsN3G0F97Hn/63WvlyigD6i1P40+EtLa1TSdNW/twX3RIzQ+TyMZ3g7iefpisDVf2hr8bh4e0y208hwyvNMJsr3BGB14718+UUAeo6n8YfGeoCUP4ju7cSPvAtZfK2+wI5A/GuIu9UlurmWe6u5Zp5GLvI7lmZickk9ySaxwzL0YjvwaTPGO1AFxrsDoob6E/4V2Ph34r+JvDeiabpegy21jb2V094xjQlrmRiv+tySCAFCjAXgnrXA0UAejf8Le8QR6laX1lbabZTW2rzayot43CmWVQsiEFz+7YA5HX5jz0xmj4i6sNX8XaiLew8/wATwTW94ux9sayMGYx/NkHI4yWri6KACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posterior rotation of the TEE probe while in the vertical (90&ordm;) imaging plane allows for identification of the coronary sinus (CS) and left lower pulmonary vein (LLPV) (panel A). In panel B, slow anterior rotation of the probe delineates the posterior leaflet of the mitral valve (PML), the anterior mitral valve leaflet (AML), the CS, body of the left atrium (LA), inferior wall of the left ventricle (INF), and anterior left ventricular wall (ANT).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Warren Manning, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_52_833=[""].join("\n");
var outline_f0_52_833=null;
var title_f0_52_834="Patient information: Corns and calluses (The Basics)";
var content_f0_52_834=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83620\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/41/2705\">",
"         Corns",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/34/34351\">",
"          Calluses on the hands",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?28/50/29473\">",
"         Patient information: Bunion (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/5/11346\">",
"         Patient information: Skin warts (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Corns and calluses (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/corns-and-calluses-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H876933350\">",
"      <span class=\"h1\">",
"       What are corns and calluses?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Corns and calluses are areas of thick, hard skin, usually on the hands or feet. They can form when something rubs or presses on the skin over time.",
"     </p>",
"     <p>",
"      Corns usually affect the bottoms of the feet and sides of the toes (",
"      <a class=\"graphic graphic_picture graphicRef83520 \" href=\"UTD.htm?2/41/2705\">",
"       picture 1",
"      </a>",
"      ). A corn looks like a small bump, and has a hard center surrounded by an area of irritated skin. Corns are often painful.",
"     </p>",
"     <p>",
"      Calluses often form on the hands, fingers, feet, or toes (",
"      <a class=\"graphic graphic_picture graphicRef83519 \" href=\"UTD.htm?33/34/34351\">",
"       picture 2",
"      </a>",
"      ). They look like thick, rough, sometimes bumpy skin. Calluses usually do not hurt.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H876933365\">",
"      <span class=\"h1\">",
"       What causes corns and calluses?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Corns and calluses can result from:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Wearing shoes that are too tight or too loose",
"       </li>",
"       <li>",
"        Wearing shoes without socks",
"       </li>",
"       <li>",
"        Walking around barefoot",
"       </li>",
"       <li>",
"        Using tools (like a hammer or rake) or sports equipment (like a tennis racket) that can rub against the skin",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have other problems with your feet, you might be more likely to get corns or calluses. For example, if you have a bunion (a bony bump at the base of your big toe), your shoes can rub against it. This can cause a corn or callus.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H876933380\">",
"      <span class=\"h1\">",
"       Is there a test for corns and calluses?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. There is no test. But your doctor or nurse can tell if you have a corn or callus by looking at your skin. If your doctor or nurse thinks that your corns or calluses are caused by problems with the bones in your feet, you might need an X-ray.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H876933395\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to get rid of corns and calluses?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To help corns and calluses heal, and prevent new ones, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Wear shoes and socks that fit properly. Tight shoes or shoes with high heels can cause corns and calluses.",
"       </li>",
"       <li>",
"        Avoid going barefoot or wearing shoes without socks.",
"       </li>",
"       <li>",
"        Use special pads inside your shoes to prevent rubbing.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H876933410\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. If you think you have a corn or a callus and it is causing pain, see a doctor or nurse. He or she can check to see if you have a corn, callus, or something else (like a wart), and whether it needs treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H876933425\">",
"      <span class=\"h1\">",
"       How are corns and calluses treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have a corn or callus that causes pain or won&rsquo;t heal on its own, your doctor can treat it. Treatment usually involves removing the top layers of skin on the corn or callus, and then applying a patch that has medicine in it. The patch will soften the skin, so that more can be removed. After it has been in place for 2 to 3 days, the doctor can trim the skin again and replace the patch. This process can be repeated until the trouble spot is gone.",
"     </p>",
"     <p>",
"      If you would like to treat yourself, you can buy the patches with medicine in them without a prescription (sample brand names: Curad&reg; Mediplast, Dr. Scholl's&reg; Callus Removers). Then your doctor can teach you how and when to change the patch yourself. But you should",
"      <strong>",
"       not",
"      </strong>",
"      use this treatment if you have diabetes or other conditions that can affect the nerves in the feet.",
"     </p>",
"     <p>",
"      If your corns or calluses are severe or keep coming back, your doctor might refer you to a foot doctor, called a &ldquo;podiatrist.&rdquo; A podiatrist can fit you with a special shoe insert (called an &ldquo;orthotic&rdquo;) to help protect and cushion your feet.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H876933440\">",
"      <span class=\"h1\">",
"       Can corns and calluses be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sometimes. You are less likely to get corns or calluses if you avoid shoes that squeeze or rub against your feet or toes. You can also wear gloves to protect your hands when using tools that might rub on your skin (such as while gardening).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H876933455\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/50/29473?source=see_link\">",
"       Patient information: Bunion (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/5/11346?source=see_link\">",
"       Patient information: Skin warts (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?0/52/834?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83620 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-E9F4F161E5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_52_834=[""].join("\n");
var outline_f0_52_834=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H876933350\">",
"      What are corns and calluses?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H876933365\">",
"      What causes corns and calluses?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H876933380\">",
"      Is there a test for corns and calluses?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H876933395\">",
"      Is there anything I can do on my own to get rid of corns and calluses?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H876933410\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H876933425\">",
"      How are corns and calluses treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H876933440\">",
"      Can corns and calluses be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H876933455\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83620\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/41/2705\">",
"      Corns",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/34/34351\">",
"       Calluses on the hands",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/50/29473?source=related_link\">",
"      Patient information: Bunion (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/5/11346?source=related_link\">",
"      Patient information: Skin warts (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_52_835="Patient information: Psoriatic arthritis in adults (The Basics)";
var content_f0_52_835=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86739\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/13/39135\">",
"         Plaque type psoriasis",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/39/14975\">",
"          Psoriatic arthritis on the joints of the fingers",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/35/13886\">",
"           Psoriasis of the nails",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?9/22/9571\">",
"         Patient information: Arthritis and exercise (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/21/26962\">",
"         Patient information: Disease modifying antirheumatic drugs (DMARDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/9/3218\">",
"         Patient information: Psoriasis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/6/7267\">",
"         Patient information: Psoriatic arthritis in children (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?27/62/28645\">",
"         Patient information: Arthritis and exercise (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/11/3252\">",
"         Patient information: Psoriasis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/36/36419\">",
"         Patient information: Psoriatic arthritis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Psoriatic arthritis in adults (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H90319136\">",
"      <span class=\"h1\">",
"       What is psoriatic arthritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Psoriatic arthritis is a condition that causes joint pain, swelling, and stiffness. It happens in people who have a long-term skin condition called psoriasis. People with psoriasis have patches of thick, red skin that are often covered by silver or white scales (",
"      <a class=\"graphic graphic_picture graphicRef74211 \" href=\"UTD.htm?38/13/39135\">",
"       picture 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Doctors don&rsquo;t know what causes psoriasis or psoriatic arthritis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H90319168\">",
"      <span class=\"h1\">",
"       What are the symptoms of psoriatic arthritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Psoriatic arthritis causes pain, stiffness, and swelling in the affected joints (",
"      <a class=\"graphic graphic_picture graphicRef69282 \" href=\"UTD.htm?14/39/14975\">",
"       picture 2",
"      </a>",
"      ). Because of this, people can have trouble moving their body. The stiffness is usually worse in the morning and lasts 30 minutes or longer. It usually gets better with exercise.",
"     </p>",
"     <p>",
"      Psoriatic arthritis can affect joints on 1 or both sides of the body. It usually affects more than 1 joint.",
"     </p>",
"     <p>",
"      In addition to joint symptoms (and the skin symptoms of psoriasis), people sometimes have other symptoms. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Swelling of a finger or toe, or the hands or feet",
"       </li>",
"       <li>",
"        Nail symptoms &ndash; The nails can look &ldquo;pitted,&rdquo; as if they were pricked by a pin. The nail can also come up off the nail bed (",
"        <a class=\"graphic graphic_picture graphicRef71998 \" href=\"UTD.htm?13/35/13886\">",
"         picture 3",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Eye pain or redness",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H90319223\">",
"      <span class=\"h1\">",
"       Is there a test for psoriatic arthritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will ask about your symptoms and do an exam. He or she will order X-rays of your painful joints. He or she might order an imaging test called an MRI. Imaging tests create pictures of the inside of the body.",
"     </p>",
"     <p>",
"      To check that another condition isn&rsquo;t causing your symptoms, your doctor or nurse might also order:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Lab tests on a sample of fluid from a swollen joint &ndash; To get a sample of fluid, the doctor will put a thin needle in your joint.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H90319238\">",
"      <span class=\"h1\">",
"       How is psoriatic arthritis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is no cure for psoriatic arthritis, but different treatments can help ease and control symptoms. Treatment for joint symptoms usually involves 1 or more of the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines called nonsteroidal anti-inflammatory drugs, or &ldquo;NSAIDs&rdquo; for short &ndash; Examples of NSAIDs are",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        ,",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil, Motrin), and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (brand name: Aleve).",
"       </li>",
"       <li>",
"        Medicines that are usually used to treat other types of arthritis &ndash; Some of these include",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?41/59/42934?source=see_link\">",
"         methotrexate",
"        </a>",
"        and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?23/42/24229?source=see_link\">",
"         leflunomide",
"        </a>",
"        .",
"       </li>",
"       <li>",
"        Medicines that block a substance called tumor necrosis factor, or &ldquo;TNF&rdquo; for short &ndash; TNF plays a role in psoriasis and psoriatic arthritis. These medicines are called &ldquo;anti-TNF&rdquo; medicines. Examples include",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?35/34/36389?source=see_link\">",
"         etanercept",
"        </a>",
"        (brand name: Enbrel) and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?2/61/3030?source=see_link\">",
"         adalimumab",
"        </a>",
"        (brand name: Humira).",
"       </li>",
"       <li>",
"        Shots of medicines called steroids that go into the painful joint &ndash; These steroids are different from the ones athletes take to build muscle. These steroids help reduce swelling and pain.",
"       </li>",
"       <li>",
"        Heat &ndash; Heat, especially in the morning, can help reduce pain and stiffness. Do not use heat for longer than 20 minutes at a time. Also, do not use anything too hot that could burn your skin.",
"       </li>",
"       <li>",
"        Physical and occupational therapy &ndash; This involves learning exercises, movements, and ways of doing everyday tasks.",
"       </li>",
"       <li>",
"        Special shoe inserts (called &ldquo;orthotics&rdquo;) &ndash; These can help keep your feet, ankles, and knees in the proper position.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Treatment for psoriatic arthritis is usually long term. That&rsquo;s because even after symptoms get better, they sometimes return later on.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H90319253\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. It is very important that you stay active. You might want to avoid being active because you are in pain. But this can make things worse. It can make your muscles weak and your joints stiffer than they already are. Your doctor, nurse, or physical therapist can help you figure out which activities and exercises are right for you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H90319268\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/9/3218?source=see_link\">",
"       Patient information: Psoriasis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/22/9571?source=see_link\">",
"       Patient information: Arthritis and exercise (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/6/7267?source=see_link\">",
"       Patient information: Psoriatic arthritis in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/21/26962?source=see_link\">",
"       Patient information: Disease modifying antirheumatic drugs (DMARDs) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/36/36419?source=see_link\">",
"       Patient information: Psoriatic arthritis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/11/3252?source=see_link\">",
"       Patient information: Psoriasis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28645?source=see_link\">",
"       Patient information: Arthritis and exercise (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?0/52/835?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86739 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C3286EAA3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_52_835=[""].join("\n");
var outline_f0_52_835=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90319136\">",
"      What is psoriatic arthritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90319168\">",
"      What are the symptoms of psoriatic arthritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90319223\">",
"      Is there a test for psoriatic arthritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90319238\">",
"      How is psoriatic arthritis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90319253\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90319268\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86739\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/13/39135\">",
"      Plaque type psoriasis",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/39/14975\">",
"       Psoriatic arthritis on the joints of the fingers",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/35/13886\">",
"        Psoriasis of the nails",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28645?source=related_link\">",
"      Patient information: Arthritis and exercise (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/22/9571?source=related_link\">",
"      Patient information: Arthritis and exercise (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/21/26962?source=related_link\">",
"      Patient information: Disease modifying antirheumatic drugs (DMARDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/11/3252?source=related_link\">",
"      Patient information: Psoriasis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/9/3218?source=related_link\">",
"      Patient information: Psoriasis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/36/36419?source=related_link\">",
"      Patient information: Psoriatic arthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/6/7267?source=related_link\">",
"      Patient information: Psoriatic arthritis in children (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_52_836="Sacrocervicopexy intraop";
var content_f0_52_836=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55086&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55086&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sacrocervicopexy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The polypropylene mesh has been attached to the posterior vaginal wall and cervix, and has been sutured to the anterior longitudinal ligament of the sacrum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter L Rosenblatt, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_52_836=[""].join("\n");
var outline_f0_52_836=null;
var title_f0_52_837="Asthma PI";
var content_f0_52_837=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F65956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F65956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Asthma and its treatment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 600px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJYAg4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr5V+LHxL1O0+LV5qGmeITa6P4WuLS3uNLW98s6huc+fiLd+8K52ng4xmvqquXtPAPhm00LWdGh0xRp2sSyTX8bTSMZ3kxuYuWLAnA6EY7YoA4Dxv8VtR0Hxp9iuDbaJ4Ye3ilttbu9KnvobpnAJwY5IwgG4LzuOcE4Brm7jUvEN/r/x0trjW0udHs9MJW1eOR1VHtJighzLti7bjtbfjIC9vWbj4aeF7q0t7O7tb+5sIEiSOyn1W7ktgsYAQeS0pQ4CjqvXk881ZvvAHhu91jUtUmsJFvNTtjaXrQ3c0SXMRjMe2REcK3ysQCRkcEEEA0AeL/C7x7rPhzRvAnh9odOuNO1LQrq7gYRussMkKyPhjvIdTs7BSM9eOdPwt8WvFurn4fG4h0JF8WreRjZbTA2skEhXdzKd6kY+Xg/7VeoW/wAN/Clu+kPDpW1tJtpbOyP2iU+VFIrK6/e+bIZuWyRngijTvhx4U04eHhZ6V5Y8PmZtN/0iU+QZTmTq3zZP97OO2KAPONF+MWp6v4N0C5H2O38SalfXFlFZW+nPd/ajERlkBuIhGAGXJdz1/Luvgv41vPHfgsapqdpFaX0VzLaTpDnYWQjlQSccEcZPfk1LH8LPB0VhYWcGlSQRWFzJd2rw3s8csMsmN7LIrhxnAyM44HFbnhLwvo/hHS307w9Z/Y7N5mnaPzXky7YycuSew4zigDaooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKOlcj4i8XJbO1rpIWe5HDSdUQ/1P6UnJLc1o0J1pcsEdRdXUFpCZbqZIox1ZzgVzF944sYyVsYZbtvX7i/mef0rj5kuL6Y3GqXDytj+I8D6DoKlhERT9ygx61i6jex61PL6UNZvmf3InuviBqlxKyWNtbQqDt3uC5z7ciqM2r6/dk+fqk6A9osR4/75ANZsmj3cUjNaTw+WSWAlyCvtxnNPjs9QmX/j4t+PTcf6Vamu5wzw1Vydo6DpYbuUEz311Kf9ud2/maiSxlzlJpQfUSEf1qQ6dqOeJ4G/A0gsdVXlWgP/AAJh/Snzoj6rV/lLUFzrVmQbbVLxcdA0pdR+DZFbNl441a0wuoW0N4o6sn7p/wCoP5CubI1WHJa3Lj1Rgf0qE6kN225jaNvSRSv86adzKVKUfiVj1XRvFuk6phEn+zz94Z/lb8Ox/A1vggjIORXhFwIbhMjAYcqwPIra8Pa5qdnaRSQXBdBkNE/IODjj06dqTly7m1DDKvdRdn+B69RWJ4f8RWurrs/1NyBzEx6/T1rbqk09Uc9SnKlLlmrMKKKKZAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU12VEZnIVQMkk4AFOrz/xTrkmqTy6fYvsskOJZQf8AWH0Ht/OplJRR0YfDyry5Vt1YzxP4jk1ZmsdLZltOkko4MnsPb+dZEUItYwIk3P3PpUkUcdrDuA4Hr3qSOVnTeB16DFc7d3dnvQjGnDkprT8xwUFf3ik+2aYzMseEQE56Cs3V9Yg0e333jZnf7kScs3+fWuP1DxdqMiExmO0U9ABvf8zx+lS5JFxpuR6FuODuwue1Zl7run2DGO4ukDj+BcsR9QOlci1xrUWjkzXiJNctuYzTqjxp2AB6E8/pWRFZBbJrqe4SO33FSYkMjs3fHb8c1Lm+haorqzuk8W6bLMIozO7nskZ/Ony+JdISZVOoAEdQFLD8wMVwLy2UsIitrSdV/iY3IDSf7w2/pTIreDIErz26+oRZAP1FTzsv2UT0631DTtQwLe7jZuuEcZ/LrV10RkxhZFPVWFeSXVpHD+9hMt3ApGZo8IF+o5K/jWvZeJb+2hWOCOB4x0MsrO355FNT7kSpdmdm2k6dK5Jt/LI6hSVH5A1fit440Xy0UbRgADt7Vzuh+K1vrpbW8iEM7cIQ25W9vY10bOyMu1SVbuO1aKVzH2XI9FYryxrJLuti0c6cjHB/Cuu8L+J/OZbLVWCXPRJD0f6+9c4SFwxGffuKhubYXCbk+91BFOLcdUTVpwrR5J/f2PWKK5Hwbr7XGNOvzi5QYRz/AMtAP6111dMZcyueDXoyoz5JBRRRTMQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKgvrqOys5rmc4jiUs1A0m3ZHM+O9Ze1hTTrNiLicZdh1VP8TXJRwNGkccZAUcufU0xJJb++mvrn/WTMWA9B2H4DirLltqqi5Zj+Qrmk+Z3Po6VJUIKmt+vr/wB2N4y2MDgZqrfXhtoJTAFluFTKx7gv4nPQe9YnirXTZk2dkw+07cs+MiMf4muQlnaG0KSyMWnxLOxOWf+6pP05/EelZOdjeNO6uyC/mWS7kur+d7udjz5R2oPYMQePoPxqee6tYoIVt7VLW6I3SSli7ID0Az0OOcjpS2S2ttIt1qYMkigPFaJ+hc9h7da3vCenSXlydQltYYICSybhveQ5+8WboPpjNQlc3bSWpyTxRjbLcBkibkBuJJvpnoP9o/hmtC11HVp1ENi8qwgYWG2iyFH1xn8Sa9FOlWBleeS3t2kJy0jIGb8zVqMIyfu12oOmeKpQMnWVtjzy08O61dyiS5trYR9zcAAn8U+b9a1NQ8InYo0xLbfjnznc8+3P8812DBQuXYYPHXFCIoXaihR9arkRLqy3PN7m08QaXFtcTRwr3twpT8QB/MVmvdmeIFYbbzo+XYQJh19SMdR7dvpXrUQlG5ZGDJ29RWNeaPaTXoukgVbpA3PRZcgjDeoOfrUuHYuNVdUcJFe3DOn2byrO6AwphQKsv8Ag36H+ex4f8V3dvciHVW8yJjtMhUBkPuPSsJo7N7mSG4W50/axVl4mVD+hx+da50uzuFe3fVIWvY1BjfyypkXGQCP4uOhHP1qVfoXJRasz0MTI7BSBhhkEdCKdFGqIVXO3r9K4/wRqQ8prG4uYJQh/csr8kdxg4Ndc0gWVRkZPb1rVO6ucs4uL5SpcGTzhLFlLiEh1cd69K8O6ouraZHOMCUfLIvowrgOC+PSr3hK6Om695LtiC5G32Ddq0hKzOfF0lWpabrVfqei0UUV0HgBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV55rHxe8MaN4r1/w/qbXdve6NZ/bJXZF8uZdivsiO7LPhxwQMnNeh15zdfCjSNS8a+IPEOtGO/OozWdzbQPEV+xy28TIrbg3z53Z2kAccg0AbXhb4geHvEXh6w1eO+isIry3lu44L+WOKZYY2ZXkK7j8o2kk5IA61fuPGHhm2azW48RaNE16iyWokvolM6scKyZb5gexGc15nD8EJbXQtGsbTxGizWOk3ujyyy6fvWaK5LEsqiUbGXee7A46Vbtfg9d2dxoUuneJF0+bTbW1tJbuytporm6jhA+RyLjyirEdGibA4yaAOp8Z/EbQ/D+ia5c2eoaZqeqaVA80mmRX0Ym+UgEEDcy4yMkrWta+LtEkfTba71XTbTVL6KOWKxlu0Ezb1BAVSQzdew5riLb4VX1p4E1nwbbeILYaDfLP5TSaaWuomkfdl5RMBJjnqgJ454qlP8ABKFvEE2orqyTwXElpNNbXcdyy+bAgVXTyrmNe2RvV9vbjIIB6lreu6RoMCTa5qlhpsLnakl5cJCrH0BYjJquvirw82o22nrr2km/ukWSC2F5H5sqsMqVXOWBHII6isbxd4OudX8VaH4j0rU4bHVNKjmijF1am5gdJQA2UDoQ3H3gw981y9/8IJb/AFS6muNeQWN9qlvrF5CliRK1xEuMRymQ7IyedpViBwGoA9AtPFfh281EafZ69pNxfkuotoryN5CUzuG0HORg59MVz3ij4seDvD+iXOpHW7HUkt5Y4Xg067hmlDO2B8u8dMEnnopPauch+DIiGnn+2YZHtNYvNWAlsdyyfaF2+UwEgOBxk559BVc/BS4k8K6xoUniiWKxu1gFpaQQSm1smikEm5I5p5G+YjkB1HPSgD0Obxv4ZVH8jXtIuZxF5yW8V/B5ko2F127nA5UEgkgYGc4yaB428OxWGm3OpazpmmnUIVmt4ru/gVnU4+6Vcq/XGUZh6E1y4+FkN34j8S69rV1p97qmsWMdpHKNNC/YnWFomki3OzDcDnAI6Yyai8K/DC98J6pY6hoevWxuE0u30u7F7pxmWVIcANHtlUxEgcglh37UAaPh/wCK/hzxBpn23SpfNA1BdOeJ7q2jkRmYqkhDSgFG2nbglmx8qnmunh8UaBPqFzYQ65pUl9ahmnt0u4zJCF+8XUHK4756VwFv8JJ4dIGkjXozp8Wvx67bg2J81SJC7RM3mYYHIAYKuMHg54raZ8FhZvp0La+ZNO0s37WEYtNswN0rBvOl8z96F3cYVc96APSdH8TaDrdw8Gi63peozogkaO0u45WVD0YhSSByOfetevNfBHwuHhfXtA1P+1xdHStDOjbPsuzzf3pk8zO846424PrmuhfwLpLuzG78R5Jzx4i1AD8hPxQB1NFcr/wgekf8/niT/wAKPUf/AI/R/wAIHpH/AD+eJP8Awo9R/wDj9AHVVyHxGvNtjb2KH5rh9zY/ur/9cj8ql/4QPSP+fzxJ/wCFHqP/AMfrzzxD4X02XxNcRJda60UACDfrl65zjJ5MpPUmoqOyO3AQcq3N/Lqa9tGVPJAUABRTp5RDFLK2AEUkn0ArnYfCumSjIudcxux/yG73/wCO1T1vwtp9to1/KtxrZby2xnWbwjp6ebz+NYaHsPnb1X9fcc2iy6leKpz515Nlj/dBP8gP5Vea0jibUL+5wXibNvbsOACSqM3txnHtXOWvh9IdRtYVuNUhneRVdl1O5BRT1HEnp1/LtXQWlpNrV3fRwylTKqMDIxYhQwAyTySF9etYaHUnLroM0HTH1m/2tuNtEd88p/jPpn1NekLCDCI0XbGBjjgY9Kr2GnwWNtFa24KQxjJ9XPqfc1ePzct07DPFaRjYxnO70IztCqo6DtSsRtx0VRk0yaIlwyNhR1AokUSIUz1IqiNCG8ljiiDuhdycKoqG1u2uHFvPG8DOuUzVmBBceILaLaWSFd+FODntjAJznB4/TrVjxzb/AGLWbWRBthQBFAHCgAH+p9+vqM1y+7zAqsfaxoW1avf8vyGRBkj+ZsleM0RyhmKjt0z2pqsTJIGGFI4PrSoAOcA+461I35nKeMtGZydStE3MoxPGBywH8X1H8q43C3FsHDHNu4UMOu1skfkR/wCPV665cXAPWNhzXHeLLSy0mFnjtwq3sgSbGeBgnco7HOD+FZyj1N6c+hyVxH5kgnLbJwwEhHGSejj6459/rXoPhLUW1WwZbvm6tTtZv7w7H/PpXDLGhu0gu2VAyFWkHIIxlXHtkA1r+BZmh16eKQgboPmweCQRgj65/Wpi7MqorxO+KuLhCD8hHNMvAxQSIcSRkMPYjvUsQIUhznBOD7VHvR5dgkXfjDJnn61scydmel6NerqGmW9yvWRASPQ9xV2uQ+Hdxm0u7QnPlSblHoD/APXBrr66Yu6ufP4mn7KrKK2CiiiqMAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACivmHWfiX8SLdfiGNNVrmzs9TvLay1AW0ZTTEtT5jrJhcHdGyqhfOWBrsbj40z6L4avpr3Sf7Qu9L0PTdSll+0iL7S9wY1YYEZCYL54z6YFAHttFec6R8Rb7WrnxHJpeiWx0zQZZILqa51AxztIke87IhEwK5wAxZc8kDjFYVl8abi9Fitl4Uury4u/Dx11Le1ufMkJ84xeSq7Bu6btw56gKT1APY6K4zwF44TxNoep6hc28VvNp0rRXNpam4nmiZVDMjRvBHJv6jaqNnHBJ4qz/AMJ5pH/Pn4k/8JzUf/jFAHVUVyv/AAnmkf8APn4k/wDCc1H/AOMUf8J5pH/Pn4k/8JzUf/jFAHVV4/az/adRvLjPMsjPn6nNdhd+PdJW0nZbTxGCEYjPh3UAOnqYK8r0rxRp0almg1nk440a8P8AKKsqvQ9bLeVRm2+x2CFSrhOq8fjWXq2qRWBt7Zv3kzgkL/sqCST+VVI/Fumxk/6NrYyef+JJe/8AxquA1jxRa3HiW4mMWp7RHJEgOm3II/dsBwY8jk1hK6R6MJQb1Zo2zl7ueZ+XS3dyf9p/lz/49W94GiAu7+dvuxqqD9Sf6Vxllrtn9h1GQw6pk+Uq40y5IwGycny8DoOtdL4M8RWEGlzvLb6wTLKWymj3bjHA6iIjsaiMXc0qVYW3O93Fo2ZeretQXUq28G65zyMcVhv4tsFjzHa62T76Lef/ABqmah4l029gAEGtrIvK/wDEkvf/AI1WjTMoThzLmehsW99ZqNrGSPPI3CpZLm3TMn2hWXHCjvWRafEHTFdItb0jVHhGBldGu8nG3s0fT5QOMd+K17DUvCdwyyw22uu6hWIHh7UHA46kCLHJyfTgds1ag3szGpi4U3+8i/k00/mbHgSwuJb9tQkzGJh8oK5DICM/qAPbHTkGtjx9pL31kZYkUyRjcCMZyO3Tvnjnr2OazdN+IXhaGykGnSahIiEgrLZTwnd6YkVfpn8znNY/iLxHrdzbpMs6WttINyxxIrY7jLMDz9MVFTEU6UbN39DzvaVatb26Vrbf5GfBqyR24S4jbcoAJx+FTWV7azErDnceRk1xUt/d6u8kU6LdhWwJpcBFHoFHB/Cug8LaN9iZp2yqk7jxtBOMcD0rKFRzei0Pag+eLk42Xr/wDoBJ5kO9R3waxPGVsbzw+ZFXLwkSgey9f0JrfTDxnbgLnApjBJAYXAYFOh7itWrkxdndHl0TwPo99DMgd4E8y2fPKhyFYfT5s496pNclNLhijG24jmP7wdQi4ZR9NzE1o6hpi297q9tayblgh3CN+GC7kfj1GPx9qyZgvl+YOVLMD7ZUY/kfyrBnaj1zTroXVnC/AMsSyY9MjNc1a2puIHuNxW43l94PIOa3fDqgaHYsR84t0H6VS09Akl3H2WR8D2zmuukeFmKtZo6L4ZX7S6zLFLxKYirgdCQcg/jzXp9eOeCmMHjmyx0mV0P4KSP5GvY61irHn16jqtSe9goooqjAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKqapqVjpFk95qt7bWNnHjfPcyrFGuTgZZiAKbperabq6SvpWoWd8kT+XI1tMsoRsA4O0nBwQcehFAF2iiigDOXQ9JW1v7VdLsBbag7y3kQt0CXLuMO0gxhyw6k5z3qnf+D/AAzqJi/tDw7o115UK28fn2MT7Il6IMrwo7DpW7RQBkSeGNAk1dNVk0TS31RAAl41pGZlAGBh8bhxx16VTXwJ4RSOVF8K6CqSp5cijToQHXcG2kbeRuAbHqAa6OigCjo+kaboln9k0bT7PT7TcX8m0gWJNx6naoAzV6iigAooooAq6qM6XeAdfJf/ANBNeT6OqvAARnDZr1+ZBJDJGejKV/MV49o3yRyB+CvBz2rGr0PYyx/u5r0/U02ZMpv4LHArzLWYvK8RSmfhRdBm/wBxj/ga9KAV9mf4TXMeNtNS4RJoiPtO0jZ3kUckD3HX86wmro9Kk0nY5Ta9hDFBOdqvcyxyntjaqZ/DJNehaFavaaBb27Da6oNw9CeT+prhdUkF/pGmyHG8wyKx9WUgZ+vSu40G9+1aBbXAO5igDf7w4P6iphuXUu0jSHyxhCcscEUk+4wBosbweR6054w0gf0xio2dhKUCnA5zWhihtxEskB84AoR37VW0rxM1hpZ0+Hzp7ydXijjEwCRq2PnI5wck/wCeRl+Itcjt18kMWYgjavVvYeg965LTTfPdSXtsisZCSS5wD2AX1A4Gaxq1HHSG4q1Pnpqk1d3vbsa+uXE+m6eLV4CIc5yo6H3p809zLoqkuD8vA3d8VDNqUl4rWN9B5UrqSuTkMB6GqWlWc11FgTShQxVFUcnFedGnKT5bamCpOTdOG5o+Fb2FI4kkAMkI2OpHIP8Aex3z612dtL9oUsjB07Y/wrhNQ0+4UDzIVmkH3ZOYpV+hHBrY8IG/QN9q/wBZz0wfpnHevRpyl8MlY7eWUo2krNLfodMzbE+VfYAUFQJUfHzBcUqBgoMn3iDmmJ5nnbjgRgdfetjI4LWJhD4z85f4Zoo29wygEfkazNIsob+xuY3lEM0xVI0x8ok5KEHsCAy4/wDrCrJH2/xHdDcoxcvIWJwMKcKPxOB+NZMJYWc8iHGPLAI7H5iD+hrB7nWtrHrdrAbdLaFP9UkYX8hisqDi9vSP7/8AQVr2k3nWsMnTdEG/MViWLb2upOzStj6ZxXXT3PFzB+4l5lzw0dvjDSiOvnEfmjCvZq8b8LIZPGelKP8Ano7H8I2NeyVsjyGFFFFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXzPbw6z4dsvilqXgjw7qVhrc2owvpciaDIrSWxljWQRh4sEcsSuPVscZr6YooA+c/G9j441vVV0q8k126sNP8X6ebS7XTow32ZkZmmJWLYyxsB82No3Hdu4Asxv4q8OP4sGl6f4ijn1HxTK0d3bWw2+UYUAlfNtOTGSOscfUYyO/0HRQB842fiP4tX+hW0k661Y3sfhy6upBHo6Zlvo7l1jUh4jhnjCnYMZByAM5q7rXiP4pWmieITZRavPef2Zpl3ZsNJVmiuJHT7RCiiPDBQWyrBmUDk8Zr6BooA8MudW+JFjrtysU2s3lla+JbWzjEmmREXFhIpMjsyRD5VIA3rgDPOeMZA1v4ieItbvNLNl4kttF1Cy1CB476yj3wSLG3lfvBaxxqHOFHzyZB+8DX0VRQB84eDYPFmmaV4HXStJv7q+stG1CNxqmkLEba5WFPKgErRKyoW6Hd8+SCxxw++8T/FNPDmrS6Smu3cyaXZyiW60VY54b9p0WaGGPyl8yMRlzu2vjH3u9fRlFAHC/Du68St4h8X6f4ikvLmwsryNdNu7q1WEzRMmWAZEVXAPGQPqa0XvvGwdgnh/w4VzwTrs4JH0+x11NFAHK/bvHH/QveG//AAfT/wDyHR9u8cf9C94b/wDB9P8A/IddVRQByv27xx/0L3hv/wAH0/8A8h15bM3iiLWdQtm0bRQwkYlf7WlwOc8H7Nz+Qr3yvN/GFv8AZfFnnAYW4iV8+4+U/wAh+dZ1FoellsvflG9rr8jkJL3xVEYz/Yui84HGrSn/ANtqxfHD+J5LKCZtL0iAwzBg8WqSuQene3Hciu+6qBn3FV9Ztftmn3MOAWZTgf7XUH88Vg9UenFNNO/5f5Hk7ajrF3pwK6VpUbwzHzQNQkGS45IXyMAEr69a2/A174iXTJ7eHS9HkUTN/rNTkQjgdhbnj/GqFr5a6gizZSK5HkS5/hJPB/BgD+FWLK7m0Zi7qRJb3ZWZB/ErLyP/AB3IrJS1vY6JU21a7/D/ACO70q41eR3GrWOn2sYA2G2vXnJIPQhokx+Zq9Ohe2lCHDkHFNVluLVJbdwUkUMrDvUiFljXcDuHcVqYJcpw6aZdzXlzC/8AqZnUuu07mA6KT2XPOB1rqrbTra1hVZNpcjABHH4VcTzS5yE68HNOaNDIGYbiO9TGKWxo5pX5dL7nLeJtI2rG8GA6nfET0BHb6Gs3wveY1FwRgs3mFcY2k8MMduea7S5j88PDIP3Y5U9xWdbaBHDeNcjblsFjjBbHSpdP31NFJxbU5PXr5msMyJsmRGHbI7UyNPIcjcuD0UACly2/n7mKkKoo3thT0GetaGV7aCSs5HyqCx6D0rG8Y6kdP0lo0P8ApEwKJjtxyfwH64rV1C+h06xkuLk7UUbie/sB7mvNb29k1m7e4uXEcOcFiflhT09z+pNTJ2Vi6cbu/QrayynUJDaqI0jdeF/ik6lj75z9KnTTpvtceloD5zuzEY+4pOAT9FGf+BVDBJGt7NcyoXihmZlT/npJklV/qfYe9dT4Jnuru9v7m6MYViBhUC5bqeepwMdfWs0rs3k3FHSXT/Y7eTYuI4YflJ9hwKoaXDs01B/ERU3iB93lWan5pWBf/dH/ANfFPkPkW/TgCuymtLnz2Oqc01HsaPw7tTP4tmmPKWsBOf8AaY4H6Bq9Trj/AIZae1tokl5MMS3snmD12Dhf6n8a7CtTgYUUUUCCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKr317bWFq9ze3EVvboMtJK4VR+JoAsUZAryLxT8cNH01mh0a1l1GUHHmOfKj/DgsfyH1rgdR+OviW4JFla2FqvbEZdvzJ/pWbqxRqqMmfTdFfKY+MfjXHN3b4P8Aet0/woi+Mfi6Jtz3lvIf+uY//VU+3iV7CR9WUV89+G/j3dLcpH4g06OW3OAZbY7XX3weD+le7aNqtlrOmQahps6z2ky7kccce47EdMGtIzUtjOUHHcvUUgIPQ5FLVEBRRRQAUUUUAFFFFABRRTJ5Y4IZJp5EjijUu7uwCqoGSST0AoAfRWboevaPr8Mk2harp+pxRtsd7O5SZVbGcEqTg4rSoAKKyv8AhI9D8nzf7Z03yvtX2Hf9qTb9ozjyc5/1n+x19qXQNe03xBBdTaRc/aI7W5ks5j5bJtljOHX5gM4PccehoA1KKKKACiiigArkviNab9Ot71QS1tJgn0VuP5gV1tQX1tHe2c1tMMxyoVP496UldWNsPV9lUjPseVhvOhUo2CDn61POXfZJGcEEbq5/WdPlh1cafdk/uiwHOATxg/iDkVLb3M2myrDdMZLVuFkbqn19R79qw5Ha57E8VCNXke3R+pj+NtFUSm6t2VWlbDRk43NjqPfjp3qleSJfSJFdDyLu4tkKFxtDyKSMHPQ5DDnsw9Oeq8S2S6ppklqD++I3x5/vDp/h+NefqW1C2jtLtyLyDKxGQ43jvGSehB6Z+lc8tGejT1jqbHh3xA+kObO+DfZNxAOPmiPcEeld1bXQlCtGQ8LjKuvINeXfapI5PL1CzhuinysJQY5eOxYdfxzVy11y70+NjpKwi0zloXU5jPvz09x+lEZWCdPm1R6USScLgGkTeF+dsH2NcbaeNXUj+0LFgp/jhO4fkf8AGtq08QaVfOohuyr/APPNgVJ9uev4VopJmLpyRtAgg7iAB3qOOIebuMrMvoBXOX/jKxgkeBLW5mlU4KlNmPrnn9Kof8JpdLnyNMSNfVpsn+VLnQKnM7IljKAEwndjVPU9Us7Bd95Iqkn5E6s30FcdceKtQvYmVIvs0YOHuEkAC+2Sp59hz6VhypC0jSx/a5WPWWeQDcfpjP60nPsaRpdza1/xAmozQo9qot423sZSWIHc7QcZ7DOetZUm7VboKFVQclY0GEgj7n04HU0tncyRIu+KAWZfJiEIYzsO2Wycep7fWr1hHf6zqBtrNhZ255mFsojVF9CR1P1qNzS3KtCrawzazqMp063Ii3NszwsYJyST6nr/APqr0LStOg0qxjQHIiBZnPG492NWY7YwwxQWwwiAAEnPAqn4i8w6cypkrkeZt67e9awhZnNWq+62uhSs993ey3r52McJkdFHT/H8a0rS0fW9Vg02IkKx3zMP4Yx1/Pp+NYy6kPIWGzXzHxj5eg+tep+BdAOkWDT3Qzf3OGkJH3R2WupdkfPSUmnUkdLFGsUaRxqFRAFUDsBTqKKowCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK85+KXxLs/CcEljYlLjWnX5Y+qw5/if39FpSkoq7HGLk7Is/Er4h2nhSE2tqEutWcZWIn5Yh/ef/DqfavnTxJ4n1jxPch7+8kuCv3c4CJ/uqOB9azJ7q51a7muLud5JJWLyyMcl2J5pfNjiHlxKWPov9a4KlVyZ6FOkoIjisEJy3zHuxpZjb26n5st6AVHMLubgDavpmgaeVTfcOAPSsvVmnoU2k858JHkf570kgwQpAz7VYlkAHl26496fbW2F3uMj1Pf6VVxWK5gAjyw5xmljubpYEhjnlEY5CByAD9KmkUyyiNe/X6VXdSM9iP0pphY19K8W67o7o9nqE6bDkHOce3Pb2r2r4d/GmG/lisPFSx28zYVLxOI2P8Atj+H69PpXglqRMwilwJT91uzfWkuLRosvFkY+8tONWUGTKlGaPuZWDKGUgqRkEd6WvnD4LfE3+x3j0TX5mOmyMFt53Ofs7f3T/sH9Pp0+jlYMMqQQe4ruhNTV0cE4ODsxaKKKsgKKKKACuJ+MvhnUPF/w71TR9HkjW8l8uRY5WKpMEkVzGxHQMFx/PjNdtRQB5X4s/4SjVPD6nRPBM+m3fnW0Mo/tJIZxCofcUNtcR71TICo0yZ3HgY55Dw34K+JWoXPhuz8Taz4jsNPtzei8ubTVUWVl3AwbvnctnBH8RA4JHWvoOigD580HwJ4w0C11Cz0q01eCeTxYl+bqPV8wz6eZMt8pmzux9/coZuMlsYCT+EvHthol5YaXpVxGbzXNTu2ubXU2ilhjkIMLhI7mFXBP95iVxnYeh+hKKAPlPx3qHjTw/o1qnirWr+LUz4eWK1trLW0huEvvOx5kkSTK8+QMAqJB6jgmuus/DvxNk8X2V7e6jrIsVms5ontZFeMQhAJIZonuoh1J3N5UjE8hu1e/UUAY+uW+vzSxHQtT0uzjCnzFvNOkuSx7EFZ48D2wazfsPjj/oYfDf8A4IZ//kyuqooA5X7D44/6GHw3/wCCGf8A+TKPsPjj/oYfDf8A4IZ//kyuqooA8l8feGfGM0A1T+2dCmmtwNyw6NLGSozzzdNnr+X0rH0L7Xe2LrrFzZ3MjfcNvatCAPQhpHyfyr3IjPB6V5n4s8LT6Xdy6npKF7NsvNAvWL1ZR3Ht2pWNebmik91+RzsbyaZIElDSWo6HGTH/AIis7xJoH2thqGlKkqyDMkYP3j6g+tbccqXsQwwNUWS5sZ2ltCMH78Z+63+B96ynTUjtw2NlStGWxxq3bWcyQ6jAbi3Q4MM6/Og/2T1H8qkmvbex1DdaaTbncuY5PNkIkQ+xOPYj1ruo72zv18m4iTzMcwyqOT7dj+FQT6Dp15Z+QIWtwH3qU4Kt3x/hXO4NHswrQmuZbHEW9xptzcBLuKfTt38UTbo/xBGR+FLqdtZWU2J7a/nU8o7OiI49QQDkfjWve+E7tQRHc20qesgKn9Aa0tD0bUbCznja7t5Y3U7IWQuit65ODj2xU8r6mnOt0c5da3bXkUaXGlI/lqFV2nO8D/e6mqKSxybnh0+Ly1+9LPI7In15A/Dk1cvdM1nzz51gg54NtAmPzAz+dSQab4ilQpEt+E6bZJdq/kTS1LukVtTvbG8aHZFdSCFQoKukKe5VdpxmqS+Zc3EdvZQKZZCAu9jIR/JcfhXW6J4XlScSau1owx/qFiUk/VsfyrqrKws7P5ra1hiJ4LKgGfy601BvciVVR2OKTw5ql3e4uGEMMYESSOwZio7gDpk5OOMZrstNsLfTLMQWq4X+Jj1c+pNTnZOxAPCnk08vHkBjz2FaKKRjObkNjWQR/M3J7D0qJn8iJnmIBPQe1PubtYVJPXtW14Z8NSXsq32roVhHzRwN1b3b29u/86Sb0RnOpGlHnqaL8/QXwZoBuZU1TUExGDut4iOp/vH+n513lAGBgdKK6Ix5VY8HEYiVefNL5LsFFFFUYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZ3iPUo9H0K+1CVlVbeJn+Y4GccD88V8W6rezatqlzeXErSzXErOzt1OT1r2r9pTxM6Gz8PW0mEZftF0FP3ucIp/U/lXh1mhZd3TPA9hXJXld2OyhGyv3LlvGWHlodsY6kdSa0oLNIk5wBUMOyCMEjp0UdzQfMuW/eE7eyjpXG3c6kLPcop2wIXYdwOBVKRJ5jl+fqa0ysVunIBb0FVy7ynJ+VPQd6EwILa0B+aU/IPwBqO/vAp2JjOOg7U++uSF8uPg46VnQQtLLgZZiapK+rE32Nzw1p0l2l9PgkRQtz7ngD+dYrHMsvoTXs3hrQl03w+IGX97Ku6Q+57V5NrlmbHV7iEjAJyv0pRmpNlyjZIoxqWOwfeHzKa2bKVblMvxIvB96yl+XY46qa0tghKXMX3WGXH1pz1IRSv7YW9yAPuPyPY19KfAjxQdb8NNp102bzTdseSeXiP3T+GCPwHrXzpdEOZInOf4kNdD8KNdl0Hxtp86sRBO32e4U9Cjev0IB/CtaM+Voxqx5kfXFFAor0DgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4jxL4LEkj3uhbYZz8z2xOEc+q/3T+h9utcalx5czW97E8Nwhw0cgwwr2ms3WNE07WFUahapKyjCvyrr9GHNA7nll1YW11GNoGetVo/t9hna32qIfwyH5h9G/xrqdT8CXtqWk0W981OohuOG+gYcH8QK5e9l1PTcrqOn3EX+1typ/EVLSe5rTlOLvA0bPULa9UqFKyj70bcMKuImMeUB9K4u8vIbsqYVfzx90oCGBrqdPlYWkQupP32wbiD3xzWMopHq4atKqmmtiy4l8z7i7fenSFSvzYGPeohJ8xLSpt7c1FLPCMhnQioOtRbJkSPfvVQWx1zT1lQybMbn64HSqa30fCRLuPQBVzWhaaXrF9/x72TQIf45hsH68/pTSvsE1y6zdvUjkCryxVB6CqsRlvbrydOt2nmP90cD3J7V1mn+C4sh9VuXuG/55x/Kn59T+ldRZWdvYwiG0hSGMfwqMfn61apt7nHUx9OnpD3n+H+Zznh/wAJx2cq3WpOtxdDlUx8iH+p966qiitkktjyqtadaXNNhRRRTMgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD45+Lt79t8f60+7dsnaMH2UkD9OK56OYRRInfGTU/jBnk8Vam8gw7XDFh7k5P86zGbJJ7ngVwS1Z6MdEalmWuJOT/9YVoy3CQIVQjPrWNAyxRhS7gnripYpIlOViLN6s2axa1NEy3Gd5Mj/d96bcXBPyRfePGaQiWcAHCLTmCWykJ80nqe1SMp3A8oBM5kPWuo+H+iG/1SN2XMEJDufU9h/WucsLWW/vkiiUs7H/JNe5eFdITS9NjiUfORlz6mipLlVupUI3dzV8rKdK8p+KGmGOdLuNeB1r2FEytc34u01b7T5UIycHFc9OXLK5rJXVjw+3USJitKxXIkt3/u8e4/yazI1a2uGRv4WKn25rWciMxTjovDfSuiW9jHoZ97CywhhndF8p+n/wCrFQ6XKqatZvJ/qxKrN9Mita5wZWBPDjIrEt4mOopCB1kAX8TWkHdGckfcFirrZQLK26QRruPqccmp6ZCu2FFByAoGafXpo8wKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKQgEEHkGlooAzrnQ9MuSTNY25Y9SECn8xVF/CGisci1ZfpK/+Nb9FKyZrGvVj8Mmvmc6vg3RR962kb6zP/jVqDwzo0Bymnwn/AHwX/nmtiijlXYbxNZ7zf3sjgghgTbBFHEvoihR+lSUUUzFu+4UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABQelFFAHxp8V7cWvxF15FGF+0lgPYgGuVXl/YV6r+0NoxsvGy3ScrewLIfZgSp/kPzryyPaD89cM9Gz0IO8UTRSHuG49KuRXcajChyfULiqJkUgLn5f7qjApNzNwnyis2rl3NB7r+7lc/mafBBNdSrFBGWkboBzWp4a8I32pMsgi2QnkySf0HevV/D3hm10pB5a75T96RuprKU1HY0jFvczfA3hVdNtxNcKGuH5JPau5SIKKdGgRcdKduXsa53du7NL20QDAFUL5Q2c9DVxyQPQVQu5Rg+tKxcXc8U8Y2H2HxDOAuI5v3i/1/WqMJbyjG3KHp7e1eg+OtN+3aabiMfvrbL/Vf4h+X8q89iJRMZyvUH2reL5kZTjyshViy+Ux+eP7p9RVnwxbJeeIre3nwPM3Lu9GxlT/AN9AVWuk8xhJHwy+la3gRWm8b6OpXJacDGOtbQ3MpaI+wk4VR7UtIowABS16Z5YUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeHfFC4t9Y1OZdShaaO2le3gjXgrg4Y+5JGefavL7rwpG72/2S5DRyyCPLLypJ71698UdNNjrRuFB8u5K3CntuGFcf+gn8TXl8fnQ6ikjOxWS5QOpPpIMEV5VRyU3dnq0+VwVkRXHw+eCPf8AbBJz0CY/rSweHraxUStdIroeWdAyj654FenMiSx4YAg1x/iHwauo2k0cTJIztu/esVYAggqD0A59uneopS9o7TlY0qR5FeMblSw17VFcfYdQsr1F6xKF6f8AAen513Gia1JfWoae3aCUHDKTkfUHuK4rwh4HTR7M2zWttHH5YQF5TI27OS/H8X0wBXW2Vv8AYo1hMzTHJ+dhg/zP50V4wg7QlcKLnP41Y22uWAqrPqX2dWOCxA6DrUs42wg+1c5IHu3nVWAYghS3QHtXOjZK5Q1LX9VlcussNrCp53fNj6kVWt5tQujubWly33R5Zx+HSm6x4Pa/0lo2VJ7vd/rRNztwRgZAC9c8DtWT4S8AXWlWYg824tyDkySzBwTk87Rn2GPbqK7VRg4cymrnL7SalblZ29ss/lBLl4plK4LqMZ+orznXtIfSbqYKC1oTuX/ZB6f4f/rr0yODyECgk4HU96yfEoQ6Ncs65YLhfxOMVywlZnXOF4nB6XBu+f7M07D1AwBXsnwm8OaVfkXptlSezlSaJ144dfun6Fc/ia8u0U3EDiAnfE0bOU9D2/UivfvhRpjWHhvzXXDXD5H+4oCj9QT+NdlBXqHDiHy0ztaKKK9E80KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooqO4nit4jLcSJHGOrOcAUAlfRElFcpfeLQzNFpFu1w3TzXBVB+HU/pWJcTajqGVv75ih/5ZRnav6dfxqeY64YST1m7fn9x1+r+I9K0oH7Xdp5naKP53P4D+tcvc/EMlv8AQdKdk7NNKEP5AH+dctrejzxXMc9jb+agTayqfmBz15qkg1EDA06fj1XFO5lUpcsrR2Oom8eayx/c2dkg/wBtXb/2YVGvjnXgfmh08j/ri/8A8XXPGTUF+9YXA+iZ/lUTai8f+uhkjPpJGV/nRcjltujr4viFfJt8/TIJPUxylP5g1uab480i6YJdGWxkP/Pdfl/76GR+eK81jv4Zf7p+lTMsEo4wDQKx7dFIk0ayROrxsMqynII9jTq8SsbrUdHcvpV08IJyYxyjfVTx+PWu/wDCvjO21X/RtQC2l+vUE/JJ7qT0+h/WncXK3sddRQOaKBBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzPxC0waj4cmZU3y2375QByQOGH/fJbj1xXzzrUZt9SiTrhDOD6kKef0zX1YRkYPSvFfiJ4eg0qW4Uxr5MsEhtJMfcyDmP8OMe30NcWKhb30duFqfYZNaqHAq6sK46VlaDOLiytpMg74lbP4VuoBivNsem2Z9ymxSazYP3lyBV/WJ1iiYk4wKpaSQ5WTHDdM0ND6XNnUIttmuPSuZsFxcOD612N+qizU7gc1xdzL5F+hz8rNjNU1rYik9Do4rcFRT/IAqO1m+QVZZwVzU2Ke5m3sYQcVyfissulgL3lBP0AJ/pXV38nGK5+78i51OOzusGFYWkcE9ckAf1px0ZUvhKfg7RptUvbVACGupMKf7qDv/ADP4Cvo+2hjtraKCFQkUShEUdgOAK5H4faAtharfSxhJZYwsSYx5cfYfU8E/gPWuyr1sNTcY3e7PGxNTnlZbIKKKK6DmCiiigAooooAKKKKACiiigAooooAKKKKACiiigAoprsqKzOQqgZJJwAK4vWdfm1JpLbTiYrP7rTfxSD29BSbsa0qMqr027mrrHiWK3drfTlFzdjg/3E+p7/QVyd6JJ5vtOr3DTSfwr/CvsAKdZqY38u2hAjAwWPUmrkgC7dyruHaobuejCMaOkfv6/wDAGQrvhAjBVcdAMUkFnFC+7JZz15pjzyje87pFAoJPOAB6k1y2seOIoXNvpMSyN086TIB+ij5m/CpclHcuEJzdonYmc8qmFx7VWjlm8x2uNuwdOa8yuNRvrx86nqUqA8eTADk+2Mrj/gXNULiKNWJVZIjnpPNk/iqgMP1rN1vI6I4To2eqvrWlbyn26zDjqDcLkfrRbXlvJKdt3BKnojgmvKVu3RlV0jmx0WQPIv5M39KjklhkY7rZEJP3SAq/hyv8zS9sX9TXc9eu9L068yZYELn+Irg/99DmsK68PJG+LO7aNu0cvzA/Q9f51xcC3ltAs1ncGEE8CG7VV+mMkE+2TW7p/iieB1j1Fllccr58fkufoQSp/Hb9apVe5zzwKfmWpbbULMEzWzuv96L5x+Q5/Sqdu0lzqNsLeKRpBIuflOAuec+2M12en6zY6gxjilUTDrGw2uPqp5q4Zool/erxn7wrVSucLw7jIl02/vdHYBN1xZ94mPK/7p7fTpXYaZqNtqUHm2r5AOGUjDKfQiuL5VhJFJviYcqeRUSPJDN9r02Ty7hOGXsw9CPSmnY0qUo1dXo+/wDmei0Vl6DrEWqwHA8u5j4liJ5U+o9RWpVnnzg4PlluFFFFBIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVTU9Os9TtTbahbQ3MBOdkqBhn1571booDY8F8Oo1pDJZScSWc0lsw9NjED9MVvyThI+tQ+NrFtI8dyyAbbXVoxMh7ecgw4/FdpqjMWdMCvEqx5JtHu0ZKpBSKl8730jwocAggn0pEsNULqYprby1GCoVsn3zmrEapaQyTTEhVBZiBnArPfxrp0A227NIx/iZSqj9KhXk9DWV3sWd9/JL9nJO4cc9KrLo14Zg93e+YqNuEaxhQD9etVG8W26yGYPbFyc7hJx+VOg8aafMcS71b+8qMyn8QKbUlshcrN6ylKHY/UVoPLhKzrd4rqFJos7GGQSpB/WnzZC4BqLjIJ5N8hyeBya6v4ZeHbG/wBJ/trUrKGa4up2lt3lQEpEMKmM+u0t/wACriZ4Jb+6tdItc/adQfyuOqR/xv8Agua94sraKztILa3QJDCgjRR2UDAFd+Dp3bmzgx1WyUETAYooor0TzAooooAKKKKACiiigAooooAKKKKACiiigAooooAKQkAEkgAckmq+p3sWm6fcXtyJWhgQyOIYmlcgf3VUEsfYCvNLjUPEGuaozXzyaZZshQaUu0siEggzuM5kOB8qnaoOCWJOE3Y0pU3UlY2da1STXbprW0YjTYzhmHHnH/4mqsjJCgit497jj0Ap8BjGbW2HC/ebtRLNFAQvXJxx1aoPSVlaMVoun6sejts4wG7msXVNWh0sGa+mwTxHCnLP+FM8S+IItPg2RkG8YfJEBkj3P+fwNeeTrdPcT3FzORIRmRhKof6FieOP4QP+Aisp1LaI6aFDm1lsbGsarqGqyLDKgtYD8ywbgrsPUlsfnxj0NZNvEz3H2ezgadzwY7XuP9qQjP1wAp9a3PD/AIZkvESS8VrezOGEa/K0nue/58+ld7Z2ttYW6x20KIo6KowPr7mojBy1ZrOvCl7sVc5LR/Csh/eX6RW6H/lhbM2cejPnJ+la8fhrTo5FK2MPl+jktn8Ca1sTPLuZht7DFVr65tLeUG6uGEg52LzWqhFHP7SpOVk/uGSaTZNGYpLS3MXZAgAqivh7SZXK/YAmPRmUfoatLrlluIDOO3K1dt7qK8TNvJG5xnHQ0+VMTVWC1ujm9R8D2z7pLGWW2fGME70Psc8/r+FcrdaNqGnboruJvIP/AC1UeZET6sMHB9yPy616jH56uQ6FfQg8Gi5SbAZAM+nY1LpJ7FwxE46Sdzy6M28ZSC6ieBwPlAJIQdQ0bcnHt8w7jvjc0rxHcWTeRqTfa7PgeaOWUdj7j+fqelbniPQ11ezyu1bhRxu+6T6HuPqP1HFcI0E1u8kcm5LiEkyRtyw/2x2YY+8O45x6ZtODOiMoVlqerWpt5rVJLGZZIWGRtqRIUVjIvI74615toWqNpl0HgPySH99ahuDx9+Mnv/snntzxjvo7gXlvFdWT7gRkHsfr6VrCakcdWi4PfRj50ktrhL2xfbOnQjow9D7V3GjalFqlks8Xyt92RCeUbuK4ibzPKJiIDHt2pdOvW0i+S7Kt5EmEnUenrj1FaJ2MalL2sLdVt/keiUU2N1kjV42DIwDKR0INOqzywooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDnPHnh0eJdBa2icRXsLie1l/uSr0z7HJB+teS6RqP2tZUmjMN5buYrmBusbg4I+le+18u+Io5h4r17UbF2il/tGdVcdCA/QjuK4cZBNJ9TvwVRpuPQ7xcMvsax77RYGcy25EUncYyD+FVfD/AIgivx5M4EF6v3oyeG919a6K3lQvhgM+9ebrFnpxlbWJyEujTSSZ8i3z/e2//WrQ0/QolkD3UnmEdIwuF/8Ar11wkjx2qrdSxDOMZ9qpyY/ayehA2FXA4Aqjf3kNnayXN04SJB+fsKj1TUYLKDzbp9qdlHLMfQCuH1S7uNbuVeZDHAn+rhznB9T6mlCF9yJS5fU9t+EejM1k3iS+CG61BB9nQc+TB2GfU9T+Fei1xvwfuRc/DvSOfmjRoWHoVdl/pXZV7lNKMUkeHVk5TbYUUUVZmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFY/ifXF0OyjdLS5vry4k8m1tLZMvNIQTjPRFABJZiAACTVHxL4iuLa+TRfD9qt9r0yCTa+RBaRnIEs7DouQcKPmYggdCRu6ZDc2+nW8V/dfa7tEAln8sRiRu5CjgDPb+dAHPW9zrGj6Bc3viG7hn1K5fMdtboBDbkjCxocbnAxks3U5wFGAMKzieCP52LzyEtI56knrVvxZfm41owp80VmvTsZD/gMD86hiLGLdJ98jH41Dd2enSp+zprz1/wAhkZUTmFOvUkVj+JdXTTtsNsnnX83EUY5I/wBrH+f51tStHaQySybU+Xc7HsBXlMt3LLfXGoMxM8rbYs8c+vsAMYHrg87TWVSXKjqoU/aO/RFa7WUag0TyNLeucSFDuIY/wg9z2z+A469x4X8Jx22y61EI86jKxnlIv8T/AJ96o+D9KS3abUJB5gVjHAcffI4Z/wATkD2rsyrmFQ5wx6gVNOHVmuIrP4Ysl3ofliGe2T1pk0vlL8qFpCcD2p0EIhQKvLnn6e9UdYv0so8L88x4VR/OtjkhHmlyx1G399LHJHa2imS8mwqqO2eM1uaB4Zhjhla4iS6u5EZZHmGfIl9MehyDn2z3FReFNAeItPqMQlvJxmSOUdI2x8yHsw7jt7cZ7iNdigZJIHJPU+5qku5hicRy/uqT06vv/wAAzNQ0iK5SXbDB80JiVSgwCT1rm9b8JW810XsFaxkMqxxBT8rnbuZsdgBnp/dPrXc0U7XOWnXqUneErHlc7atowA1CAz2+5lE8ZyDjIP8ALvirNpqdvdHEUoD/ANxuDXfzWEbxhYyYykTRIRzt3Y5+vH86wdU8JWN1JKwtUjLFI4vI+TYv8Tt6nr69B6mly9jrji6c/wCJGz7r/IxJZ/LZeOG449aztd0e31eLcCI7uP7kg7ex9RV280PU9NWaawmN5ZROVKy8McdceuDxx37UlhdQ3kTCIGO5Xho36g1DV9GdCslz03df1ujy25tHiupLO5HkzA/KD/C3YA/3T29Cfc51vCviGTTJDDdDdbM3znuh6Z9x0yPy9K6PxJpP9sWTNGgS/h+4em4f3fof0NcKkLny2IIaRSMEchhwQff29G9AK52nB6HfGUa0LSPWWlQRiVcNGwyCDwRRcFBBuJ3RsOtcp4K1UOo026OVxmE+3dfw7e34V1zRARFBhoyOK3jLmVzz5w9nKzNnwXfELJpsrZaIb4Se6Ht+B/nXUV5wZGs5LW+tuTC3IHcdCPyr0SCVJ4Y5YjuR1DKfUHpWkWcWKhaXOuv5j6KKKo5AooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAGSyLGjO5AVQWJPYCvnbw8BeWjyyLn7TNLMQf8Aacn+tes/FDV20/w3La25BvtRzawrnkBh87fQLn8SK4LRtPEEUUaj5Y1Cj8K83HVFpE9LAw3kZF94VWbLxD3A7iqDDXdPIQMLiNeizLk/99DmvRgmEFJ5auMMoNcSm+p2NdUcCmt3yjEmmEt/szYH6io31HVLtilvbJb5/iPzsP6V3ps4epiXP0qJoUjPyoB+FNyXYFd6XOETw/PLIZblmeU9Xc5NXE0lLdOnPrXWlciqc0Ocioc2ylFGr8D7/wAo63okh+aGf7VEPVHGDj6EfrXqleBWF4/hjxXY6zg/Zc/Z7vH/ADyYj5j9Dg/hXvUciuqsjBlYZVgcgj1FexhainTXkeRiqfJUv3H0UUV0nMFFFFABRRRQAUUUUAFFFFABRRTJ5o7eGSaeRIoY1Lu7sFVVAySSegFAD65GbxHea1rTaZ4SWF4bSbZqGpzKWghKn5oYwCPMl7HBwmecn5TP4d1++8R6kbrTrVIvDKIRHdzqwlvX4w0S8bYhz87Z354AHzHpY0WNdsaqq5JwowMk5P60ALgZJwMnjNNmkWGJ5JDhEUsx9AKfWN4wnMHh28K/edRGP+BEA/oTQy6cOeaj3OMsC1x5tzKMPO7St+JzVoZ3j+6P50lsAqJH32gU7B85Ao4zzWZ6kneTZyvxB1ExRRWCN80h3uT0xnjPtnn6LXLadZteapBBuddwDA90j/h/Fsgn2JPc1Y1+7S78QXk043IjmKNc9lB3fyP/AH3Wl4Nhe51wzzHMjI1xIR/eY4Uf98lj/wACrmfvSO+K9lS+R2dtHFbrFBGoWONQFXHQDgU50KuZppgiDnk4oEq/O+RhOpPaqmmabL4id7q8FymnhjHGI03Zb1IznHI5A/KulHCkknObskQy6pNdS/ZNHheeVjgEDj/P14rY8K+HZEdb+aVZbxvmjkwHRG7q6nBDfTGP59PZaLBDCYhEsMJ+9FGSRuGMOrfeB4/yea1VRVyVABPU9z9apROWrjLxcKSsn97GW0CW8QjiXYnUKCSF9h6D2qWiiqOEKKKKACiiigBkkUcrIZEDFG3LnsfWuF8Y6VKjNqdsJZL6Ah52WPZHsx0Hc4/E+vau9qpqVuLiDDpLKo4MKPsD5455GR14zj2PFJq5rQqujNSRwttPHcxRzqCVcZPqDXLeM9L8qGa8gA8hiskmOquON4/AjPstbujx/ZLrUNPbIEMpCg4yAenT6VZe2EtjNb3HzJICpHseKylHmVj1rqlUutv0PL7SVzcu6/LOuZoz6SJyR+Iz+g7V6bZXq3elwX1sCUkXJX0PcfhyK8vWP7HeeXLkeTJ5blepAOGx+Bz+Brsvh/OTY3tnIRuhfcAOgzkED8VP51jSdnY6cTBOPN2OpyrI0ZxtfkV0Hgu6MmmyWsh/eWrlP+Anlf6j8K52WMPtHQjBFX/Dsv2fxHsz8tzEVx/tLyP0zXStzzakVKm18/u/4B2dFFFWeaFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFY/iHxFpegQq+p3Sxu33Il+aRz/sqOTSbSV2NJt2RsE4rkfE3ja00yVrLT0Ooap08mI/LGfWRuij261y2r69q/iJmjQy6Vph48tG/fyj/aYfdHsOaj0+whtIVjgjWOMdgP8AOa4K2NS0gd9HB9ahUW1vL++Oo6zcfab4jaCBhIl/uoOw9+prVt4gvGKmOyOMlsACs6bUApIhH4muKMJ1nc9CMdLRNcx8YxxUWNrVhtqVwW/1hq9aXhuEO7h16+4q6mHlTXMNwa1NMgbKzZj8xqdJHmuY4orcTkqxKlwuAMc81TuY5Y7khrQwqDgsZAcfTBNNUXKHOtjm9soz5HuOQFqjdfmxVhisMDO/AArFkvWaTIyoPYVlSoSq7HXFX2NGa0jnhZJEDKwIII4Ipmja7qfhDagWXUdCXrb9ZrcesZP3lH90/hUEGoNHgP8AMh9a0F2TpujOa05KmHfMiKtJTVpo9I0PWLHXLBLzS7lJ4G7jgqfRh1B9jWhn1rxKWyurG/8A7Q0a5eyvx1ZRlJR6OvRh+tdt4d8fWty8NnryDTdRf5QW/wBTMf8AYfoM+h5+tehRxUamj0Z5NbCyp6rVHcUUgpa6jlCiiigAooooAKKKxfFHiO08PW8JnSa5vblvLtLG2UNNcv8A3VHHHqxIVRySBQBb1zV7DQtMm1DVrlLa0ixuducknAUAclicAAZJPAqjoNxfa7p11Jrukx2dncErBZ3GHlaHGMzL91Wb+4M4HU5yBas7V9RsdOuNf06yXUYGE6xqfOW3lwRlHKg5AYjcAOp7Vp0AAGBgdKKKKACuZ8fMf7Ltox1kuVB+gBP+FdNXMeOOU08f9Nif0pPY6ML/ABUYUMOLkyZz8uAPSn7sIzdwKWM/vCD0wRmqF+72em385JJjjeQD6KTWex3W5meWH96nmMPmdDI3+9uH9K7H4fLtm1Dn5ljiUH6Bh/QVy7WzRz39uo/1EQI+gMYz+RJrpvAEvy6lIwOfKgYj6hjXNT+JHpV9abt/Wx0Wt/6Po0gU8t1P1P8AhXT+DrW3SysfKktmkECu4hyjjIBw+Gw3XuK5zWY/tGlOEzkoGAHtzXR+Br83ek2oWS4lMSeU67VEcWOnOATwB0J611x3PLxKbw6fnr9x1VFFFWeWFFFFABRRRQAUUUUAFVtRAa1ZSsTbiBiSUxj/AL6AJBqzWV4gujbWkjCR0Kxs2DAZI3GOjHHH5j8aBpXdkef2EgGqapOciPzyq5dn6E9zye3NamQQufWszw7AP7MjyM+YxY/5/CtKRMq23IHTNZns1rc7S6afdoefeK7M23iWVUAxMFkA9c8E/lvNWPAcm67vEPLPCjZ9wAGP5mtDxqBBrOn3BGf3Ug59lP8A8VWD4MfytctF5/eo6/8AoR/9lrn2mdafNR+X9fkelRfLgHrspkchTWNLmB/5bqp/Hg/zp5bjnrjFVo49s1ouc/6Sjf8AjwroOGG+p6RRRRWh5AUUUUAFFFFABRRRQAUUUUAFFFZHiLxFpvh61E2p3AQtxHEo3SSH0VRyf5Um0tWNJt2Rr1g+IvFuj6ARHf3Wbph8ltCPMlb/AICOn44rhL/xF4i8QSkRu2i6aeiREG4ce7dF/Dmq+m6Ja2LM1vCPNfl5WJZ2Pux5riq42MdIanbTwbes9C9qHi3xFrKsmnQJotq3HmSYkuCPYfdX9TWXp2gxQ3LXTmW5vH+9c3Dl5D+JrcitwOtW0RVHArz6ladT4mdsKcKfwopJbBBzSTSJCm5vy9at3TpFEzucAVzt3OZWLE/QelXQoOo7vY1iuYS7unmcZ4HYVAkZYZbpT4IvMervlhQAa9SMVFWRo2o6GdKgjRyR0Gab4cuPtUpYDAaMnH5Grl4ivE4HUgqPyrK8AN5kkYPaMiprL93IL3i2dDHAs9yq/ZbW6IU4jnl8v05U4PNUmtDHq+42NvbnOMpcGQ/QZFWpFjivpYrl9NVCMp9vTKn6HPBqtZrCNXHlDSt2T/x59en8qypaYb5M8irriPuHa7JsgROzHn8BWLBmSbtWp4tBjS2J6Et/SsrSiJJ2XqQM5owqtSR7VP4bli5hIOefUU6zujBIMHFazwho/XisK9jMTEgYrosmrMSlzaM6e3ZblNwHPcUXWk295A0NxEskTDBVhkVg6NftDKO46EV2EcqyIHQ8EZryq9H2crrYymnEx9L/ALd8MjGkXn26xHSxvGJ2j0STqv0ORXW6B4503Up0s75ZNL1I8fZrrgOf9h+jfz9qy2YEVR1Cxtr+ExXcCTRns4z+XpV0sXOGj1RyVMNCeuzPTqK8ps7zXfD7j+zLr7fYKP8Ajxu2yVHoknUewORXaeGvF+m665t0MlrqCjL2lyNsg9x2Ye4r0aWIhV23OCph5099joqKKwbPxLb6j4im0vSoJbyO13Le3keBBbyAcRbj9+T1Vc7f4sZAO5gM1zxMllq1vo+mWr6nrMxVmtonCrbxE8yzPyEXrjqWPCg841hptkNVbUvssP8AaDQi3NxsG/ywS2zPXGSTj/AVHpWj2Gkm7bT7ZYnu5muLh8lnlkY8szEkn0HPAAAwABV+gAooooAKKKKACuW8dNsj05sZHnkfp/8AWrqa5zx0mdLt3/553Cn9CP60nsb4V/vUYKFTMRnnriqviNN+jaht/jt3H47TVlIh9s3+2KWTEkLxOMqwwRWb2O5OzTR5FJfFZ1kbJMsISXHXG0Ej8lA/Gum8AS/6bdwNgtJArHHTKMy/yI/OuZvLVojLAykvbysuO7YOWH1Izj/c4rW8FsI79NjL5i7k46MCvOP++Y//AB6uaF1JHqVUnTdj0R1LIoU4rPiabQrx3WN59NmOZ4FYr/ke3Q9DWhI7CwWRVy4PNPDeZGN3XFdR50ZWTTV090dToetW+pRI8UyMZPuwoh3RAf3vT68DsM1sV5p4ZnOneI7m0SfyLe4UOQqFySOcKPXqOhr0mNg8auAwDAHDDB/EHpVp3PPxNFUp2js9UOooopnOFFFFABRRRQAVgeLxP/ZV4YhdbPs77/LMezGD97cd3/fNb9YfitITYSs/2QSeTIB5wwxGOinP6c0Muk7TT8zktBP/ABKoCOoQmprUu8cxYYAOBVLQ5QNPgXkEof51oy7ltmVfvNzWZ6tVWnJeZyHj9v8ASNOXqzGQD8hWH4UX/if6a2M8uv0+Rm/k4p/iW9M+vorMWjtSkQx/eJBY/oR+FP8ABseNeg3HcY0Zh9ANtczd5nco8lGz7Hok6bt6jj3pkvyzWfvLH/6EKdBIHaYdwCDSTfvLqwC97iMD/voV0nnx3sz0KiiitDyQooooAKKKKACiiigAoorz/wCIXii4jux4f0OXy7+RN9zcj/l3jPp/tnt6dfpE5qEeZlwg5y5UWfFvjX7LcyaV4fRLvVBxJI3+qtvdj3b/AGR+PpXI2GlYupL28le81GXmS5l5Y+w/uj2FP0XS4bG2WG3XA6sx5LHuSfWtyGLjivIrV5VX5HrUqMaK8yKKELUvAqUxnHFQvGa57Gt7gJMU7zcVAUaoLtzFET3PApxi5PlQ0rlXU7kzShVPyLWaTualdiTjNOt4yXHFezCChFJGyskXrSMjFS3HSp7eMrHmobnkGrMW7sqsQU5A4rL8AwmPUrxMfLDuX824rSI4ZaseHo4rae9kORJKVJGOvbj8T+tY1m/ZtI0btFl+8nkg1K3EN3Dal0KkzLlG5GAT271TkS7t9dH20wmPdwYoHUEkYHzEYPWrMl+1vZ3V7k+bEoFxYTRgZXk8H1xnB5B5qobaxvpUi01TNKq+esk8jMkCHoEXPX0FXTpNUuRnhzqJ1edFTx2wWC0HfLf0rN8MxNsedhgOfl+gqxrOdYvYI9wMcOVZl6Mc84rSjiWCNUUAYGKmjFwpqL3PbhNOmrdSzFg5FUtUt9yHAq1D1qxMgePmtUZ3szjtogk5yDXSaNdfKEJ4PT61kanAokyaSwl2sMHoetRVgqkbM2+JHZLk0babayCWFHHcc1ZAzXjNWdmYbFV48isrWdMtru3P2tQFj+dZQdrRkfxBu1a2qXtnpdhNfalcR21rCu55ZDgD/Ek8AdSeBWZc2Fp4p0a2N/a3cVpIwla1nBjMgGcLIoPKnhtp9sjqKai1qLm6Gb4X8fTTadeWmsrfah4bkDW8erxZjkKFcFgVIZlGeJVx6gnrXq/hmLSoNCs4vDyW6aWqYgEH3Mf45655znPNcPLaqE2ooCgYAA4ArFspr7wlfyXukAy2Mh3XWn5+VvV4/RvbvXbRxlnyz2OSthLrmhuey0VT0fUrXV9NgvrCUS20y7lYfqD6EHgirlemnc87YKKKKACiiigArI8Wwmfw/eBRlkUSD/gJBP6A1r02RFkjZHGVYEEeoNBdOXJJS7HnVrcbjCQDymc0+cOskZToTz9Kr2im1nntJCC9tI0YPqM8GrqsNrKefSsz1JpRlocD4ztVttbWQnZFdqNzdNkg+63t0HPoWrFWR7C7W4iXbKrBJY8Y2SA5HTscY+hf0rtfG9slzpkdyVLJAcSBepQ8Nj3B2t/wGuJvQkkwimZTcBBGzjpcJxtf69Oe5GDjNc01aR30Jc0EmeoafeRXlnHcQnMMygj2/wDripyv7skeuK868JanJaXraddybEkcFWPZz0I9m/Q+ma9HQjyyPzreEuZHHWpezlYx4neDxNpcjPKjN8haMAnnI4yD616la58lQyyqRx+8ILH3OCa8w1+2f7PFdwn97bvuBHUf5wK7LwpqVveWokt1RfMG6REGfKI673P3ieP881pE58bFzhGoumjOiopFYOoZSCpGQRyDS1R5oUUUUAFFFFABXMeN71rTSrnbJIhkjMIQpuSTdwcEdGGe/YHg9Rr6nqCWtvMwdFaNQ7FzjCn+If3vpkfyrgLy8Ov6qvl5XTrdy/BJV5M8sAemfT/Gk2dWEpOc+d/CtX/l8yexh+zWcCEDcqgH61FrmoJp2nPdSkE4wgP8Tdh/ntV2SPz8qCUUDlvQV5x4x1ZdRvhFbtm0tv3aHszd2/z/ACJrGcuVHo0oe1nr8zIuWEq73yWCnLN1eQ8kn6FlB/Cus8A2atPe3gyUH7qNsdR1P6BK4wB7uRSFJjULHEnqSflH1Jy3/wCqvWdEsV07S4bUEFwMuw7k8n9aypK7udWKnyw5e5chRY4pGHBbgfWo9PWSTWtKib73mmQj2Xn+lZ+p6zBYzrHL5jnGdka5Kj1NbPhEpqHiBbqI7oYrfcp924H6ZroPPU0lJ9kd3RRRWh5QUUUUAFFFFABRRRQBQ1/UU0jRL7UHwRbQtIAT94gcD8TgfjXkXh60k2Pc3rGS/u2864kPUsecfQdMV2Hxdutuj6fp6n5r28QMPVE+c/qBWHp68CvLx1S8lA9PBQtFzNGCMADAq7EnFRQLVsLgVyxRvNjdtRulTAGkccYqmiEyoyisLWpR5pQHhB+tb7/KCT0HNcXcXRmi844DSZJHpW+FheTl2OmlqysZCZBzWzYL071gwHdJ+NdFpoIUV6BrU2NY4WMcVn3Ddauyt8tUJjQc8EVd3zHipfKmhh85JDDcD5osdSf88VXYEPnJFNupiwBJPBFCFWhOdox26mxbwtqlxFqN/CY38pUWMnHvyPTPTNM1y1iS1doHNtLJ8haIAbh3/TPPvWhZSedZxNnkrisHxHOzX0cQPCDp7n/IrghKdStq9iaeHh8FhbQW5RYJT5KgAIw4wafOktrIBcgtGfuyqMg/lVePDRBWANWrS4eFvLllYxsOCeefSvQVmYVY1KEueLuiSKSPjDqfxq4uGTAINUWuZzJJHiMIH5yOowOKnti4Ylypz/dGKLJFQqznZuOhQ1SAFScVjRDy5MV098m6OuauFKSk44pHfTd0dLoM24NHntkVZ1jWbLR44GvZD5lxIIYIY1LyTOf4VUcn1PoAScCuX0nWLW3161sGlzdzIXESgsQg/ibH3RngE4yeBXQ6boNtaazdarK8t1qM+VE05BMMWciKMAAKv05J5JNebiIqM7vqY1VroWLzQrS+1m11K8Ms72i/6PA7ZijfJ/ehcffwcbjnA6Yyc6pGaQGnCsb3MbWIJErPvIgQT3rVk6VTnXINZyRpBmb4JvToXij7EX26ZqZJVD0juAM8em4A/iK9TFeK+JbaSTT5WtyVuISJoWHUOpyMflXrXh7Uo9X0Wyv4sbLiJZMehI5H4HIr08FV5o8r6HDjaajLnXU0aKKK7jhCiiigAooooA4fxhZ/ZNZhvlX91cjZJ7OOh/EfyrkrLxPbyXDGWCSKBjhZScj6kdv1r1bXLAajpk9sQN5GUPow5FeK6bahPtFpMu2WF2Qqeowam2p2e3k6cbdNP8jsoYYZbaaFiskEwPuCCK8w1q2a0lk0+6AYRMfKkYchT0P0xwR+nykHqNLv20mYwz5+yMc56+WfX6Vo67pH9s2JZSn2iP5oXHIYen0NZVIXWh3YTEK92edTyM0KJcLvKDGDjcg9A38SngjPTj6nuPCOufaAljfTB7gDMUp485f/AIodx/UGuMnidEZXUqYTtZT96Js/mVJ+uCff5oUOyRSSoUkNtbIUnsysD8p49QOOo6DnjJxdz0KlNVI2PX/mUOsuCh/UVkr5+jTm408GaykwJrfJwy+nHb3/AJio9H8QW1yIbW6ZoLoqCFlORJ7q3Rs/h9K244VjB2/cJzxXUnfY89N07xktH06M2NF8V2d4qDz1SRmeSYTNtEaDOAvqeg49CT77dpqPmwl5oTEQ0cZXOTvcKcfhuHP19K4C90izu23kbXzncvB/wNVI9GlgXZBqFxHHnIVSQAfXg1XMc8sJRlrGVvJq56X/AGnH5bsqOSFmbB4z5bbT+Z6UyXVoY0U7oskxYBkA4dsE/hyfwrzeLR7eeQ+fdzylSTgn1OasHQ9PC42MeMZLGnzC+p0lvN/d/wAE9BTVoGVGLxhGleLdvHy4YgE+xx+orE1TxXb2sRYzp5wClYoiHJdWIdCewIxg++fauSOkWJk2CKTnuCcVestNs7N96R5fsWOTS5hrC0Y6tt/K36lWWC51mQT3w+z2asTFaqeFB/ln/OKuxxNHsjgRUhUcmm3d8lqklxeukMCdCx/z+Vcj4h8Tzy7oLXMQAzsPDkerH+Ae3X1x0MSkludcYzqWilZfgi14v15Y1fT7SUq54mdOqj+6P9o/oK4hisg3ugVANsUK9/r6j1Pc8fRJJNpeMgFifm4wc+nqB7de57Vt+GtJGp3SbhvgTDTvjjHaNfr3/wA5523NnbGMaMDX8I6QzeXe3SfKmXjB6u56v9AMAfia6TUb82GmNM6g3Eh2RJ7n1/nV6XbDHuchQBuOegFcfcTvql+bg58pfliB7L6/U/4V0wjbQ8nE129SPZtgeadi8rncznqTXo/wxsjB4eW5cYe5O4f7oJx/M1579ll1XUrbS7X78zYJH8K9Wb8BmvbLSCO1toreEbY4lCKPYDFaHn8zSa7ktFFFMzCiiigAooooAKKKKAPK/iTMLnxrp9tnItLNpfoztj+Sml05flFZeuTm78da9N1WOSO2X22IM/qTW1pyfIK8LEy5qrPboR5aKRp24qznioIjUhNJMiSux+RTDSbqaWptgkVdQfZaSt7Y/PivP7p/LaWL+6xYfRjn+ZI/Cu4119tlj1YCuC1bcZN6j5gMYHcV3YRe7c66C0JbDlq6eyGEFcxpJDEMvINddaAeWM+ldbHVY6Q8VXYZ61NKwHFQM3BpGSKdydvFU5zmM1an5Y1XnX91SN4qyN/QJCbAA87WIrF1o51eQ/T+QrT8PH/RWAPeszXgU1Msehx/KuSlpXkTFe+xyHoKe4BjweQahiOQMVYAyK6wkk9ydB58JdR++hHKjneg7/UZqzCQyhgcg8g1ThzG4dThl5+o7irMhjt3MkbA2zjfgEZT1+o61W559/YT5H8L2J5hujwa428vYbya/s7G6U3Nv8kjKu4RORxnsSOuPpnrW1qbDX9DQ6Pqphtpmw1zbYZmQEhgjfwkkY3c47c4IyVsbXTLKO0sIUht4hhVX9ST1JPUk8nvSOyjdvyIPDOlwaUrCEvJcSnfPcSndJM3qx/kOg6AAV6PC2+FH9QDXA2j/OK7fTW3WURz2xXFjFomXViklYting1GDS5xXCmc7Q5jUElS5qNulJjWhk3y9a2fhFMy6Jfae33bG8eOP/cbDj/0I1l3q5FWfhxN5PifWLTtPbw3I+oLIf8A2WujBStVt3MsWr0r9j0aiiivZPICiiigAooooAK82+Iukf2ffrrdsP3MxEdyoH3W/hf8eh/CvSaiureK7t5Le5jWSGRSrow4INA07Hi9xGlzHuUjJFM0nU301ha3LH7KThJD1iPv/s/yq34j0ebwxqQjJeTTpjmCU/w/7DH1H6j8aqXMSXMZZcEkcik0XCTi7o1NY0P7fGtzavGl+i43MuUlX+6w7g1xF1HHbXEkVzD9jlzn7PcEtG3ukg5HTg98YyeldHpGrS6W4guWY2nRHxkxe3uP5V0L21tq9uEu4oZ0PKt1B9we34VjOnfY9bD4rTXY8pkXdEybsRhiQM7gnqWA5U/hz71uaBr+q22IlC38Q6KZBuA+vUf8CA9qt6z4TubRzJYDz4F6Rk4kT6Hvjt/I9a5t3IkKSxK0gP3WTY+fqOSfrk/SufWDPQThVjpqd/B4htJJF+2x3enyjtPGVU/RuhFdHa3KXEQkgmhlQ9CCGB/EV47I8jsGaeUsOpbBc+2SR+ABNPiu7yAFk1KeNQf9WskgY/UYI/WtFV7mM8IpbM9iY+pjA74qOSX5cxKjn36V5X/b+qbQILi4YHqZJF/qKY+t6p1lvJ0A5+WVcf8AjvNV7ZGawcu6PVkxszK2G7gCuf1bxRa27eTp6i5mJxuydgPpkAlj7KD74rh/t/2tT9svWWPuEDyF/YlzkfyquZrcb/JSZww24z8zD/aIz+hAPtUur2LhhEn72poX2pT3l55kk6vOh4kbiO3H+yBkbvpk+me2dNKinZAJNpO4yH/WSn177e/POPzNOtbS4uJhDDbO0nUIEyR+B4HblsfjXY6R4TijX7Rq7BieTCG3f99N1Y/kKhKUjeU4Ulqc7oHh+51qYSOBa2C8DYOPoM9T7nP9K9J0y3tbGAW1kihY+w9fUnuaVp7eC23krDAoxk8ACucutUlv3a30tWgtT96XGGf6eg/Wt4U1E83EYnm+L7ibXtSN9M9laklAcTSDv/sj+v5VWk2WVuWY84qWKOCwgAIAIFafhDQJPEN8L2+jI0qI5VW489h2H+yO579PWtkeXObk7s3vhnorW9rJq92m24uhiIHqsXXP4nn6AV3FAAAAAwB2opmYUUUUAFFFFABRRRQAUGioruYW9rNM3SNC5/AZoA8St5Bc6pqdyv3Z76dx7jeQP0ArrbJcRiuM8LKX060durKHP1PP9a7e2GIxXz0nebZ77VopEy07dTR0oJwKLmY2SQA0qMGHFU7l8GpLZ8ilcq2hU8QNi3jHfJNcTecyYrq/EsxE8EXYxu+foQP61y0wBcjtmvWwytTR00V7pNp0fzboyEk9/ut9f8a6W3lCgJICj46Hv9D3rA09eRXRJhoNkih0x91hmugipuMkb5qgY5pskLRk+TMwH9yT5h+B6/zqAvOv3oQ/vG4P88UhIJOWqvdkiLHrUgnUt86SIR/eQ1DdOHj+RWP4Y/nSNEbXh7/j1Y+4qPxNbF4451HT5T/T+tSeHd32A7sZ3cAdhgVrtGk8LRyDKMMEV5s6nJXcjJy5ZXOLtJf4TWnGQwqPUtHe0Jkj+eL+93H1/wAaqwSlThuK9CM1NXia6SV0WtTvrbS9Pmvb2Ty7eFdzNgk+wAHJJOAAOSTiuT1bSvEXiq1iNzJaaRpaPvayliaeSWM4+WYq6ALkAlFJ64JPSr/ip0lufDcc/wDx7NqieZ6EiKVo8/8AbRY/xxXX2rJ5m2QAo4KN9DWiOLEQ5k/I5a1vrvR7q207XLW2iiuMQ2t7Z5WB2A4jZGJMbYHHLA9M5wDLqXel+IY2+B9ZR+bm3iJhPczqQYiPcuEP40/U1+9SNcNZaLYzrNsSiu10KYPYtjojlf5VxEHD5PQV1vh87NJyeCzFz+PP9a5sWv3Z0VtjZEgJqUHIrKhm3OfrV+JuK8tM52iftTW6GnDpTX6GmSihddDVbwo/kfEOz9Liymi/Jlb/ABqzc96ztPfyPGnh2X1mkh/76jb/AArTDu1WLFWV6Uj12iiivdPECiiigAooooAKKKKAIL+zt7+0ltbyJZYJBhkbv/n1rybxH4cvfDkrzxBrjTAfllHLRj0cf16fSvYKRlDqVcBlIwQRkEUAeGb4ruLK43VDbyXWmyF7Rtqk5aNhlW/z613uv/D+J5HudAlW1mPJt3/1TfTuv6j6Vx10brTZRba1aPbydiw+Vvo3Q0i1K2qNSy12C8VYJ2NtO3AVjwT7NVy90e3voQl/Ak+Oj9GA9iORXNS29tcL8pBBpItQvdNXbDc+ZEOiS8gfj1qXG51U8S47k914VtRiGK6lRP4Y5kEqr/u8Aj86zrzwpqdnn+yriaaJvvIJ/K/QDB/Ouz066W9sYLqX93vUHB5xV7fJlTDNFt75HWs3TizujiZpK34nlEmh6urETWFzn1WUN/IGlh0DUnPy6UX95iQf/Q1H6V6zvLkh9pPrUDxSmQMrlUHVRjmp9iu5osZLsvxPO4PB+qXUu65+y2keeRtD/kvI/WumtfDlhZxoLm6uZtoxhpSB+AGMD2H45rfMoVtpOG9CaQBGPzqXPaqVOKM5Yict9vIbZQW8MIis4o4IRzhFxVDXtSj0+BRGnmTSHbGp7nuT7CtCeR0XEUYA9OlYeu2a6g9v5MrLcx5Cqq792ccY/CrMJRnJXjuY729xeyifUJi+OVToq/QVainRXS2sonmuX4WONdzH8BW9pHgS/vAr6rePbw/3I1Ac/wA8V3mi6Jp+iwmPT7dYy33nPLv9WPJq0efO6eu5xug+BprmZbrxEQEBytmhzn/fP9B+favQ0VURURQqKMBQMAClopmYUUUUAFFFFABRRRQAUUUUAFYnjac23hDWpQcFbOXB99hArbrk/irL5fgTU1HWURxD33SKKmbtFsqCvJI4Pw7D5djbJjG2NR+ldTB9wVi6UmFFbkYwK+eR70x1RSvipDVSdutNkJFO/kIjYjrijRrkTQo+eozUNydwIrN8NTbPPt2+9BMyY9uo/Qiki2tC34u+WSzm7AlD9G/+viucI+b2rovFCmaEIvXZkfUHI/kK5tZA4DDo1exh/wCGjel8Jp2K8ityMHYKx9POe2K2o2GytjGb1K03WoqlnPz1AetIpbCiqOoNiM81fOFU5NZF/IC+M5AoLjudH4dGbA8fxf0FbMfFUtKt2t7CJJBhyNzD0J7VeFeRValNtHPJ3Y7rXNa/pwtnWe3XETHBA/hP+FdKDVTW0MulXI7qu8fhz/SqoTcJIIScZHF6jYQatpstlcl1R8EOhw0bKQVdT2YEAj3FVrW/8RWCeReaWmqlRhbmzmSIyD1aNyNrfQkfTpV+2cZNXraVfMR3UmLOWOcZHt6/59q9ZDxDjBczdjkNRufEes6vb3Ou+Fb+30u3kjeO2gubSTzZRykkrGYYAPIQDqFOTgCtjxFdTWkatBp91fFiQVt2iBX3PmOv6ZreguA+6SX5lmyZB6g8/p2+lZuoHaJFZlYplWI6cd6b1MsNF0/cbOZ0q8uL2doJtKvbNSPvzvCQR3A2SMc49q3hrt7axyRReHdVuY1biaKS1CMMdQGmDfmBVKAmMl2GGcYUei//AF60JrnytObJ5wTXPi/4Z1TTtuTaTfzvpL3v9n3RmLMwtN0XmnnGM79mf+BY96t6frl/NcxRSeGdYt0dgGmkltCqD1O2ctj6An2qHRDjTrb1KA/nW7bngV5N1d6GTTstRmp6nd2Lxra6JqOpKwyXtXt1Cex82VD+QNP0q/ub9JTdaRfaYUI2i6eFi/08qR+nvjrV+I8UsnSqvpsRbU5G913UVldV8Ka04BIDiWzw3uMz5/Om6neTWlxoN/Fp91cTpfQn7LE0Ql+bIK5Zwmecfex710NwKwvEL/Z7aC4PAguYJfykWnCSU07DkrxauelaTruoX18kFz4V1rTomBJuLqWzaNcDoRHO7c9OFP4U7WNc1CwvTBa+F9Z1OIKD9otZbRUJPbEs6Nkf7uK3Fpa988IztM1C5vNOkubjR7/T5lLAWty8DSPgZBBjkZOegyw98Vjp4n1ZnUHwN4jUE4LGfT8D34uq6migDN1zUrrToons9F1DVmdsMlm8ClB6nzpYxj6E1BomsX2o3Ekd54c1bSUVdwlvJLVlc5+6PKmc578gDjrWzRQBzuoeINTtb2aCDwfr15GjYW4gmsQkg9QHuFbH1UVorqFydF+3HR79bnaW/s8vB5+c4258zy89/v49+1aNFAHN2XiLU7i8hhm8G6/aRuwVp5prEpGP7zBLlmwPYE+1XNc1e906WJLPw9qmrK6ks9nJbKEPofOmjOfoDWxRQBl6Hqd3qSTG80PUdJKEBVvXt2Mme6+TLJ098deM1jX+u384lt5/AWvXUGSvMmnlHHrhrnOPqAa62igDg9c8J6aulpeWOhaqbpwpNpYzwrKpPUHzJBHx3w30zXMaf4W1G61FI38P6xbxHJ87UpbQxrgZwRFO7HPT7v1xXsdFKxcKjg7o4JtI1eBAhsIpUAx+7cdPpmq5t9RjGP7LuAPRUJ/lXotFLlOlYx9Yr8TzQw3zSB/7MvgfaJv8KsLDft93TbvPuhH869Doo5RvGX+yefJpOrySb000IT/FJIo/rmrkPh3WpD+9u7aBfRAWI/QfzrtaKOUl4yfRL+vU5u28KQ8G+u7i5PcA7FP4Dn9a2bHTrOwUi0t44s9So5P1PU1bop2sYzrTnpJhRRRTMgooooAKKKKACiiigAooooAKKKKACuG+L0mPD1jD/wA99QhTHsMt/wCy13Nec/FiXfqXhu07NNNOR/upgf8AoVY4h2pyZth1erFFLTVworXTpWbYjCitRfu14UT2JbjW6VQuT1q9JwKzblutNhEpTNWCJxaeJinRbqIN/wACU4/litmdq5rXRu17SADgnf8AlgUoasuW1zo9UkMkKFeoFc5InlyBh/qpCT/ut3H9a3ZN/kEN1ArElxgq4yh6j+tevhX+7RtDY0bKTGK1YZMjrXNwXHktslbjs/Y/Wrq3qqOGFdDJcDUnYbuKrtKB3rNN3LO+2FXdj2UZNaNpot9c4M+23T1b5m/If1NZzlGGsmKyitWVLm83MEjBZmOAoGSTW1o2imNkub4DzBykXUKfU+/8q0dO0q1sfnjTdNjBlflv/rfhV1q4a2J5lyw2IlUvog604dKjp69K5DMXvUV4jSWk6LyzIyj6kVKaQ007CPPA7Rv86kH0I5FaUepRLYugDeceMdj9T19uv4dK6a6s7e5OZ4I5D0yV5/PrWdceHrCZcKssR9UkP9c16McbDqrFVowrJc/QwluVS3CGTAC7dxqxqcEJ0xZMAMMHAPUZ7/8Ajo6Aeg70s3hQod1tcCQ9hMP6/wD1qytRgvbVQl0jiMH5TnK546H8BW9OtCfwsVSj7WcZRdrEK7nkJJyTU2uYi0aeQ9QmBTbEeYaj8XnZosnpkfzrHFP3UvM6KzsrG5pnFpb44GwfyrbtjwKw9NbNlAw7oK17ZuleT1IexqxHpT36GooTUzdKoyKM4rnfFqb9Bvh6RFvy5/pXSzjisbWI/NsLmP8Avxsv5ikty0erabL52n2sv/PSJW/MCrVYnguYz+ENElPVrOLP12Ctuvoou6PBkrMKKKKZIUUUUAFFFFABRRRQBzc/jnw5b+NIfCc+ppH4gmj8yO1aJxuXBbh9uzOAeM54q94a8RaX4msJL3RLr7VbRzPbs/lumJEOGGGAPB79K8R+IPgDVfFHxc8SX1jb3drd2uk211pGpeWyxi8ifIQSYxyMgjPGc9q5jw74d8TP4D8Itrug6mdKj8SXF3rel/Y5Gd42ZSjNBjdJGDu4AOc9DQB9V0V8nar4M8QX2i2Nsui6unh2bxstxY2IglSW0sTuBYqBuhTkYzt29eK3vFPw3htPiHq1jpPhq6l8PQeDLmC0zDJPF9oLu6ortnMm5sgZLZwR2oA+k6iu51tbSa4kDFIkaRgvUgDPFfMPhvQPE+k6l4I1Gy8O30t//wAIxew3yXNtIEnmVJPJhuSQOpCAKxHGAMcUz4daJrtv460m/i0bVLGO90O6j1WKPQv7Otop8OVhCpEgfB24ZixJ6HsAD6A8J+M9O8T+BYfFdhDdx6dLFLMsc6qJcRsytkBiM5Q459Kn8CeKbHxr4UsPEGlRXMNleBzGlyqrINrshyFJHVT36VwvwY0rUdP/AGeLHTb+wu7XUVs7xWtZ4WSUFpZSoKEZyQQRxzkV5f8ACzwxq0N38LFsPD2raXq2mPeNrl5Pp8tqvkNISkTu6qJMqeACcZ+uAD6por5O8LfDTW4PgHq99pOkanY+N5fNtSsrzQzPaGZHeNI2IA3Bc8AFuRk5wbfiLwxqdzY+PW8G+HdV0/wxc6HbQJpx0+W3a4vRJESyQFQxIQMGYLye560AfU1c58QfF9h4F8LXWv6vDdTWduyK6Wqq0hLsFGAzKOpHevn2Xwh4jsdWv08OaRf2P27wDHFOyWzpHLeBVDIxxgzFQwwfmyaXxR4btLj4BNpvhjwVrlr4gFjaJeKNJmieWRZojICCB5rZBbcA2FB5HSgD6ftJ1urSG4jDBJUWRQ3UAjPNS18v+IfBWtnUPiPYaHol9DY3/h+0eKOO3ZIZ7lPKLheNrSYD5/iJJ7mrOhaRqd541trmWx8RaVYr4DTTJL9dLuBJBcDAYIuzczg5IAGTjI4waAPpeivDP2f9J1bQ9f1HTZ9Dsm0mC0URa+dFl026uX3D93IJQHk4yxbB57nivc6ACiiigAooooAKKKKACiiigArzD4ht5vjrTY+0Fg8n0LOB/wCy16fXkniGb7V4+1d+ot0htl/Bdx/Vq5MbK1JnXgo3qmhZj5RV9elUrIfKKvDpXkI9OQyc4U1k3Lda1Lk/LWNcnO6kyoFKU5aucv2EvjCyjBz5UJY+2T/+qug6vXLWYabxU94f9XKZY4/cR7Vz+eadNbsqo7WR18qPJb4iG5vT1qpFoc85zLIseT2G41csn2tg1t2xBArWFedOPLEOdrYyIPDFuR+9nmb2GAKt2vh7TLY5W2Dn/bJb9Ola6gYp1N16j3Zm5N9SOONY1CxqqqOgUYFOxTqSsrkhTXp9MbpQMjzUq9Krk/NU6HikDH0lLRTAbimlRUlJQAwriqt1jYwYAg8EGrjdKqXCgjmkxo5w6aguN8PyJnle34Vi+OIzJpJjiBLtIigDuSa62YheKwdTXfqGkr2a/gH/AI+K1VSU5JSZU37o3w5L5uiWjHrsAP1HFbtuelZUUAsNZ1vTgu1ba8covoj/ADL+hrSgPSs6keWTQQfNFM14D8oq12qnbH5RVtelJEMrzjg1mXYypFasw4NZl0OKTLidf8NZPM8D6UM5MSNCf+AOy/0rp64f4TzhtG1K16G2v5VA/wBlsOP/AEI13Ar36TvBM8OqrTaCiiitDMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8S0mU32q6zfE5Fxfysp9VB2j9BXrXifUF0nw9qN85x5EDuP8AexwPzxXk3hS3NvpFoj/e2Bm+p5P8687MJaKJ6GAjq5HU2w+QVYFRQDCCpe1ecjtZBcHg1jXHG6ta5PFZdz3pMuJk304s7C6um6RRs/4gcVHqGlvo9l4LhlGJjZzPLnrvcq5B/Fqmv7T+0ZdM0sc/bryNHHrGvzv+i10fxZixqXh2UdA88f5qCP8A0GuqjD9zKRhWn++jExokDBSOtatmxAwayLOTHymtm1wa5Tdmgp4FOpqfdp1UQFFFFABUbmn0xhQBAfvVMnSo2HNSp0pAPFLTadTAKKKKAGmq0/3TVlulVZjxSYIyrgFjzWXKu/X9AjxndqMP6HP9K1btwo96z9LXz/G/h2Lri4eT/vmNjV0VeaCq7Qb8jU8f2n2Hxxb3SjEepWpRveSI9f8Avk/pVW3PNdV8V7PzNAt79B82n3Uc5PfYTsb9Gz+FctEuHrbGw5al+5lg581O3Y1bU8VdWqVt0q4tcyNmRzdKzrsYBrUdcis+8TApMcR/wxm8jxVrtmePtEMVyg+mUb+lelr0rx3Sbn+zPHGiXbHbFOz2Uh/3xlP/AB4CvY+9ezg5c1JeR5WMjy1G+4UUUV1HKFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcL8Xpt+gWumI2G1C6SNh38tfnY/+Oj86xLGLAHGBUHiO9bWfHd0wObTTF+yxehkODIf5L+FaMA2AV4uLnz1Ldj2MLDkpLzLqcCnZqokwzycVKHB6Guc1sRXBrOuRWhN1qjc46+nWky4jvBNub/x4ZMZh020Jz6SSnA/8dU/nWt8X48aRplwP+WF9GT9GDL/AFFSfCO1zoV1qjj95qNy8gJ/uKdij9D+daHxOtTdeCdU2jLQx+eP+AEN/SvYp0rUOXyPLnUvXuefwLvIIrYsty9aw7GTIR1+6wBH0Nbdm+SK8c9VmtHyKfUURyKlqjMKKKKACkIpaSgREw5p6DAp2KWgLiYpaSloAKKKSgYxzVS5OAatPVS4PWkxoyp1Ltk9KXwfF5/xHsgRn7NZyzfQkhP6mnzHANWvhmgl8a6xN3hs4oh/wJif/Za3wivVRniXakz0PXLEanot9YtjFzA8WT23KRmvJdBma40y2eUYlVfLkB6hlO0/qK9oFeR3EP2DxjrtgoxGZVu4x7SLlv8Ax4GuzHwvFS7HHgZ2k4mlb8Yq4pqrEMDNNlu1TgmvMPQaLxNVbpQyHFVDelzhATVmMM0ZLUAlY5jX43FhLLD/AK63K3Ef+8h3D+VeyaVfRalptrewHMc8Syr9CM/1rzC5jB3AjIPBFbHwkvzHa32gzt+90+TdDnq0D8r9cHI/Ku3AVLScGcuOhzRU+x6FRRRXqnlhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZXirVk0Pw9fagxG6GMlAf4nPCj8SQK1a83+LF59pvNI0VD8rObyf/AHU4Ufix/Ss6s/ZwcjSjD2k1E53wzZvbWUazEtO2XlY9Wdjkn8zXS24rP05cLmtSEYFeAnd3Z7ctNBstqknPQ1CtltOQxq924prHAqiblWVdq4rG1aTyrK6fPKxsf0Na9w4rmvEsxXSrsKMu6GNB6s3yj+dTuy1tc9R8C2/2XwZosQGMWkRP1Kgn9TWpqNut3p9zbOMrNG0Z+hGP60adALXTra3HSKNUH4DFTn7tfQpaWPBb9654X4aBfSLQSfeEYU/UcVv2q4Nc94YP/Etg/wCBf+hGukhxXz0viZ762RpwGp6rW/SrNNGbCkpaKYgooFOApiG4op+2gigLjKSnkUw0hi0hpaKBkT9Koz96vP0qhc8ZqWOJnXBwprS+Ehzr3ic+n2Yfo9Zlxyv41p/CJca54oPqbf8A9BeurBfxUZYz+Ez0yvNfGUXl/ESCTtPpu36lJD/Rq9L9a4H4kR+TrHh++x8heW1dvd1DL+qGvRxSvSZ52FdqiIYsEYpklortkgGmxvVqNsivFR6zIorVU7CpmACYFSU1ulAjKnT71ZljdDSPF2k6kTtjkf7FOf8AYk+6T9Gwa2p161z3iC0N1ptzCvDspKkdmHI/UCnTlyTUipR54uLPa6KyfCmqDWvDenahxunhVnA7P0YfmDWtX0Cd1c8FqzswooopiCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArxnV7ltS8ba3ctykMi2UXsEHzf+PE17Ddzpa2s1xKcRxIXY+gAya8R8OBprKO4k5kuC1w59Wclj/OuDHztBR7nfgI3m5djo7MYArRj6VTt1xirqDivLR6Eh9QTvgVM3SqN23FNiRTuJetUNKsjrXjDTLHBMFs3264+in5B+Lfyqa4bmug+FNtufXdQYcy3It1P+zGo/qzVthIc9VX6GeJnyUnY74kCmyNtQsewzTioNVdUby9OuW/uxMf0Ne2zxkeJeFju0i1f++u78yT/WulgHArm/C67dD08f8ATFP5V0lv1FfOy3Z9B0Ro244qamQ9KlpmbEFLRQOaaEKKeKRRmpAKdibjcUYp1LwadguRYpCPSpCtNPFDQ0yOkNKaKkZFJ0rPuj1rRk6Vm3fepZUSi4ypFavwoGNd8S+4tj+j1lt0Na3wsGNd8Rn/AGbb+UldOC/ioyxn8Jno9c18RNMbVPCV8kGftUC/aYCOokT5hj64I/GulPWgjIwelezJcyszx4vlaaPIdHv1vrC3uU6SoGx6HuK17d65fR4DptzqemEYFleSRIP9gncv6Guhtm6V89Jcsmj3k+aKZp54oNNQ5WnUyStOOtZV0vNbEw4rMuhxUsuLNf4RTMmmapp7Hi0vG8seiOAw/Umu9rzD4d3AtvGuoWpOBeWaTD/ejYr/ACavT69zDS5qSZ42Jjy1WgooorcwCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDmfiVdfZPA2sODhpITCv1chP/Zq4TSYBFBHGvRFCj8Biuj+L0+dP0iwHW6vVZh6rGCx/XbWLYL8grycfK80j1cDG1Ns0YVq2vAqGIcVP2rjR0MY5wKzbtuTV6ZsA1lXTcGkyooz7qVYw7vwqgsT7CvQPhpbG38F6czjElwpuWz6yMX/AK15hrKSXNulnAf397Klsn1c4J/LJr3G0gS1tYbeIbY4kCKPQAYFehl8N5HHj5aKJLWb4kz/AGDqRXqLaQ/+OmtKoL2MS2c8Z6PGy/mK9J7HmrRnifhsf8Saw/64p/IV0Fv1FYPhjB0KyPpEo/IYrftuor517s+g6GpD92pKji+7UlMzYUCkp6imJsevFI8m0ZpQKinQshAqtiSs+oIH21cicPGGWuS1e1uWI8lGbnoK6bSIpI7CJJuXC80RuxySRbBprU7tSNTZKITRQetFQWiOTpWdc1oyHis6461LKiUJOjVt/C051XxAfe3H/jr/AONYz9TW38K1zd+IJPWeNPyjz/WurBfxTHGfwmeg0UUV7J455J4th+xfEC+X+G+torkfVcof5CprV+BWh8WrTyZ9E1dR/qpjayn/AGJBxn6MB+dY9s2DivExceWq/M9rCy5qS8jcgbIqaqds1XBWCLZHL0rNuRlTWnJ92qE460mOJjWExsPG3h+6zhHma0f38xSB+oFezV4Z4o3Q6ebqP/WWkkdwvsVYH+Wa9xRxIiOhyrAEH1FergJXg12PPx0bTT7jqKKK7jhCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDy/4nSGbxfo0Ha3tZZ/xZlX+hptiuI1qPxtIJ/HdwP8An3s4Y/xZnY/0qzaD5Frw8U71me1h1aii9EOKeaROlEhwKxLKl0+AayLl81eu35NZcrc5JwKlmsUXPBlkdQ8cW7kZg02Bp2P/AE0fKqPyDGvWa4b4S2rf2HdapIMNqNw0iZ7Rr8ifyJ/Gu5r3MLDkppHi4qfPUbCmyfcP0NOpsv3a6Gc6PD/DA26PGh6o7ofwcit+27Vj6UnlPqMI/wCWV9cJj/toT/Wtm36CvnZq0mfQRd4o0ojU1V4jwKnHShEMWnr0plOU0ySVaeFBqNalU8VrEhieSvoKCABgU5mqMnNN2FqBpj9KUmmMc1DZSGGkp2OM01qgtEUp4qjN1NXJKqSDOallIouOa3fhQPl14/8AT9j/AMhp/jWLMuK2fhMcpr+f+f8AP/otK68D/FMMZ/CO/ooor2DyDG8Y6V/bXhnUbAD95LEfL9nHK/qBXlmjXJubG3mfh2Qbh6N0I/PNe2V43qdsdL8W6vYEYjeT7ZBxjKSckD6NuFefj6d4qZ6GAnZuBq27citGNsisi3bgVoQPXmI75Ist0qnOKu9RVeZeKbJRz2uwedp93FjO+F1/NTXpPgu4N34P0WduWaziJ+u0A1wt4B3rq/hjJv8AA+nITzD5kB9tkjL/AEruy9+9JHLjl7qZ1VFFFeoeYFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFB6UAeRasklx4v1ycg7TcLEv0SNR/PNatuhCiuml0qN5JJCo3SOzk+5NR/wBlAH5a8mrh5Obl3PUp4iKgo9jIXgVHcNha2JNMkH3Rmsu/s5k/hNc8qUo7o2jUjLqYd0/JrF1SOa6jisbXi4vZVtkP93d1P4Lk1tTwPkjBq94H0uS58VvfSJ/o1hCUQkdZX64+ijH/AAKihSc6iRdWqqdNs9D06zh0+wt7O2XbBBGsaL6ADAqxRRXvHhBTZPuGnUjDKmgDxmzUrrXiFPTUZT+eDWtbDinrpc6a5rkvlkJLdllPr8qg/wAquRWjr1WvBrQamz26c04ISOrC9KQQsO1O2kdqiw20xKcDTaKAJQacDUQNOBqkybEmaQmkzSE07iSEJpuKWipKFPSqWp3DW1qzxKGlZlRFPQsxAGfbn8qtmqt9bfaodm5kYMHV16qwOQeaBmU9zcW0d+00yT/Z4w3K7AGwSRxnjG2otLvJrrzkka3lkjVSWiyFDkHK9T04596sDSMW1zC087m4k815Djdu46cYx8o4pkugPdhzNPI0zbcSBQNoGeAB/vHrnr9KmzZV0ila309wYUmgCM0JlZwwweQBgc8Hk8+ldN8KDh/ECd/tav8AgY1/wqnb6JKm9nYySuACwXaAo6KB2AyfzNbPgrTZdM1jUNw/d3MUbj6qWH8mH5V14OMlUu0c2KknTtc7KiiivXPKCvP/AIq2BQabrcK/NbSfZ5yO8UnGT9G2n8TXoFU9YsI9U0q8sZv9XcRNETjOMjGfw61FWHPFxNKU+SakeW2r84rSgbkViadb3ccPlXSEXMDGGX/eXjP49fxrXtkkOMqa+f5WnZnuNpq6NOM5FRyjipoIJCB8pqylhJIfu1ahKWyMnOK3Zz14uRxW/wDCxmXSNSgcEeVfy7QfRgrfzY1dg0MM2ZBWzptnHZmURLjeQx+uMV34ShKEuZnHiq8Zx5UXqKKK9E4AooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoPQ4oooAg2Y6ilCe1TUUrDuRbBiq1xbo/UVexTSgNJxTGpNGDLpMbnIFa2m2kdlarFEABksfcnqasCNRTqmFNRd0VKo5KzCiiitDMKKKKAKT2yksccscnim/YoyOVq/RUOmnuWptbGa9gh6CoH0wHpWzRiodCD6FKtJdTBbSf84pn9lGuhoqPqtMr6xPuc9/ZOaX+yT610FGBR9Vph9Ymc8dKNJ/ZZ966LA9KTaPSj6rAf1mZzv9lNT10o+tdBgelGBQsLATxEzBGletPGlCtvFFV9Wh2F7eZjppUeeRVhNPiXoK0KKpUYLoS6sn1KqWqg9KmSJVYMOoGKkorRRS2IcmwooopiCiiigDJu9JhkupZwoDS4LfUcZpsWmRKfuitiis3Si3exoqkkrXKkdpGo4WplhUdqloqlFIlybECgdqWiiqJCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    When asthma flares, the muscles around the airways tighten (constrict), and the lining of the airways gets inflamed. Then, mucus builds up. All of this makes it hard to breathe.",
"    <br/>",
"    Asthma medicines work in different ways. Short-acting beta agonists (SABAs) and long-acting beta agonists (LABAs) relax the muscle constriction around the airways. Steroids reduce inflammation in the airways. Leukotriene modifiers relax muscles and reduce inflammation and mucus buildup. Omalizumab lowers or stops the allergic reaction that starts inflammation. All these medicines make it easier to breathe and reduce the risk of asthma attacks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_52_837=[""].join("\n");
var outline_f0_52_837=null;
var title_f0_52_838="Sodium nitrite and sodium thiosulfate: Drug information";
var content_f0_52_838=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sodium nitrite and sodium thiosulfate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/37/34387?source=see_link\">",
"    see \"Sodium nitrite and sodium thiosulfate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/33/32277?source=see_link\">",
"    see \"Sodium nitrite and sodium thiosulfate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F11566635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F11460129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nithiodote&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F11566638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidote",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F11567004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Cyanide poisoning:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Administer sodium nitrite first, followed immediately by the administration of sodium thiosulfate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Sodium nitrite:",
"     </i>",
"     300 mg (10 mL of a 3% solution); may repeat at one-half the original dose if symptoms of cyanide toxicity return",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Alternatively, in patients who are unable to tolerate significant methemoglobinemia (eg, patients with comorbidities that compromise oxygen delivery, such as heart disease, lung disease), dosing may be based on hemoglobin levels (when rapid bedside testing is available) to prevent fatal methemoglobinemia; see table (Berlin, 1970):",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"200\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Hemoglobin Level (g/dL)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dose of 3%",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Sodium Nitrite Solution",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (maximum dose: 10 mL)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.19 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.22 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         9",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.25 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.27 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         11",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.3 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.33 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         13",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.36 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         14",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.39 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <i>",
"      Sodium thiosulfate:",
"     </i>",
"     12.5 g (50 mL of a 25% solution); may repeat at one-half the original dose if symptoms of cyanide toxicity return",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Monitor the patient for 24-48 hours; if symptoms return, repeat both sodium nitrite and sodium thiosulfate at one-half the original doses.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F11566803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/33/32277?source=see_link\">",
"      see \"Sodium nitrite and sodium thiosulfate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Cyanide poisoning:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Administer sodium nitrite first, followed immediately by the administration of sodium thiosulfate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Sodium nitrite:",
"     </i>",
"     6 mg/kg (0.2 mL/kg or 6-8 mL/m",
"     <sup>",
"      2",
"     </sup>",
"     of a 3% solution); maximum dose: 300 mg (10 mL of a 3% solution); may repeat at one-half the original dose if symptoms of cyanide toxicity return",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Alternatively, in patients who are unable to tolerate significant methemoglobinemia (eg, patients with comorbidities that compromise oxygen delivery, such as heart disease, lung disease): Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:0em;\">",
"     <i>",
"      Sodium thiosulfate:",
"     </i>",
"     7 g/m",
"     <sup>",
"      2",
"     </sup>",
"     or 250 mg/kg (1 mL/kg or 28-40 mL/m",
"     <sup>",
"      2",
"     </sup>",
"     of a 25% solution); maximum dose: 12.5 g (50 mL of a 25% solution); may repeat at one-half the original dose if symptoms of cyanide toxicity return",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Monitor the patient for 24-48 hours; if symptoms return, repeat both sodium nitrite and sodium thiosulfate at one-half the original doses.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14599428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling; however, renal elimination of sodium nitrite and sodium thiosulfate is significant and risk of adverse effects may be increased in patients with renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14599429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13165159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [combination package]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nithiodote&trade;: Sodium nitrite 300 mg/10 mL (10 mL) and sodium thiosulfate 12.5 g/50 mL (50 mL)",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11567020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer via slow I.V. injection as soon as possible after diagnosis of acute, life-threatening cyanide poisoning.  Administer sodium nitrite first at a rate of 2.5-5 mL/minute, followed immediately by the administration of sodium thiosulfate over 10-20 minutes. Decrease rate of infusion in the event of significant hypotension, nausea, or vomiting.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F11566791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Y-site administration: Incompatible:",
"     </b>",
"     Hydroxocobalamin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F11566639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute, life-threatening cyanide poisoning",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F11566785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sodium nitrite:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, cyanosis, flushing, hypotension, palpitations, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety, coma, confusion, dizziness, fatigue, headache, lightheadedness, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Acidosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Methemoglobinemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site tingling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Numbness, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea, tachypnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sodium thiosulfate:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Disorientation, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, salty taste, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Bleeding time prolonged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Warmth",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F11566643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11566684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypotension:",
"     <b>",
"      [U.S. Boxed Warning]: Sodium nitrite may cause severe hypotension resulting in diminished oxygen-carrying capacity; serious adverse effects may occur at doses less than twice the recommended therapeutic dose. Monitor for adequate perfusion and oxygenation; ensure patient is euvolemic. Use with caution in patients where the diagnosis of cyanide poisoning is uncertain, patients with pre-existing diminished oxygen or cardiovascular reserve (eg, smoke inhalation victims, anemia, substantial blood loss, and cardiac or respiratory compromise)",
"     </b>",
"     and in patients who may be susceptible to injury from vasodilation; the use of hydroxocobalamin is recommended in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Methemoglobinemia:",
"     <b>",
"      [U.S. Boxed Warning]: Sodium nitrite may cause methemoglobin formation resulting in diminished oxygen-carrying capacity; serious adverse effects may occur at doses less than twice the recommended therapeutic dose. Monitor for adequate perfusion and oxygenation. Use with caution in patients where the diagnosis of cyanide poisoning is uncertain, patients with pre-existing diminished oxygen or cardiovascular reserve (eg, smoke inhalation victims, anemia, substantial blood loss, and cardiac or respiratory compromise), and in patients at greater risk for developing methemoglobinemia (eg, congenital methemoglobin reductase deficiency);",
"     </b>",
"     the use of hydroxocobalamin is recommended in these patients. Use with caution with concomitant medications known to cause methemoglobinemia (eg, nitroglycerin).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &bull; Antihypertensives: Concurrent use of antihypertensives or diuretics and sodium nitrite should be done with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &bull; Phosphodiesterase-5 enzyme (PDE5) inhibitors: Concurrent use of PDE5 inhibitors and sodium nitrite should be done with caution due to the increase in vascular nitric oxide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &bull; Anemia: Use with caution; patients with anemia will form more methemoglobin. Dosage reduction in proportion to oxygen-carrying capacity is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &bull; G6PD deficiency: Patients with G6PD deficiency are at an increased risk for hemolytic crisis following sodium nitrite administration; monitor for an acute drop in hematocrit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &bull; Fire victims: Fire victims may present with both cyanide and carbon monoxide poisoning. In this scenario, sodium thiosulfate may be used alone to promote the clearance of cyanide. Hydroxocobalamin, however, may be considered because sodium thiosulfate has a slow onset of action.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &bull; Pediatrics: Methemoglobin reductase, which is responsible for converting methemoglobin back to hemoglobin, has reduced activity in pediatric patients. In addition, infants and young children have some proportion of fetal hemoglobin which forms methemoglobin more readily than adult hemoglobin. Therefore, pediatric patients (eg, neonates and infants &lt;6 months of age) are more susceptible to excessive nitrite-induced methemoglobinemia. Hydroxocobalamin may be a more effective and rapid alternative.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &bull; Pregnancy: Nitrites should be avoided due to fetal hemoglobin's susceptibility to oxidative stress.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &bull; Sulfite hypersensitivity: The presence of sulfite hypersensitivity should not preclude the use of this medication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &bull; Appropriate use: Cyanide poisoning: Due to the risk for serious adverse effects, use with caution in patients where the diagnosis of cyanide poisoning is uncertain. However, if clinical suspicion of cyanide poisoning is high, treatment should not be delayed. Treatment of cyanide poisoning should include decontamination and supportive therapy. Consider consultation with a poison control center at 1-800-222-1222.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &bull; Initiation of treatment: Collection of pretreatment blood cyanide concentrations does not preclude administration and should not delay administration in the emergency management of highly suspected or confirmed cyanide toxicity. Pretreatment levels may be useful as postinfusion levels may be inaccurate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &bull; Return of symptoms: Patients receiving treatment for acute cyanide poisoning must be monitored for return of symptoms for 24-48 hours; repeat treatment should be administered if symptoms return.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &bull; Smoke inhalation: Use nitrites cautiously in patients with cyanide poisoning related to smoke inhalation because methemoglobinemia and carboxyhemoglobinemia may worsen oxygen-carrying capacity.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F12608847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F11566640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11566641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed following maternal exposure to high concentrations of sodium nitrite in drinking water. Teratogenic effects were not observed in animal reproduction studies of sodium nitrite or sodium thiosulfate. Embryotoxic and nonteratogenic effects were observed in animal reproduction studies of sodium nitrite. Methemoglobin reductase is lower in the fetus compared to adults and may result in adverse effects due to nitrite-induced prenatal hypoxia. There are no adequate and well-controlled studies of Nithiodote&trade; in pregnant women. In general, medications used as antidotes should take into consideration the health and prognosis of the mother (Bailey, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F11566642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Nithiodote Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300MG/10ML-12.5 gm/50 mL (60 mL): $330.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F11567023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for at least 24-48 hours after administration; blood pressure and heart rate during and after infusion; hemoglobin/hematocrit; co-oximetry; serum lactate levels; venous-arterial PO",
"     <sub>",
"      2",
"     </sub>",
"     gradient; serum methemoglobin and oxyhemoglobin. Pretreatment cyanide levels may be useful diagnostically.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F11566792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium nitrite: Promotes the formation of methemoglobin which competes with cytochrome oxidase for the cyanide ion. Cyanide combines with methemoglobin to form cyanomethemoglobin, thereby freeing the cytochrome oxidase and allowing aerobic metabolism to continue.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium thiosulfate: Serves as a sulfur donor in rhondanese-catalyzed formation of thiocyanate (much less toxic than cyanide).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F11566794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Sodium nitrite:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Onset: Peak effect: Methemoglobinemia: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Duration: Methemoglobinemia: ~55 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Metabolism: To ammonia and other metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Excretion: Urine (~40% as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Sodium thiosulfate:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Half-life elimination: Thiosulfate: ~3 hours; Thiocyanate: ~3 days; Renal impairment: &le;9 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Excretion: Urine (~20% to 50% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Agency for Toxic Substances and Disease Registry (ATSDR), &ldquo;Medical Management Guidelines for Hydrogen Cyanide (HCN).&rdquo; Available at",
"      <a href=\"file://www.atsdr.cdc.gov/MHMI/mmg8.pdf\" target=\"_blank\">",
"       file://www.atsdr.cdc.gov/MHMI/mmg8.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bailey B, \"Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?\"",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(2):133-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/52/838/abstract-text/12769509/pubmed\" id=\"12769509\" target=\"_blank\">",
"        12769509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berlin CM, &ldquo;The Treatment of Cyanide Poisoning in Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1970, 46(5):793-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/52/838/abstract-text/4320419/pubmed\" id=\"4320419\" target=\"_blank\">",
"        4320419",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Geller RJ, Barthold C, Saiers JA, et al, &ldquo;Pediatric Cyanide Poisoning: Causes, Manifestations, Management, and Unmet Needs,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 118(5):2146-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/52/838/abstract-text/17079589/pubmed\" id=\"17079589\" target=\"_blank\">",
"        17079589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gracia R and Shepherd G, &ldquo;Cyanide Poisoning and Its Treatment,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2004, 24(10):1358-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/52/838/abstract-text/15628833/pubmed\" id=\"15628833\" target=\"_blank\">",
"        15628833",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hall AH, Dart R, and Bogdan G, &ldquo;Sodium Thiosulfate or Hydroxocobalamin For The Empiric Treatment of Cyanide Poisoning?&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2007, 49(6):806-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/52/838/abstract-text/17098327/pubmed\" id=\"17098327\" target=\"_blank\">",
"        17098327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Howland MA, &ldquo;Antidotes in Depth: Sodium and Amyl Nitrite,&rdquo;",
"      <i>",
"       Goldfrank's Toxicologic Emergencies",
"      </i>",
"      , 9th ed, Nelson LS, Hoffman RS, Lewin NA, et al, eds, New York, NY: McGraw-Hill Companies, Inc, 2011, 1519-22.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Howland MA, &ldquo;Antidotes in Depth: Sodium Thiosulfate,&rdquo;",
"      <i>",
"       Goldfrank's Toxicologic Emergencies",
"      </i>",
"      , 9th ed, Nelson LS, Hoffman RS, Lewin NA, et al, eds, New York, NY: McGraw-Hill Companies, Inc, 2011.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16469 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-93.125.6.160-7DBF348CA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_52_838=[""].join("\n");
var outline_f0_52_838=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11566635\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11460129\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11566638\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11567004\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11566803\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14599428\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14599429\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13165159\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11567020\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11566791\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11566639\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11566785\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11566643\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11566684\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300061\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12608847\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11566640\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11566641\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11566642\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322886\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11567023\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11566792\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11566794\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16469\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16469|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/37/34387?source=related_link\">",
"      Sodium nitrite and sodium thiosulfate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/33/32277?source=related_link\">",
"      Sodium nitrite and sodium thiosulfate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_52_839="Trichinellosis life cycle";
var content_f0_52_839=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 513px\">",
"   <div class=\"ttl\">",
"    Trichinellosis life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 493px; height: 476px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Depending on the classification used, there are several species of",
"    <em>",
"     Trichinella",
"    </em>",
"    :",
"    <em>",
"     T. spiralis",
"    </em>",
"    ,",
"    <em>",
"     T. pseudospiralis",
"    </em>",
"    ,",
"    <em>",
"     T. nativa",
"    </em>",
"    ,",
"    <em>",
"     T. murelli",
"    </em>",
"    ,",
"    <em>",
"     T. nelsoni",
"    </em>",
"    ,",
"    <em>",
"     T. britovi",
"    </em>",
"    ,",
"    <em>",
"     T. papuae",
"    </em>",
"    , and",
"    <em>",
"     T. zimbabwensis",
"    </em>",
"    , all but the last of which have been implicated in human disease. Adult worms and encysted larvae develop within a single vertebrate host, and an infected animal serves as a definitive host and potential intermediate host. A second host is required to perpetuate the life cycle of",
"    <em>",
"     Trichinella",
"    </em>",
"    . The domestic cycle most often involved pigs and anthropophilic rodents, but other domestic animals, such as horses, can be involved. In the sylvatic cycle, the range of infected animals is great, but animals most often associated as sources of human infection are bear, moose, and wild boar.",
"    <br>",
"     Trichinellosis is caused by the ingestion of undercooked meat containing encysted larvae (except for",
"     <em>",
"      T. pseudospiralis",
"     </em>",
"     and",
"     <em>",
"      T. papuae",
"     </em>",
"     , which do not encyst) of",
"     <em>",
"      Trichinella",
"     </em>",
"     species",
"     <strong>",
"      (1)",
"     </strong>",
"     . After exposure to gastric acid and pepsin, the larvae are released from the cysts",
"     <strong>",
"      (2)",
"     </strong>",
"     and invade the small bowel mucosa where they develop into adult worms",
"     <strong>",
"      (3)",
"     </strong>",
"     . Females are 2.2 mm in length; males 1.2 mm. The life span in the small bowel is about four weeks. After one week, the females release larvae",
"     <strong>",
"      (4)",
"     </strong>",
"     that migrate to striated muscles where they encyst",
"     <strong>",
"      (5)",
"     </strong>",
"     . Diagnosis is usually made based on clinical symptoms, and is confirmed by serology or identification of encysted or nonencysted larvae in biopsy or autopsy specimens.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Trichinellosis. Available at:",
"      <a href=\"file://www.dpd.cdc.gov/dpdx/html/Trichinellosis.htm\" target=\"_blank\">",
"       file://www.dpd.cdc.gov/dpdx/html/Trichinellosis.htm",
"      </a>",
"      .",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_52_839=[""].join("\n");
var outline_f0_52_839=null;
var title_f0_52_840="Sodium bicarbonate: Drug information";
var content_f0_52_840=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sodium bicarbonate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/21/4437?source=see_link\">",
"    see \"Sodium bicarbonate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"    see \"Sodium bicarbonate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Brioschi&reg; [OTC];",
"     </li>",
"     <li>",
"      Neut&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F221638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alkalinizing Agent;",
"     </li>",
"     <li>",
"      Antacid;",
"     </li>",
"     <li>",
"      Electrolyte Supplement, Oral;",
"     </li>",
"     <li>",
"      Electrolyte Supplement, Parenteral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F221615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cardiac arrest (ACLS, 2010):",
"     </b>",
"     I.V.: Initial: 1 mEq/kg/dose; repeat doses should be guided by arterial blood gases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Routine use of NaHCO",
"     </b>",
"     <sub>",
"      3",
"     </sub>",
"     <b>",
"      is not recommended.",
"     </b>",
"     May be considered in the setting of prolonged cardiac arrest only after adequate alveolar ventilation has been established and effective cardiac compressions.",
"     <b>",
"      Note:",
"     </b>",
"     In some cardiac arrest situations (eg, metabolic acidosis, hyperkalemia, or tricyclic antidepressant overdose), sodium bicarbonate may be beneficial.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Metabolic acidosis:",
"     </b>",
"     I.V.: Dosage should be based on the following formula if blood gases and pH measurements are available:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HCO",
"     <sub>",
"      3",
"     </sub>",
"     <sup>",
"      -",
"     </sup>",
"     (mEq) = 0.5 x weight (kg) x [24 - serum HCO",
"     <sub>",
"      3",
"     </sub>",
"     <sup>",
"      -",
"     </sup>",
"     (mEq/L)]",
"     <b>",
"      or",
"     </b>",
"     HCO",
"     <sub>",
"      3",
"     </sub>",
"     <sup>",
"      -",
"     </sup>",
"     (mEq) = 0.5 x weight (kg) x [desired increase in serum HCO",
"     <sub>",
"      3",
"     </sub>",
"     <sup>",
"      -",
"     </sup>",
"     (mEq/L)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Administer",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     dose initially, then remaining",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     dose over the next 24 hours; monitor pH, serum HCO",
"     <sub>",
"      3",
"     </sub>",
"     <sup>",
"      -",
"     </sup>",
"     , and clinical status.",
"     <b>",
"      Note:",
"     </b>",
"     These equations provide an estimated replacement dose. The underlying cause and degree of acidosis may result in the need for larger or smaller replacement doses. In most cases, the initial goal of therapy is to target a pH of ~7.2 and a plasma bicarbonate level of ~10 mEq/L to prevent overalkalinization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     If acid-base status is not available: 2-5 mEq/kg I.V. infusion over 4-8 hours; subsequent doses should be based on patient's acid-base status",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hyperkalemia (ACLS, 2010):",
"     </b>",
"     I.V.: 50 mEq over 5 minutes (as appropriate, consider methods of enhancing potassium removal/excretion)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic renal failure:",
"     </b>",
"     Oral: Initiate when plasma HCO",
"     <sub>",
"      3",
"     </sub>",
"     <sup>",
"      -",
"     </sup>",
"     &lt;15 mEq/L Start with 20-36 mEq/day in divided doses, titrate to bicarbonate level of 18-20 mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Renal tubular acidosis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Distal:",
"     </i>",
"     0.5-2 mEq/kg/day in 4-5 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Proximal:",
"     </i>",
"     Initial: 5-10 mEq/kg/day; maintenance: Increase as required to maintain serum bicarbonate in the normal range",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Urine alkalinization:",
"     </b>",
"     Oral: Initial: 48 mEq (4 g), then 12-24 mEq (1-2 g) every 4 hours; dose should be titrated to desired urinary pH; doses up to 16 g/day (200 mEq) in patients &lt;60 years and 8 g (100 mEq) in patients &gt;60 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antacid:",
"     </b>",
"     Oral: 325 mg to 2 g 1-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of contrast-induced nephropathy (unlabeled use):",
"     </b>",
"     I.V. infusion: 154 mEq/L sodium bicarbonate in D",
"     <sub>",
"      5",
"     </sub>",
"     W solution: 3 mL/kg/hour for 1 hour immediately before contrast injection, then 1mL/kg/hour during contrast exposure and for 6 hours after procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     To prepare solution, remove 154 mL from 1000 mL bag of D",
"     <sub>",
"      5",
"     </sub>",
"     W; replace with 154 mL of 8.4% sodium bicarbonate; resultant concentration is 154 mEq/L (Merten, 2004); more practically, institutions may remove 150 mL from 1000 mL bag of D",
"     <sub>",
"      5",
"     </sub>",
"     W and replace with 150 mL of 8.4% sodium bicarbonate; resultant concentration is 150 mEq/L",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F221628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"      see \"Sodium bicarbonate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cardiac arrest (PALS, 2010):",
"     </b>",
"     I.V., I.O.: Infants and Children: 1 mEq/kg/dose; repeat doses should be guided by arterial blood gases; children &lt;2 years of age should receive 4.2% (0.5 mEq/mL) solution.",
"     <b>",
"      Note:",
"     </b>",
"     If I.O. route is used for administration and is subsequently used to obtain blood samples for acid-base analysis, results will be inaccurate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Routine use of NaHCO",
"     </b>",
"     <sub>",
"      3",
"     </sub>",
"     <b>",
"      is not recommended.",
"     </b>",
"     May be considered in the setting of prolonged cardiac arrest only after adequate alveolar ventilation has been established and effective cardiac compressions.",
"     <b>",
"      Note:",
"     </b>",
"     In some cardiac arrest situations (eg, metabolic acidosis, hyperkalemia, or tricyclic antidepressant overdose), sodium bicarbonate may be beneficial.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Metabolic acidosis:",
"     </b>",
"     I.V.: Infants and Children: Dosage should be based on the following formula if blood gases and pH measurements are available:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HCO",
"     <sub>",
"      3",
"     </sub>",
"     <sup>",
"      -",
"     </sup>",
"     (mEq) = 0.5 x weight (kg) x [24 - serum HCO",
"     <sub>",
"      3",
"     </sub>",
"     <sup>",
"      -",
"     </sup>",
"     (mEq/L)]",
"     <b>",
"      or",
"     </b>",
"     HCO",
"     <sub>",
"      3",
"     </sub>",
"     <sup>",
"      -",
"     </sup>",
"     (mEq) = 0.5 x weight (kg) x [desired increase in serum HCO",
"     <sub>",
"      3",
"     </sub>",
"     <sup>",
"      -",
"     </sup>",
"     (mEq/L)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Administer",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     dose initially, then remaining",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     dose over the next 24 hours; monitor pH, serum HCO",
"     <sub>",
"      3",
"     </sub>",
"     <sup>",
"      -",
"     </sup>",
"     , and clinical status.",
"     <b>",
"      Note:",
"     </b>",
"     These equations provide an estimated replacement dose. The underlying cause and degree of acidosis may result in the need for larger or smaller replacement doses. In most cases, the initial goal of therapy is to target a pH of ~7.2 and a plasma bicarbonate level of ~10 mEq/L to prevent overalkalinization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     If acid-base status is not available: Dose for older Children: 2-5 mEq/kg I.V. infusion over 4-8 hours; subsequent doses should be based on patient's acid-base status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic renal failure:",
"     </b>",
"     Oral: Children: Initiate when plasma HCO",
"     <sub>",
"      3",
"     </sub>",
"     <sup>",
"      -",
"     </sup>",
"     &lt;15 mEq/L: 1-3 mEq/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Renal tubular acidosis, distal:",
"     </b>",
"     Oral: Children: 2-3 mEq/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Renal tubular acidosis, proximal:",
"     </b>",
"     Children: Initial: 5-10 mEq/kg/day; maintenance: Increase as required to maintain serum bicarbonate in the normal range",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Urine alkalinization:",
"     </b>",
"     Oral: Children: 1-10 mEq (84-840 mg)/kg/day in divided doses every 4-6 hours; dose should be titrated to desired urinary pH.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F221616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F221592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules for solution, oral [effervescent]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Brioschi&reg;: 2.69 g/capful (120 g, 240 g) [contains sodium 770 mg/capful; lemon flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Brioschi&reg;: 2.69 g/packet (12s) [contains sodium 770 mg/packet; lemon flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 4.2% [5 mEq/10 mL] (10 mL); 8.4% [10 mEq/10 mL] (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neut&reg;: 4% [2.4 mEq/5 mL] (5 mL) [contains edetate disodium]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 4.2% [5 mEq/10 mL] (5 mL); 7.5% [8.92 mEq/10 mL] (50 mL); 8.4% [10 mEq/10 mL] (10 mL, 50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, oral: USP: 100% (120 g, 480 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 325 mg [3.8 mEq], 650 mg [7.6 mEq]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F221578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes granules",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F221596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For I.V. administration to infants, use the 0.5 mEq/mL solution or dilute the 1 mEq/mL solution 1:1 with",
"     <b>",
"      sterile water",
"     </b>",
"     ; for direct I.V. infusion in emergencies, administer slowly (maximum rate in infants: 10 mEq/minute); for infusion, dilute to a maximum concentration of 0.5 mEq/mL in dextrose solution and infuse over 2 hours (maximum rate of administration: 1 mEq/kg/hour)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral product should be administered 1-3 hours after meals.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F221645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with acids, acidic salts, alkaloid salts, calcium salts, catecholamines, and atropine;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, LR, fat emulsion 10%, TPN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, amifostine, asparaginase, aztreonam, bivalirudin, caffeine citrate, cefepime, ceftriaxone, cladribine, cyclophosphamide, cytarabine, daunorubicin, dexamethasone sodium phosphate, dexmedetomidine, docetaxel, doripenem, doxorubicin, etoposide, etoposide phosphate, famotidine, fentanyl, filgrastim, fludarabine, furosemide, gallium nitrate, gemcitabine, granisetron, heparin, heparin with hydrocortisone sodium succinate, ifosfamide, indomethacin, insulin (regular), levofloxacin, linezolid, melphalan, mesna, methylprednisolone sodium succinate, milrinone, morphine, oxaliplatin, paclitaxel, pancuronium, pemetrexed, piperacillin/tazobactam, potassium chloride, propofol, remifentanil, tacrolimus, telavancin, teniposide, thiotepa, tolazoline, vancomycin, vasopressin, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, amiodarone, amphotericin B cholesteryl sulfate complex, anidulafungin, calcium chloride, doxorubicin liposome, fenoldopam, hetastarch in lactate electrolyte injection (Hextend&reg;), idarubicin, imipenem/cilastatin, inamrinone, leucovorin calcium, midazolam, nalbuphine, ondansetron, oxacillin, sargramostim, verapamil, vincristine, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ciprofloxacin, cisatracurium, diltiazem, pantoprazole, TPN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Caffeine citrate, milrinone, pentobarbital.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Dimenhydrinate, glycopyrrolate, mepivacaine, metoclopramide, pantoprazole, thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Bupivacaine, chloroprocaine, lidocaine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F221595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of metabolic acidosis; gastric hyperacidity; as an alkalinization agent for the urine; treatment of hyperkalemia; management of overdose of certain drugs, including tricyclic antidepressants and aspirin",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F5524440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of contrast-induced nephropathy (CIN)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F221636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cerebral hemorrhage, CHF (aggravated), edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Tetany",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Belching, flatulence (with oral), gastric distension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypernatremia, hyperosmolality, hypocalcemia, hypokalemia, increased affinity of hemoglobin for oxygen-reduced pH in myocardial tissue necrosis when extravasated, intracranial acidosis, metabolic alkalosis, milk-alkali syndrome (especially with renal dysfunction)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pulmonary edema",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F221599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alkalosis, hypernatremia, severe pulmonary edema, hypocalcemia, unknown abdominal pain",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F221582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cirrhosis: Use with caution in patients with cirrhosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Edema: Use with caution in patients with edema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Use with caution in patients with heart failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peptic ulcer disease: Not to be used in treatment of peptic ulcer disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; may cause sodium retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Not the antacid of choice for the elderly because of sodium content and potential for systemic alkalosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Rapid administration in neonates and children &lt;2 years of age has led to hypernatremia, decreased CSF pressure and intracranial hemorrhage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injection:",
"     <b>",
"      Use of I.V. NaHCO",
"     </b>",
"     <sub>",
"      3",
"     </sub>",
"     <b>",
"      should be reserved for documented metabolic acidosis and for hyperkalemia-induced cardiac arrest.",
"     </b>",
"     Routine use in cardiac arrest is not recommended. Avoid extravasation, tissue necrosis can occur due to the hypertonicity of NaHCO",
"     <sub>",
"      3",
"     </sub>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F221587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Antacids may decrease the serum concentration of ACE Inhibitors.  Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Enalaprilat; Ramipril.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AcetaZOLAMIDE: May enhance the adverse/toxic effect of Sodium Bicarbonate. Specifically, the risk of renal calculus formation may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Antacids may decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Alkalinizing Agents may decrease the excretion of Amphetamines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antacids may decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Antacids may decrease the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antacids may decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Antacids may decrease the absorption of Atazanavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisacodyl: Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine.  Gastric irritation and/or cramps may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Antacids may decrease the serum concentration of Bosutinib.  Management: Administer antacids more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the cation exchange resin.  Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of CPS effects. Avoid magnesium hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Antacids may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy. If antacid therapy can not be avoided, separate dosing by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefpodoxime: Antacids may decrease the serum concentration of Cefpodoxime.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefuroxime: Antacids may decrease the serum concentration of Cefuroxime.  Management:  Consider administering antacids and cefuroxime at least 2 hours apart.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloroquine: Antacids may decrease the serum concentration of Chloroquine.  Management: Separate administration of antacids and chloroquine by at least 4 hours to minimize any potential negative impact of antacids on chloroquine bioavailability.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Oral): Antacids may decrease the bioavailability of Corticosteroids (Oral).  Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Antacids may decrease the serum concentration of Dabigatran Etexilate.  Management: Dabigatran etexilate Canadian product labeling recommends avoiding concomitant use with antacids for 24 hours after surgery. In other situations, administer dabigatran etexilate 2 hours prior to antacids. Monitor clinical response to dabigatran therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Antacids may decrease the absorption of Dasatinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Antacids may decrease the serum concentration of Delavirdine.  Management: Separate doses of delavirdine and antacids by at least 1 hour. Monitor for decreased delavirdine therapeutic effects with this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Antacids may increase the absorption of Dexmethylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Antacids may decrease the serum concentration of Elvitegravir.  Management: Separate administration of antacids and the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product by at least 2 hours in order to minimize the risk for an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Antacids may decrease the serum concentration of Erlotinib.  Management: Separate the administration of erlotinib and any antacid by several hours in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flecainide: Sodium Bicarbonate may diminish the arrhythmogenic effect of Flecainide. Sodium Bicarbonate may increase the serum concentration of Flecainide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gabapentin: Antacids may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after antacid administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy when both of these drugs are being used.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Antacids may decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Antacids may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Antacids may decrease the absorption of Isoniazid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Antacids may decrease the serum concentration of Itraconazole.  Management: Administer itraconazole at least 1 hour after and 2 hours before administration of any antacids.  Itraconazole oral suspension may be less sensitive to the effects of decreased gastric acidity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Antacids may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any antacid product.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Sodium Bicarbonate may increase the excretion of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Memantine: Sodium Bicarbonate may decrease the excretion of Memantine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Antacids may diminish the therapeutic effect of Mesalamine. Antacid-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Avoid concurrent administration of antacids with sustained-release mesalamine products.  Separating antacid and mesalamine administration, and/or using lower antacid doses may be adequate means of avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: Antacids may diminish the therapeutic effect of Methenamine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antacids may increase the absorption of Methylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Antacids may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, antacids may decrease the absorption of orally administered iron.  Management: Separate dosing of oral iron-containing multivitamin preparations and antacids by as much time as possible in order to minimize impact on therapeutic efficacy of the iron preparation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Antacids may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and any antacid by several hours whenever possible in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PenicillAMINE: Antacids may decrease the serum concentration of PenicillAMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Antacids may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Antacids may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Antacids may decrease the absorption of Protease Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Darunavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Antacids may decrease the excretion of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Alkalinizing Agents may increase the serum concentration of QuiNINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Antacids may decrease the serum concentration of Rilpivirine.  Management: Administer antacids at least 2 hours before or 4 hours after rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Antacids may decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Antacids may decrease the absorption of Trientine.  Management: Separate trientine dosing from other oral drugs (eg, antacids) by at least 1 hour. Monitor for decreased therapeutic effects of trientine if an antacid is initiated/dose increased, or increased effects if an antacid is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Antacids may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F221609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Concurrent doses with iron may decrease iron absorption.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F221589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13888241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. The use of sodium bicarbonate in pregnant women for the management of cardiac arrest and metabolic acidosis is the same as in nonpregnant women (Campbell, 2009; Vanden Hoek, 2010). Antacids containing sodium bicarbonate should not be used during pregnancy due to their potential to cause metabolic alkalosis and fluid overload (Mahadevan, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F221619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13888242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium is found in breast milk (IOM, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F221601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium. Oral product should be taken 1-3 hours after meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5687043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Neut Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (5 mL): $5.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Sodium Bicarbonate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4.2% (10 mL): $5.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5% (50 mL): $3.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8.4% (50 mL): $7.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Sodium Bicarbonate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     325 mg (1000): $11.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     650 mg (1000): $13.65",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F221602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Betsol \"Z\" (MX);",
"     </li>",
"     <li>",
"      Natrium bicarbonicum (PL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F221581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dissociates to provide bicarbonate ion which neutralizes hydrogen ion concentration and raises blood and urinary pH",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F221598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oral: Rapid; I.V.: 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Oral: 8-10 minutes; I.V.: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;1%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Adrogu&eacute; HJ and Madias NE, \"Management of Life-Threatening Acid-Base Disorders. Second of Two Parts,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(2):107-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/52/840/abstract-text/9420343/pubmed\" id=\"9420343\" target=\"_blank\">",
"        9420343",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brierley J, Carcillo JA, Choong K, et al, &ldquo;Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: 2007 Update from the American College of Critical Care Medicine,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2009, 37(2):666-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/52/840/abstract-text/19325359/pubmed\" id=\"19325359\" target=\"_blank\">",
"        19325359",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Briguori C, Airoldi F, D&rsquo;Andrea D,  et al, &ldquo;Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL). A Randomized Comparison of 3 Preventive Strategies,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 115(10):1211-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/52/840/abstract-text/17309916/pubmed\" id=\"17309916\" target=\"_blank\">",
"        17309916",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Campbell TA and Sanson TG, \"Cardiac Arrest and Pregnancy,\"",
"      <i>",
"       J Emerg Trauma Shock",
"      </i>",
"      , 2009, 2(1):34-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/52/840/abstract-text/19561954/pubmed\" id=\"19561954\" target=\"_blank\">",
"        19561954",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Del Beccaro MA and Robertson WO, &ldquo;Baking Soda Poisoning,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1988, 30(2):164-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/52/840/abstract-text/2837866/pubmed\" id=\"2837866\" target=\"_blank\">",
"        2837866",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Carlet JM, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,&rdquo;",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2008, 34(1):17-60. Available at",
"      <a href=\"file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616/pdf/134_2007_Article_934.pdf\" target=\"_blank\">",
"       file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616/pdf/134_2007_Article_934.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/52/840/abstract-text/18058085/pubmed\" id=\"18058085\" target=\"_blank\">",
"        18058085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/52/840/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122 (Suppl 3):640-56.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Forsythe SM and Schmidt GA, &ldquo;Sodium Bicarbonate for the Treatment of Lactic Acidosis,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2000, 117(1):260-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/52/840/abstract-text/10631227/pubmed\" id=\"10631227\" target=\"_blank\">",
"        10631227",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate",
"      </i>",
"      , Washington, DC: National Academy Press, 2004.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al, &ldquo;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):876-908.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/52/840/abstract-text/20956230/pubmed\" id=\"20956230\" target=\"_blank\">",
"        20956230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levin T, &ldquo;What This Patient Didn't Need: A Dose of Salts,&rdquo;",
"      <i>",
"       Hosp Pract (Off Ed)",
"      </i>",
"      , 1983, 18(7):95-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Linford SM and James HD, &ldquo;Sodium Bicarbonate Abuse: A Case Report,&rdquo;",
"      <i>",
"       Br J Psychiatry",
"      </i>",
"      , 1986, 149:502-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/52/840/abstract-text/3028562/pubmed\" id=\"3028562\" target=\"_blank\">",
"        3028562",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      MacCara ME, &ldquo;Extravasation - A Hazard of Intravenous Therapy,&rdquo;",
"      <i>",
"       Drug Intell Clin Pharm",
"      </i>",
"      , 1983, 17:713.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/52/840/abstract-text/6628223/pubmed\" id=\"6628223\" target=\"_blank\">",
"        6628223",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mahadevan U and Kane S, \"American Gastroenterological Association Institute Medical Position Statement on the Use of Gastrointestinal Medications in Pregnancy,\"",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2006, 131(1):278-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/52/840/abstract-text/16831610/pubmed\" id=\"16831610\" target=\"_blank\">",
"        16831610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mahadevan U, \"Gastrointestinal Medications in Pregnancy,\"",
"      <i>",
"       Best Pract Res Clin Gastroenterol",
"      </i>",
"      , 2007, 21(5):849-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/52/840/abstract-text/17889812/pubmed\" id=\"17889812\" target=\"_blank\">",
"        17889812",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Merten GJ, Burgess WP, Gray LV, et al, &ldquo;Prevention of Contrast-Induced Nephropathy With Sodium Bicarbonate: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2004, 291(19):2328-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/52/840/abstract-text/15150204/pubmed\" id=\"15150204\" target=\"_blank\">",
"        15150204",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/52/840/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Narins RG and Cohen JJ, &ldquo;Bicarbonate Therapy for Organic Acidosis: The Case for Its Continued Use,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1987, 106(4):615-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/52/840/abstract-text/3103511/pubmed\" id=\"3103511\" target=\"_blank\">",
"        3103511",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neumar RW, Otto CW, Link MS, et al, &ldquo;Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):729-67.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nichols MH, Wason S, Gonzalez Del Rey J, et al, &ldquo;Baking Soda: A Potentially Fatal Home Remedy,&rdquo;",
"      <i>",
"       Pediatr Emerg Care",
"      </i>",
"      , 1995, 11(2):109-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/52/840/abstract-text/7596870/pubmed\" id=\"7596870\" target=\"_blank\">",
"        7596870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perrone J and Hoffman RS, &ldquo;Profound Metabolic Alkalosis With Respiratory Compensation From Sodium Bicarbonate Ingestion,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1995, 33(5):547.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stork CM, Redd JT, Fine K, et al, &ldquo;Propoxyphene-Induced Wide QRS Complex Dysrhythmia Responsive to Sodium Bicarbonate - A Case Report,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1995, 33(2):179-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/52/840/abstract-text/7897759/pubmed\" id=\"7897759\" target=\"_blank\">",
"        7897759",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vanden Hoek TL, Morrison LJ, Shuster M, et al, &ldquo;Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):829-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/52/840/abstract-text/20956228/pubmed\" id=\"20956228\" target=\"_blank\">",
"        20956228",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wax PM and Hoffman RS, &ldquo;Sodium Bicarbonate in Contemporary Management in Critical Care,&rdquo; 1991, 1(3):81-108.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9928 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-73EC6B31EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_52_840=[""].join("\n");
var outline_f0_52_840=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221612\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221638\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221615\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221628\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221616\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221592\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221578\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221596\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221645\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221595\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5524440\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221636\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221599\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221582\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300051\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221587\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221609\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221589\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13888241\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221619\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13888242\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221601\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5687043\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221602\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221581\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221598\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9928\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9928|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/21/4437?source=related_link\">",
"      Sodium bicarbonate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=related_link\">",
"      Sodium bicarbonate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_52_841="Protein C deficiency";
var content_f0_52_841=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Protein C deficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/52/841/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/52/841/contributors\">",
"     Kenneth A Bauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/52/841/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/52/841/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/52/841/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/52/841/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/52/841/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/52/841/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited thrombophilia is a genetic tendency to venous thromboembolism. The Factor V Leiden and prothrombin gene mutations are the most common causes of the syndrome accounting for more than 50 percent of cases. Deficiencies in protein S, protein C, and antithrombin account for most of the remaining cases, while rare causes include the dysfibrinogenemias [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The total incidence of an inherited thrombophilia in subjects with a deep vein thrombosis ranges from 24 to 37 percent overall compared with about 10 percent in controls. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Inherited thrombophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will discuss the genetics, prevalence, clinical presentation, and diagnosis of protein C deficiency. Issues related to screening for and the general treatment of the inherited thrombophilias are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=see_link\">",
"     \"Evaluation of the patient with established venous thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=see_link\">",
"     \"Screening for inherited thrombophilia in asymptomatic populations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=see_link\">",
"     \"Management of inherited thrombophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14234?source=see_link\">",
"     \"Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY OF PROTEIN C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein C is a vitamin K-dependent protein synthesized in the liver. It has a molecular weight of about 62 kilodaltons and consists of two chains connected by a disulfide bridge. The gene for protein C is located on chromosome 2 (2q13-14) and appears to be closely related to the gene for factor IX [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Protein C circulates as a zymogen and exerts its anticoagulant function after activation to the serine protease, activated protein C (aPC) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/5\">",
"     5",
"    </a>",
"    ]. This process can be mediated by thrombin alone, but occurs more efficiently when thrombin is bound to endothelial thrombomodulin.",
"   </p>",
"   <p>",
"    The primary effect of aPC is to inactivate coagulation factors Va and VIIIa, which are necessary for efficient thrombin generation and factor X activation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/5\">",
"     5",
"    </a>",
"    ]. The inhibitory effect of aPC is markedly enhanced by protein S, another vitamin K-dependent protein.",
"   </p>",
"   <p>",
"    However, aPC has another set of functions aside from the coagulation pathway. In reactions mediated by the endothelial protein C receptor and the effector receptor, protease-activated receptor-1 (PAR-1), aPC acts directly on cells to exert multiple cytoprotective effects, including anti-inflammatory activities and protection of endothelial barrier function [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Levels of protein C in preterm and term infants are approximately 7 to 18 percent and 14 to 42 percent of those seen in adults, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENETICS OF PROTEIN C DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heterozygous protein C deficiency is inherited in an autosomal dominant fashion. The frequency of this abnormality ranges from 1 per 200 to 1 per 500 in a healthy general population [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two major subtypes of heterozygous protein C deficiency have been delineated using immunologic and functional assays. Over 160 different gene abnormalities have been associated with the two subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Type I deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type I deficiency state is more common. Most affected patients are heterozygous with the plasma protein C concentration being approximately 50 percent of normal in both immunologic and functional assays [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/13\">",
"     13",
"    </a>",
"    ]. Missense and nonsense mutations account for more than one-half of the identified gene mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/12,14,15\">",
"     12,14,15",
"    </a>",
"    ]. Other types of mutations include promoter mutations, splice site abnormalities, in-frame deletions, frameshift deletions, in-frame insertions, and frameshift insertions [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/12\">",
"     12",
"    </a>",
"    ]. In several Dutch families, the linkage between a rare polymorphism and a particular mutation has indicated the presence of a founder effect (ie, the families are related to a common ancestor) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is marked phenotypic variability among patients with heterozygous type I protein C deficiency. Similar mutations have been found among symptomatic and asymptomatic individuals, implying that the nature of the protein C gene defect alone does not explain the phenotypic variability [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/15,17,18\">",
"     15,17,18",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Type II deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with the type II deficiency state have normal plasma protein C antigen levels with decreased functional activity. A variety of different point mutations affecting protein function have been identified in this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/12,19\">",
"     12,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are also a number of acquired causes of protein C deficiency, including severe infection and septic shock (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Acquired protein C deficiency'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three clinical syndromes are associated with protein C deficiency:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Venous thromboembolism in heterozygous and rare homozygous or doubly heterozygous teenagers or adults",
"     </li>",
"     <li>",
"      Neonatal purpura fulminans in homozygous or doubly heterozygous newborns",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      -induced skin necrosis in certain heterozygous teenagers or adults",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Venous thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The phenotype of patients with heterozygous protein C deficiency is quite similar to hereditary antithrombin III deficiency. The thrombotic risk associated with protein C deficiency and other inherited thrombophilias has been assessed in two ways: evaluation of patients with deep vein thrombosis and evaluation of families with thrombophilia.",
"   </p>",
"   <p>",
"    It is estimated that congenital protein C deficiency is present in 2 to 5 percent of patients presenting with thromboembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/1,20,21\">",
"     1,20,21",
"    </a>",
"    ]. In a Spanish study of 2132 consecutive unselected patients with venous thromboembolism, for example, 12.9 percent had an anticoagulant protein deficiency (including 3.2 percent with protein C, 7.3 percent with protein S, and 0.5 percent with antithrombin III) and 4.1 percent had antiphospholipid antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/1\">",
"     1",
"    </a>",
"    ]. The relative risk of an isolated protein deficiency was increased in patients with a family history of thrombosis, recurrent episodes of thrombosis, or apparently spontaneous thrombosis and in those under age 45. Similar findings were noted in another series of 277 outpatients with deep vein thrombosis: 8.3 percent had an isolated deficiency of antithrombin III, protein C, protein S, or plasminogen compared with 2.2 percent of controls [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Inherited thrombophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The absolute risk of thrombosis among patients with inherited thrombophilia was evaluated in a report of 150 pedigrees that compared the risk for thrombosis in individuals with inherited thrombophilia due to factor V Leiden or to antithrombin III, protein C, or protein S deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/22\">",
"     22",
"    </a>",
"    ]. The lifetime probability of developing thrombosis compared with those with no defect was 8.5 times higher for carriers of protein S deficiency, 8.1 for antithrombin III deficiency, 7.3 for protein C deficiency, and 2.2 for factor V Leiden. Similar data were obtained from the Leiden Thrombophilia Study, which found that individuals from the general population with heterozygous protein C deficiency had about a sevenfold increased risk of an initial episode of deep vein thrombosis when compared with normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, there is marked variability in risk among families with protein C deficiency that cannot be explained by the genetic defect. In severely affected families, as many as 75 percent of protein C-deficient individuals experience one or more thrombotic events [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]; in other families, the thrombosis rate is much lower [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/15,27\">",
"     15,27",
"    </a>",
"    ]. One risk factor for more severe disease is the presence of a second thrombotic defect in carriers of any of the causes of inherited thrombophilia, particularly with factor V Leiden [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. In one series, factor V Leiden was present in 6 of 15 with protein C deficiency and 4 of 14 patients with protein S deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/29\">",
"     29",
"    </a>",
"    ]. Carriers of two defects have a higher risk for thrombosis than their relatives with a single defect. In one review of four studies, approximately 75 percent of family members who were carriers of two defects had experienced thrombosis compared with 10 to 30 percent of carriers of a single defect [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial episode of venous thromboembolism in patients with protein C deficiency is apparently spontaneous in approximately 70 percent of cases. The remaining 30 percent have the usual risk factors (eg, pregnancy, parturition, oral contraceptives, surgery, or trauma).",
"   </p>",
"   <p>",
"    Most patients are asymptomatic until their early twenties, with increasing numbers experiencing thrombotic events as they reach the age of 50. The median age at onset is similar in both protein C deficiency and factor V Leiden (aPC resistance): 45 years in unselected patients and 30 years in members of thrombophilia families [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/31\">",
"     31",
"    </a>",
"    ]. Approximately 60 percent of affected individuals develop recurrent venous thrombosis and about 40 percent have signs of pulmonary embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common sites of disease are the deep veins of the legs, the iliofemoral veins, and the mesenteric veins. Cerebral venous thrombosis has been associated with protein C deficiency and with the other congenital prothrombotic conditions, particularly when combined with acquired risk factors for thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/25,32,33\">",
"     25,32,33",
"    </a>",
"    ], such as oral contraceptives [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Arterial thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been reports of nonhemorrhagic arterial stroke in young adults with hereditary protein C deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/34-36\">",
"     34-36",
"    </a>",
"    ], but larger studies have not convincingly demonstrated that protein C deficiency is a risk factor for the development of arterial thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. In one series, for example, antithrombin III, protein C, and protein S levels were measured in 127 consecutive patients with a mean age of 34 years admitted for an ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/37\">",
"     37",
"    </a>",
"    ]. Abnormal anticoagulant protein levels were found in nine patients. However, seven of these patients had an acquired cause of deficiency, such as pregnancy or estrogen administration, and the other two patients had transiently low levels in the absence of an obvious acquired cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Neonatal purpura fulminans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Purpura fulminans in newborns is a rare life-threatening condition characterized by disseminated intravascular coagulation and hemorrhagic skin necrosis. It usually is caused by homozygous or compound heterozygous deficiency in protein C. Laboratory testing reveals evidence of disseminated intravascular coagulation and extremely low levels of protein C antigen. Diagnosis and management of this disorder are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14986?source=see_link&amp;anchor=H21#H21\">",
"     \"Management of thrombosis in the newborn\", section on 'Neonatal purpura fulminans'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Older homozygotes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been a number of cases of older patients with homozygous or doubly heterozygous protein C deficiency who had not developed purpura fulminans. These individuals generally had plasma protein C levels under 20 percent of normal in the absence of oral anticoagulant therapy, and their clinical presentation was similar to that of severely affected subjects from thrombophilic kindreds with heterozygous protein C deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genotyping of these homozygous individuals identified several missense mutations in the protein C gene; the variant protein C molecules were either synthesized at a decreased rate or rapidly cleared from the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/42-44\">",
"     42-44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Warfarin-induced skin necrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    -induced skin necrosis typically occurs during the first several days of warfarin therapy, often in association with the administration of large loading doses [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. The skin lesions occur on the extremities, breasts, trunk, and penis (in males) and marginate over a period of hours from an initial central erythematous macule (",
"    <a class=\"graphic graphic_picture graphicRef80462 \" href=\"UTD.htm?42/34/43553\">",
"     picture 1",
"    </a>",
"    ). If a product containing protein C is not rapidly administered, the affected cutaneous areas become edematous, develop central purpuric zones, and ultimately become necrotic.",
"   </p>",
"   <p>",
"    The dermal manifestations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -induced skin necrosis are clinically and pathologically similar to those seen in infants with purpura fulminans due to severe protein C deficiency. Biopsies demonstrate diffuse microthrombi within dermal and subcutaneous capillaries, venules, and deep veins, with endothelial cell damage, resulting in ischemic skin necrosis and marked red blood cell extravasation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    -induced skin necrosis is induced by a transient hypercoagulable state. The initiation of warfarin at standard doses leads to a decrease in protein C anticoagulant activity to approximately 50 percent of normal within one day (",
"    <a class=\"graphic graphic_figure graphicRef50940 \" href=\"UTD.htm?26/56/27534\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/49\">",
"     49",
"    </a>",
"    ]. Factor VII activity follows a similar pattern but the levels of the other procoagulant vitamin K-dependent factors decline at slower rates, consistent with their longer half-lives. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link\">",
"     \"Therapeutic use of warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increased thrombin generation has been documented during this early phase of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy utilizing a sensitive assay for fragment F1+2, an index of the in vivo activation of prothrombin mediated by factor Xa [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/50\">",
"     50",
"    </a>",
"    ]. Thus, during this period, the suppressive effect of warfarin on protein C has a greater influence on thrombin generation by the hemostatic mechanism than the associated reduction in factor VII.",
"   </p>",
"   <p>",
"    These effects are likely to be more pronounced when more than 10 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    per day is administered to initiate oral anticoagulation or the patient has an underlying hereditary deficiency of protein C. However, only about one-third of patients with warfarin-induced skin necrosis have underlying protein C deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/51\">",
"     51",
"    </a>",
"    ], and this complication is only infrequently reported in individuals with the heterozygous deficiency state. This syndrome has also been described, mostly in case reports, in association with an acquired functional deficiency of protein C [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/52\">",
"     52",
"    </a>",
"    ], heterozygous protein S deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/53\">",
"     53",
"    </a>",
"    ] and factor V Leiden [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate intervention after diagnosis is required to prevent rapid progression and to minimize complications. Therapy should consist of immediate discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , administration of vitamin K, and infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    at therapeutic doses. However, lesions may continue to progress despite adequate anticoagulation with heparin.",
"   </p>",
"   <p>",
"    The administration of a source of protein C should be seriously considered in patients with hereditary protein C deficiency; it may also be appropriate in other patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -induced skin necrosis who invariably have reduced plasma levels of functional protein C when the skin lesions first appear. Fresh frozen plasma has been used, but improved results can be expected with the administration of a highly purified",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/50/6949?source=see_link\">",
"     protein C concentrate",
"    </a>",
"    (Ceprotin, Baxter), which facilitates the rapid and complete normalization of plasma protein C levels [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Retreatment with warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with heterozygous protein C deficiency and a history of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -induced skin necrosis have been successfully retreated with oral anticoagulants. In this situation, protein C administration, either in the form of fresh frozen plasma or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/50/6949?source=see_link\">",
"     protein C concentrate",
"    </a>",
"    , should be administered until a stable level of anticoagulation is achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/46,57\">",
"     46,57",
"    </a>",
"    ]. The dose of warfarin should be increased gradually, starting from a relatively low level (eg, 2 mg for the first 3 days and then in increasing amounts of 2 to 3 mg until therapeutic anticoagulation is achieved).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Fetal loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein C deficiency has also been linked to fetal loss [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. In a report from the European Prospective Cohort on Thrombophilia, the odds ratio for stillbirth (fetal loss after 28 weeks gestation) was 2.3 for protein C deficiency and was also increased in other thrombophilias: 5.2 for antithrombin deficiency, 3.3 for protein S deficiency, and 2.0 for factor V Leiden (which represents activated protein C resistance) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=see_link\">",
"     \"Inherited thrombophilias in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein C circulates in human plasma at an average concentration of 4",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    The logarithms of the values for protein C antigen in healthy adults are normally distributed, with 95 percent of the values ranging from 70 to 140 percent of normal [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/9\">",
"     9",
"    </a>",
"    ]. There is no significant gender dependence, but mean protein C concentrations increase by approximately 4 percent per decade.",
"   </p>",
"   <p>",
"    Protein C levels in full term newborns are 20 to 40 percent of normal adult levels [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/61,62\">",
"     61,62",
"    </a>",
"    ], while preterm infants have even lower levels [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/63\">",
"     63",
"    </a>",
"    ] and babies with significant perinatal thrombosis can have levels suggestive of the homozygous deficiency state [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/64\">",
"     64",
"    </a>",
"    ]. As methodologies for measurement of protein C differ among laboratories and the concentration is substantially lower in normal newborns and young infants compared with adult values, it is important to use age-based norms for the specific laboratory performing the test in neonates.",
"   </p>",
"   <p>",
"    Protein C activity and antigen appear to be associated with serum lipids. In one study of 150 adults, mean levels of protein C activity and antigen rose approximately 25 percent as total cholesterol and triglyceride concentration each rose from the 5th to the 95th percentile [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relatively wide normal range of protein C measurements in the general population occasionally makes it difficult to identify a given individual as having heterozygous protein C deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/66\">",
"     66",
"    </a>",
"    ]. In the absence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy and medical causes of low levels, ie, acquired protein C deficiency (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Acquired protein C deficiency'",
"    </a>",
"    below), patients with a protein C level less than 55 percent of normal are very likely to have the genetic abnormality, while levels from 55 to 65 percent are consistent with either a deficiency state or the lower end of the normal distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/9\">",
"     9",
"    </a>",
"    ]. Thus, to document the presence of protein C deficiency with confidence, it is often useful to obtain repeat laboratory determinations and to perform family studies to identify an autosomal dominant inheritance pattern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of immunologic and functional techniques have been developed to measure protein C levels in plasma samples.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common procedures for antigen determination are electroimmunoassay, enzyme-linked immunosorbent assay, and radioimmunoassay [",
"      <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Functional assays have utilized either thrombin or the thrombin-thrombomodulin complex to activate protein C [",
"      <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/49,68,69\">",
"       49,68,69",
"      </a>",
"      ]. Enzyme activity is then assessed using either a chromogenic substrate or by measuring its anticoagulant activity in a factor Xa one-stage clotting assay.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The development of simpler functional assays has been facilitated by the observation that the venom of the Southern copperhead snake (Agkistrodon contortrix) is able to activate protein C in plasma. After activation of protein C by this venom, the enzyme's amidolytic activity can be measured using a suitable chromogenic substrate, or its anticoagulant activity can be measured in a clotting assay (partial thromboplastin time).",
"   </p>",
"   <p>",
"    Functional assays are preferred in screening for protein C deficiency since they will detect both type I and II defects. Clotting assays may occasionally pick up type II defects that are missed by amidolytic assays (see below); they cannot, however, be used in patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or reliably interpreted in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . Amidolytic assays are frequently preferred by routine laboratories because they generally have better performance characteristics than clotting assays. The use of an immunologic assay will assist in characterizing patients as having a type I or II defect.",
"   </p>",
"   <p>",
"    Functional assays utilizing amidolytic and clotting endpoints may also give useful information regarding the nature of the molecular defect in patients with type II protein C deficiency.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several individuals have been described with normal protein C antigen measurements who have substantial reductions in protein C anticoagulant activity, but normal or near normal amidolytic activity [",
"      <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/49\">",
"       49",
"      </a>",
"      ]. These defects may reflect a reduced ability of activated protein C to interact with platelet membranes or its substrates such as factor V and factor VIII. The molecular abnormality in one of these families has been determined and is characterized by two gamma-carboxyglutamic acid (Gla) domain mutations (Glu20 to Ala and Val34 to Met) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other patients have abnormal protein C molecules that are normally activated by the thrombin-thrombomodulin complex, but fail to exhibit proteolytic activity as measured by amidolytic or anticoagulant assays [",
"      <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/71,72\">",
"       71,72",
"      </a>",
"      ]. These patients may have mutations near the active site of the protein.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Timing of screening and effect of warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important consideration in the laboratory evaluation of patients with a suspected deficiency of antithrombin, protein C, or protein S is the timing of testing. Erroneous diagnoses can be made due to the influence of acute thrombosis, comorbid illness, or anticoagulant therapy on the concentrations of these plasma proteins.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    therapy reduces functional [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/49,68,73\">",
"     49,68,73",
"    </a>",
"    ] and, to a lesser extent, immunologic measurements of protein C [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/24,74\">",
"     24,74",
"    </a>",
"    ], making it difficult to diagnose individuals with heterozygous protein C deficiency. Several research laboratories have used a reduced ratio of protein C antigen to prothrombin or factor X antigen to identify patients with a type I deficiency state [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/24,74\">",
"     24,74",
"    </a>",
"    ]. This approach, however, can only be used in subjects in a stable phase of oral anticoagulation, and the diagnostic criteria for the disorder vary with the intensity of warfarin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/74\">",
"     74",
"    </a>",
"    ]. Other groups have successfully used protein C activity assays in conjunction with functional and antigenic measurements of factor VII, a vitamin K-dependent factor with a similar plasma half-life to protein C [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/75-77\">",
"     75-77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In practice, it is preferable to investigate patients suspected of having protein C (or protein S) deficiency at least two weeks after oral anticoagulation has been discontinued and to perform family studies. If it is not possible to discontinue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    due to the severity of the thrombotic diathesis, such individuals can be studied with regard to their level of protein C antigen or activity (amidolytic) while receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy, which does not alter plasma protein C levels.",
"   </p>",
"   <p>",
"    If, however, the plasma level of protein C is obtained at presentation and is well within the normal range, then a deficiency of this protein is essentially excluded. A low concentration, on the other hand, must be confirmed by repeat testing after anticoagulation is discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     ACQUIRED PROTEIN C DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited protein C deficiency must be distinguished from an acquired deficiency which occurs in a variety of settings including liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/78\">",
"     78",
"    </a>",
"    ], severe infection, septic shock, disseminated intravascular coagulation, acute respiratory distress syndrome, the postoperative state, breast cancer patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and 5-fluorouracil, and in association with L-asparaginase therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/36/6730?source=see_link\">",
"     \"Drug-induced thrombosis and vascular disease in patients with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A particularly severe form of acquired protein C deficiency, characterized by purpura fulminans and disseminated intravascular coagulation, has been described in patients with acute viral or bacterial infections, including meningococcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/79-81\">",
"     79-81",
"    </a>",
"    ]. The administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/50/6949?source=see_link\">",
"     protein C concentrate",
"    </a>",
"    has been beneficial in this setting as it is in neonatal purpura fulminans [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/79,82,83\">",
"     79,82,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most uremic patients have low levels of protein C anticoagulant activity, but normal levels of protein C amidolytic activity and antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/84\">",
"     84",
"    </a>",
"    ]. This is attributable to a dialyzable moiety in uremic plasma that interferes with most clotting assays for protein C activity [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/84\">",
"     84",
"    </a>",
"    ]. Among patients with the nephrotic syndrome, the antigenic concentrations of protein C are often elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3273?source=see_link\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An acquired inhibitor of protein C has been documented in an Australian patient [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/841/abstract/87\">",
"     87",
"    </a>",
"    ]. This individual had a bleeding diathesis for several years and developed purpura fulminans before his death. Autopsy revealed arterial and venous thrombi in many organs. The IgG fraction of the patient's plasma completely inhibited the functional anticoagulant activity of activated protein C.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23517046\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein C is a vitamin K-dependent protein produced in the liver. It exerts its anticoagulant function after activation to activated protein C (aPC). This process is mediated by thrombin, but more efficiently when thrombin is bound to endothelial thrombomodulin. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Physiology of protein C'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Function",
"      </strong>",
"      &mdash; The primary function of aPC is to inactivate factors Va and VIIIa, an effect markedly enhanced by protein S. When mediated by the endothelial protein C receptor and protease-activated receptor-1 (PAR-1), aPC also exerts multiple cytoprotective effects.",
"     </li>",
"     <li>",
"      <strong>",
"       Genetics",
"      </strong>",
"      &mdash; Protein C deficiency is inherited in an autosomal dominant fashion at a frequency ranging from 1 per 200 to 1 per 500 in the general population. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Genetics of protein c deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Clinical presentation",
"      </strong>",
"      &mdash; Clinical syndromes of protein C deficiency include venous thromboembolism, neonatal purpura,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      -induced skin necrosis, and fetal loss. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Diagnosis",
"      </strong>",
"      &mdash; 95 percent confidence limits for protein C antigen in adults range from 70 to 140 percent of normal. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Protein C levels &lt;55 percent are likely due to a genetic abnormality; levels from 55 to 65 percent are indeterminate and require re-testing.",
"     </li>",
"     <li>",
"      Erroneous diagnoses can be made due to the influence of acute thrombosis, comorbid illness, or anticoagulant therapy with vitamin K antagonists.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Acquired deficiency",
"      </strong>",
"      &mdash; Acquired protein C deficiency occurs in a variety of settings, including liver disease, severe infection (especially meningococcemia), septic shock, and disseminated intravascular coagulation. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Acquired protein C deficiency'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/1\">",
"      Mateo J, Oliver A, Borrell M, et al. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost 1997; 77:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/2\">",
"      Margaglione M, Brancaccio V, Giuliani N, et al. Increased risk for venous thrombosis in carriers of the prothrombin G--&gt;A20210 gene variant. Ann Intern Med 1998; 129:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/3\">",
"      Foster DC, Yoshitake S, Davie EW. The nucleotide sequence of the gene for human protein C. Proc Natl Acad Sci U S A 1985; 82:4673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/4\">",
"      Plutzky J, Hoskins JA, Long GL, Crabtree GR. Evolution and organization of the human protein C gene. Proc Natl Acad Sci U S A 1986; 83:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/5\">",
"      Clouse LH, Comp PC. The regulation of hemostasis: the protein C system. N Engl J Med 1986; 314:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/6\">",
"      Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109:3161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/7\">",
"      Danese S, Vetrano S, Zhang L, et al. The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood 2010; 115:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/8\">",
"      Reverdiau-Moalic P, Delahousse B, Body G, et al. Evolution of blood coagulation activators and inhibitors in the healthy human fetus. Blood 1996; 88:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/9\">",
"      Miletich J, Sherman L, Broze G Jr. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/10\">",
"      Tait RC, Walker ID, Reitsma PH, et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost 1995; 73:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/11\">",
"      Reitsma PH. Protein C deficiency: from gene defects to disease. Thromb Haemost 1997; 78:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/12\">",
"      Reitsma PH, Bernardi F, Doig RG, et al. Protein C deficiency: a database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 73:876.",
"     </a>",
"    </li>",
"    <li>",
"     Broekmans AW, Bertina RM. Protein C. In: Recent Advances in Blood Coagulation, Poller L (Ed), Churchill Livingstone, New York 1985. Vol 4, p.117.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/14\">",
"      Romeo G, Hassan HJ, Staempfli S, et al. Hereditary thrombophilia: identification of nonsense and missense mutations in the protein C gene. Proc Natl Acad Sci U S A 1987; 84:2829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/15\">",
"      Reitsma PH, Poort SR, Allaart CF, et al. The spectrum of genetic defects in a panel of 40 Dutch families with symptomatic protein C deficiency type I: heterogeneity and founder effects. Blood 1991; 78:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/16\">",
"      Reitsma PH, te Lintel Hekkert W, Koenhen E, et al. Application of two neutral MspI DNA polymorphisms in the analysis of hereditary protein C deficiency. Thromb Haemost 1990; 64:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/17\">",
"      Aiach M, Gandrille S, Emmerich J. A review of mutations causing deficiencies of antithrombin, protein C and protein S. Thromb Haemost 1995; 74:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/18\">",
"      Petrini P, Segnestam K, Ekelund H, Egberg N. Homozygous protein C deficiency in two siblings. Pediatr Hematol Oncol 1990; 7:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/19\">",
"      Lind B, Johnsen AH, Thorsen S. Naturally occurring Arg(-1) to His mutation in human protein C leads to aberrant propeptide processing and secretion of dysfunctional protein C. Blood 1997; 89:2807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/20\">",
"      Gladson CL, Scharrer I, Hach V, et al. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost 1988; 59:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/21\">",
"      Heijboer H, Brandjes DP, B&uuml;ller HR, et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/22\">",
"      Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92:2353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/23\">",
"      Koster T, Rosendaal FR, Bri&euml;t E, et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 1995; 85:2756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/24\">",
"      Griffin JH, Evatt B, Zimmerman TS, et al. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/25\">",
"      Broekmans AW, Veltkamp JJ, Bertina RM. Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N Engl J Med 1983; 309:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/26\">",
"      Horellou MH, Conard J, Bertina RM, Samama M. Congenital protein C deficiency and thrombotic disease in nine French families. Br Med J (Clin Res Ed) 1984; 289:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/27\">",
"      Bovill EG, Bauer KA, Dickerman JD, et al. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood 1989; 73:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/28\">",
"      Koeleman BP, Reitsma PH, Bertina RM. Familial thrombophilia: a complex genetic disorder. Semin Hematol 1997; 34:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/29\">",
"      Mustafa S, Mannhalter C, Rintelen C, et al. Clinical features of thrombophilia in families with gene defects in protein C or protein S combined with factor V Leiden. Blood Coagul Fibrinolysis 1998; 9:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/30\">",
"      Aiach M, Borgel D, Gaussem P, et al. Protein C and protein S deficiencies. Semin Hematol 1997; 34:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/31\">",
"      Lensen RP, Rosendaal FR, Koster T, et al. Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients. Blood 1996; 88:4205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/32\">",
"      Wintzen AR, Broekmans AW, Bertina RM, et al. Cerebral haemorrhagic infarction in young patients with hereditary protein C deficiency: evidence for \"spontaneous\" cerebral venous thrombosis. Br Med J (Clin Res Ed) 1985; 290:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/33\">",
"      de Bruijn SF, Stam J, Koopman MM, Vandenbroucke JP. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in [correction of who are] carriers of hereditary prothrombotic conditions. The Cerebral Venous Sinus Thrombosis Study Group. BMJ 1998; 316:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/34\">",
"      Kohler J, Kasper J, Witt I, von Reutern GM. Ischemic stroke due to protein C deficiency. Stroke 1990; 21:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/35\">",
"      Grewal RP, Goldberg MA. Stroke in protein C deficiency. Am J Med 1990; 89:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/36\">",
"      Camerlingo M, Finazzi G, Casto L, et al. Inherited protein C deficiency and nonhemorrhagic arterial stroke in young adults. Neurology 1991; 41:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/37\">",
"      Douay X, Lucas C, Caron C, et al. Antithrombin, protein C and protein S levels in 127 consecutive young adults with ischemic stroke. Acta Neurol Scand 1998; 98:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/38\">",
"      Munts AG, van Genderen PJ, Dippel DW, et al. Coagulation disorders in young adults with acute cerebral ischaemia. J Neurol 1998; 245:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/39\">",
"      Ganesan V, McShane MA, Liesner R, et al. Inherited prothrombotic states and ischaemic stroke in childhood. J Neurol Neurosurg Psychiatry 1998; 65:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/40\">",
"      Bauer KA, Broekmans AW, Bertina RM, et al. Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency. Blood 1988; 71:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/41\">",
"      Melissari E, Kakkar VV. Congenital severe protein C deficiency in adults. Br J Haematol 1989; 72:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/42\">",
"      Grundy CB, Melissari E, Lindo V, et al. Late-onset homozygous protein C deficiency. Lancet 1991; 338:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/43\">",
"      Conard J, Horellou MH, van Dreden P, et al. Homozygous protein C deficiency with late onset and recurrent coumarin-induced skin necrosis. Lancet 1992; 339:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/44\">",
"      Yamamoto K, Matsushita T, Sugiura I, et al. Homozygous protein C deficiency: identification of a novel missense mutation that causes impaired secretion of the mutant protein C. J Lab Clin Med 1992; 119:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/45\">",
"      McGehee WG, Klotz TA, Epstein DJ, Rapaport SI. Coumarin necrosis associated with hereditary protein C deficiency. Ann Intern Med 1984; 101:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/46\">",
"      Zauber NP, Stark MW. Successful warfarin anticoagulation despite protein C deficiency and a history of warfarin necrosis. Ann Intern Med 1986; 104:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/47\">",
"      Bauer KA. Coumarin-induced skin necrosis. Arch Dermatol 1993; 129:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/48\">",
"      Nazarian RM, Van Cott EM, Zembowicz A, Duncan LM. Warfarin-induced skin necrosis. J Am Acad Dermatol 2009; 61:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/49\">",
"      Vigano D'Angelo S, Comp PC, Esmon CT, D'Angelo A. Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. J Clin Invest 1986; 77:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/50\">",
"      Conway EM, Bauer KA, Barzegar S, Rosenberg RD. Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses. J Clin Invest 1987; 80:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/51\">",
"      Broekmans AW, Teepe RG, van der Meer FJ, et al. Protein C (PC) and coumarin-induced skin necrosis. Thromb Res 1986; 6:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/52\">",
"      Teepe RG, Broekmans AW, Vermeer BJ, et al. Recurrent coumarin-induced skin necrosis in a patient with an acquired functional protein C deficiency. Arch Dermatol 1986; 122:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/53\">",
"      Sallah S, Abdallah JM, Gagnon GA. Recurrent warfarin-induced skin necrosis in kindreds with protein S deficiency. Haemostasis 1998; 28:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/54\">",
"      Makris M, Bardhan G, Preston FE. Warfarin induced skin necrosis associated with activated protein C resistance. Thromb Haemost 1996; 75:523.",
"     </a>",
"    </li>",
"    <li>",
"     prescribing information for this product is available at the following website: file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=22370 (Accessed on November 17, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/56\">",
"      Schramm W, Spannagl M, Bauer KA, et al. Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. Arch Dermatol 1993; 129:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/57\">",
"      De Stefano V, Mastrangelo S, Schwarz HP, et al. Replacement therapy with a purified protein C concentrate during initiation of oral anticoagulation in severe protein C congenital deficiency. Thromb Haemost 1993; 70:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/58\">",
"      Preston FE, Rosendaal FR, Walker ID, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/59\">",
"      Brenner B, Blumenfeld Z. Thrombophilia and fetal loss. Blood Rev 1997; 11:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/60\">",
"      Sarig G, Lanir N, Hoffman R, Brenner B. Protein C global assay in the evaluation of women with idiopathic pregnancy loss. Thromb Haemost 2002; 88:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/61\">",
"      Mannucci PM, Vigano S. Deficiencies of protein C, an inhibitor of blood coagulation. Lancet 1982; 2:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/62\">",
"      Polack B, Pouzol P, Amiral J, Kolodie L. Protein C level at birth. Thromb Haemost 1984; 52:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/63\">",
"      Karpatkin M, Mannuccio Mannucci P, Bhogal M, et al. Low protein C in the neonatal period. Br J Haematol 1986; 62:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/64\">",
"      Manco-Johnson MJ, Marlar RA, Jacobson LJ, et al. Severe protein C deficiency in newborn infants. J Pediatr 1988; 113:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/65\">",
"      MacCallum PK, Cooper JA, Martin J, et al. Associations of protein C and protein S with serum lipid concentrations. Br J Haematol 1998; 102:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/66\">",
"      Pabinger I, Allaart CF, Hermans J, et al. Hereditary protein C-deficiency: laboratory values in transmitters and guidelines for the diagnostic procedure. Report on a study of the SSC Subcommittee on Protein C and Protein S. Protein C Transmitter Study Group. Thromb Haemost 1992; 68:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/67\">",
"      Michiels JJ, Hamuly&aacute;k K. Laboratory diagnosis of hereditary thrombophilia. Semin Thromb Hemost 1998; 24:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/68\">",
"      Bertina RM, Broekmans AW, Krommenhoek-van Es C, van Wijngaarden A. The use of a functional and immunologic assay for plasma protein C in the study of the heterogeneity of congenital protein C deficiency. Thromb Haemost 1984; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/69\">",
"      Comp PC, Nixon RR, Esmon CT. Determination of functional levels of protein C, an antithrombotic protein, using thrombin-thrombomodulin complex. Blood 1984; 63:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/70\">",
"      Bovill EG, Tomczak JA, Grant B, et al. Protein CVermont: symptomatic type II protein C deficiency associated with two GLA domain mutations. Blood 1992; 79:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/71\">",
"      Faioni EM, Esmon CT, Esmon NL, Mannucci PM. Isolation of an abnormal protein C molecule from the plasma of a patient with thrombotic diathesis. Blood 1988; 71:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/72\">",
"      Sala N, Borrell M, Bauer KA, et al. Dysfunctional activated protein C (PC C&aacute;diz) in a patient with thrombotic disease. Thromb Haemost 1987; 57:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/73\">",
"      Sala N, Owen WG, Collen D. Functional assay for protein C in human plasma. Thromb Res 1984; 32:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/74\">",
"      Bertina RM, Broekmans AW, van der Linden IK, Mertens K. Protein C deficiency in a Dutch family with thrombotic disease. Thromb Haemost 1982; 48:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/75\">",
"      Pabinger I, Kyrle PA, Speiser W, et al. Diagnosis of protein C deficiency in patients on oral anticoagulant treatment: comparison of three different functional protein C assays. Thromb Haemost 1990; 63:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/76\">",
"      Jones DW, Mackie IJ, Winter M, et al. Detection of protein C deficiency during oral anticoagulant therapy--use of the protein C:factor VII ratio. Blood Coagul Fibrinolysis 1991; 2:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/77\">",
"      O'Brien AE, Tate GM, Shiach C. Evaluation of protein C and protein S levels during oral anticoagulant therapy. Clin Lab Haematol 1998; 20:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/78\">",
"      Tripodi A, Salerno F, Chantarangkul V, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/79\">",
"      Smith OP, White B, Vaughan D, et al. Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet 1997; 350:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/80\">",
"      Fourrier F, Lestavel P, Chopin C, et al. Meningococcemia and purpura fulminans in adults: acute deficiencies of proteins C and S and early treatment with antithrombin III concentrates. Intensive Care Med 1990; 16:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/81\">",
"      Gerson WT, Dickerman JD, Bovill EG, Golden E. Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: treatment with protein C concentrate. Pediatrics 1993; 91:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/82\">",
"      Rintala E, Sepp&auml;l&auml; OP, Kotilainen P, et al. Protein C in the treatment of coagulopathy in meningococcal disease. Crit Care Med 1998; 26:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/83\">",
"      White B, Livingstone W, Murphy C, et al. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 2000; 96:3719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/84\">",
"      Faioni EM, Franchi F, Krachmalnicoff A, et al. Low levels of the anticoagulant activity of protein C in patients with chronic renal insufficiency: an inhibitor of protein C is present in uremic plasma. Thromb Haemost 1991; 66:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/85\">",
"      Schlegel N. Thromboembolic risks and complications in nephrotic children. Semin Thromb Hemost 1997; 23:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/86\">",
"      al-Mugeiren MM, Gader AM, al-Rasheed SA, et al. Coagulopathy of childhood nephrotic syndrome--a reappraisal of the role of natural anticoagulants and fibrinolysis. Haemostasis 1996; 26:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/841/abstract/87\">",
"      Mitchell CA, Rowell JA, Hau L, et al. A fatal thrombotic disorder associated with an acquired inhibitor of protein C. N Engl J Med 1987; 317:1638.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1354 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-190.102.30.19-126470AF74-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_52_841=[""].join("\n");
var outline_f0_52_841=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23517046\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSIOLOGY OF PROTEIN C",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENETICS OF PROTEIN C DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Type I deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Type II deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Arterial thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Neonatal purpura fulminans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Older homozygotes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Warfarin-induced skin necrosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Retreatment with warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Fetal loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Timing of screening and effect of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ACQUIRED PROTEIN C DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23517046\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1354\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1354|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/56/27534\" title=\"figure 1\">",
"      Warfarin and clotting proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1354|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/34/43553\" title=\"picture 1\">",
"      Cutaneous necrosis warfarin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14234?source=related_link\">",
"      Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/36/6730?source=related_link\">",
"      Drug-induced thrombosis and vascular disease in patients with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=related_link\">",
"      Inherited thrombophilias in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=related_link\">",
"      Management of inherited thrombophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14986?source=related_link\">",
"      Management of thrombosis in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3273?source=related_link\">",
"      Renal vein thrombosis and hypercoagulable state in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=related_link\">",
"      Screening for inherited thrombophilia in asymptomatic populations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_52_842="Cardiac remodeling: Clinical assessment and therapy";
var content_f0_52_842=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiac remodeling: Clinical assessment and therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/52/842/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/52/842/contributors\">",
"     Jay N Cohn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/52/842/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/52/842/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/52/842/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/52/842/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/52/842/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic heart failure (HF) is a major cause of mortality due to progressive pump dysfunction associated with progressive myocardial remodeling as well as arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4058?source=see_link\">",
"     \"Prognosis of heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As heart disease progresses into HF, there is remodeling of the left",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    right ventricle (called cardiac or ventricular remodeling). Heart size increases, cardiac function further deteriorates, and symptoms of HF become evident.",
"   </p>",
"   <p>",
"    Cardiac remodeling is thought to be an important aspect of disease progression in HF, regardless of cause [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is manifested clinically by changes in cardiac size, shape, and function in response to cardiac injury or increased load (",
"    <a class=\"graphic graphic_figure graphicRef69944 \" href=\"UTD.htm?38/34/39458\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19865?source=see_link&amp;anchor=H2#H2\">",
"     \"Cardiac remodeling: Basic aspects\", section on 'Basic concepts of cardiac remodeling'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of remodeling as a pathogenic mechanism is incompletely understood, since the factors leading to remodeling could be the major determinants of HF prognosis rather than ventricular dilation itself. Consistent with the hypothesis that remodeling is pathogenetically important in HF is the observation that angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, beta blockers, and the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    and nitrates, which improve survival in patients with HF, can slow and in some cases reverse, certain parameters of cardiac remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/3-11\">",
"     3-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, therapeutic interventions aimed at increasing contractility in patients with HF may improve symptoms but either have no impact on survival (as with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/12\">",
"     12",
"    </a>",
"    ] or actually increase mortality (as with certain other inotropes) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=see_link\">",
"     \"Use of digoxin in heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7769?source=see_link\">",
"     \"Inotropic agents in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical assessment and treatment of cardiac remodeling will be reviewed here. The basic aspects of cardiac remodeling, such as the mechanisms involved, the factors influencing remodeling, its role in heart failure progression, and measurement of remodeling, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19865?source=see_link\">",
"     \"Cardiac remodeling: Basic aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     REMODELING AFTER MYOCARDIAL INFARCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observations in patients with acute myocardial infarction illustrate the frequency and importance of remodeling in patients with left ventricular dysfunction (",
"    <a class=\"graphic graphic_figure graphicRef69944 \" href=\"UTD.htm?38/34/39458\">",
"     figure 1",
"    </a>",
"    ). The frequency with which remodeling occurs in this setting was assessed in the GISSI-3 Echo Substudy in which serial echocardiograms were performed in 614 patients with an average infarct size that was relatively small (26 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/17\">",
"     17",
"    </a>",
"    ]. Using the end-diastolic volume index (EDVI) as a marker of remodeling, the following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Between 24 to 48 hours after symptom onset to hospital discharge, the EDVI fell in 26 percent, was stable in 23 percent, increased modestly in 32 percent, and increased more than 20 percent in 19 percent (severe early remodeling).",
"     </li>",
"     <li>",
"      Between hospital discharge and six months after infarction, the EDVI fell in 31 percent, was stable in 25 percent, increased modestly in 28 percent, and increased more than 20 percent in 16 percent (severe late remodeling).",
"     </li>",
"     <li>",
"      In-hospital left ventricular enlargement was not predictive of subsequent remodeling, but late remodeling, which most often occurred in the absence of in-hospital left ventricular enlargement, was associated with a progressive deterioration of global left ventricular function and more extensive wall motion abnormalities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Determinants of infarct expansion and ventricular remodeling include large infarct size [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], Q-wave MI [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/20\">",
"     20",
"    </a>",
"    ], anterior location [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/21\">",
"     21",
"    </a>",
"    ], lack of patency of the infarct vessel [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/19,22\">",
"     19,22",
"    </a>",
"    ], elevated intraventricular pressure, and lack of use of thrombolytic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/19\">",
"     19",
"    </a>",
"    ]. Data from the GISSI-3 trial suggest that serial ECG changes, particular involving negative T waves, can predict postinfarction remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/23\">",
"     23",
"    </a>",
"    ]. Lack of negative T wave resolution or the late appearance of new negative T waves were associated with less recovery of wall motion abnormalities, more pronounced left ventricular enlargement, and progressive deterioration of ventricular function; in contrast, normalization of negative T waves was related to functional recovery of viable myocardium and was more useful than QRS changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurements of the extent of LV remodeling have prognostic value; the greater the extent of the remodeling, the poorer the prognosis. Among patients with coronary heart disease, a recent myocardial infarction, or HF, relatively small increases in ventricular volume are associated with major increases in the risk of death [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Measures of remodeling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measures that assess the extent of LV remodeling include LV end-diastolic and end-systolic dimensions and volumes, shape, mass, ejection fraction (LVEF) and myocardial strain (",
"    <a class=\"graphic graphic_figure graphicRef69944 \" href=\"UTD.htm?38/34/39458\">",
"     figure 1",
"    </a>",
"    ). Each measure is indicative of a different aspect of the disease state and none can currently be considered as definitive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Ventricular mass and shape",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging methods such as echocardiography, cardiovascular magnetic resonance, and computed tomography provide a means for measuring left ventricular mass and evaluating ventricular shape.",
"   </p>",
"   <p>",
"    Although electrocardiography is commonly used clinically to diagnose left ventricular hypertrophy, the sensitivity of the various ECG criteria for left ventricular hypertrophy may be as low as 7 to 35 percent with mild disease and 10 to 50 percent with moderate to severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/27\">",
"     27",
"    </a>",
"    ]. Thus, echocardiography is preferred over ECG for detection of left ventricular hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=see_link\">",
"     \"Electrocardiographic diagnosis of left ventricular hypertrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=see_link\">",
"     \"Clinical implications and treatment of left ventricular hypertrophy in hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measurements of ventricular hypertrophy (by echocardiography, cardiovascular magnetic resonance imaging or computed tomography) expressed as LV mass provide some indication of overall ventricular structure. However global measures of hypertrophy do not provide information on specific structural abnormalities, the degree of myocyte slippage, or the relative contributions of myocyte hypertrophy and fibrosis. The distribution of hypertrophy may be assessed by more detailed segmental evaluation of LV mass",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    wall thickness. Myocardial",
"    <span class=\"nowrap\">",
"     scarring/fibrosis",
"    </span>",
"    may be identified by contrast-enhanced cardiac magnetic resonance or computed tomography methods. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Left ventricular volume and systolic function",
"    </span>",
"    &nbsp;&mdash;&nbsp;LV end-systolic and end-diastolic volumes, LVEF, ventricular linear dimensions, and fractional shortening have all been measured in clinical studies of remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/3,4,18,21,24,30\">",
"     3,4,18,21,24,30",
"    </a>",
"    ] and have identified the extent of remodeling in patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The LV end-diastolic volume is a reflection of both structural remodeling and diastolic filling (end-diastolic myocyte fiber length).",
"     </li>",
"     <li>",
"      The LV end-systolic volume is influenced by both the LV end-diastolic volume and fiber shortening; however, asymmetric contraction may make measures of LV end-systolic volume derived from M-mode or two-dimensional echocardiography estimates inaccurate.",
"     </li>",
"     <li>",
"      The LVEF is derived from LV volume. Although heart rate and fiber shortening both affect LVEF, it is influenced to a far greater extent by LV end-diastolic volume because changes in stroke volume tend to be much smaller than changes in LV end-diastolic volume.",
"     </li>",
"     <li>",
"      Fractional shortening is an echocardiographic measure of ventricular contractile function. However, since fractional shortening is derived from a single linear measure of LV cavity at end-diastole and end-systole it may not provide a representative estimate of function, particularly when systolic impairment is regional.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of these factors is variable. As an example, a reduced LVEF is associated with a poor prognosis in HF (",
"    <a class=\"graphic graphic_figure graphicRef54758 \" href=\"UTD.htm?27/30/28141\">",
"     figure 2",
"    </a>",
"    ). In an analysis from the SOLVD trials and registry, a one standard deviation reduction in LVEF increased all-cause mortality (risk ratio 1.62) and cardiovascular hospitalization (risk ratio 1.59) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/32\">",
"     32",
"    </a>",
"    ]. However, relying on a univariate predictor such as the LVEF to estimate survival is not very accurate in the individual patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=see_link\">",
"     \"Predictors of survival in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients who have had a myocardial infarction, LV volumes, particularly LV end-systolic volume, are important prognostic indicators [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/24\">",
"     24",
"    </a>",
"    ]. Such patients who have subsequent morbid events have greater increases in LV diastolic and systolic volumes, as determined by echocardiography, than those without such events [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/33\">",
"     33",
"    </a>",
"    ]. In addition, the in-hospital LVEF and the extent of wall motion abnormalities after the infarct are among the significant predictors of progressive LV dilatation and chronic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/17,30\">",
"     17,30",
"    </a>",
"    ]. On the other hand, in-hospital left ventricular enlargement is usually not predictive of subsequent remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/17,30\">",
"     17,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35658?source=see_link\">",
"     \"Risk stratification for cardiac events after acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    LV systolic dysfunction is difficult to identify solely on the basis of signs and symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/34\">",
"     34",
"    </a>",
"    ]. As an example, one epidemiologic study evaluated 1467 men and women who underwent echocardiography; LV systolic dysfunction, defined as an LVEF &le;30 percent, was present in 2.9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/35\">",
"     35",
"    </a>",
"    ]. Approximately 50 percent of those with LV dysfunction were asymptomatic, ie, remodeling had occurred before the onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/35\">",
"     35",
"    </a>",
"    ]. On the other hand, there is clear benefit from treating patients with asymptomatic LV dysfunction (mostly following myocardial infarction) with an angiotensin converting enzyme (ACE) inhibitor (",
"    <a class=\"graphic graphic_figure graphicRef75136 \" href=\"UTD.htm?11/15/11517\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/33,36\">",
"     33,36",
"    </a>",
"    ]. Since symptoms alone are not a good indicator of the state of LV function; identification of patients with LV dysfunction will require screening of a high risk population [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/35,37\">",
"     35,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Choice of imaging technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both radionuclide imaging and echocardiography provide a simple assessment of LV systolic function and chamber size&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/34\">",
"     34",
"    </a>",
"    ]. However, the application of these diagnostic tools in evaluation and management of remodeling needs to be further refined. Although the LVEF is of prognostic importance, opinions differ regarding the value of the LVEF in guiding therapy and there are no data that definitely support the use of changes in LVEF as a basis for altering therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=see_link\">",
"     \"Predictors of survival in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=see_link\">",
"     \"Noninvasive methods for measurement of left ventricular systolic function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although echocardiography is reliable in clinical trials, repeat measurements of LV mass and volume or LVEF in individual patients may vary considerably and methods are poorly standardized between centers [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/38\">",
"     38",
"    </a>",
"    ]. Further limiting its use is the inability to obtain adequate images in some patients, such as those who are obese or have airway disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/39\">",
"     39",
"    </a>",
"    ]. Thus, one must be cautious in using standard echocardiographic monitoring to guide management. Echocardiography using harmonic imaging and contrast injection improves the accuracy and reproducibility of echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13145?source=see_link\">",
"     \"Contrast echocardiography: Clinical applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiac magnetic resonance imaging provides better accuracy and reproducibility than echocardiography. However, it is less available and more expensive than echocardiography, which limits routine use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Use of LVEF to guide management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The LVEF, regardless of how it is measured, is an important predictor of outcome. As an example, the V-HeFT I and V-HeFT II trials identified LVEF, as determined by radionuclide imaging, as a powerful predictor of all-cause mortality in patients with HF. The mortality increased in a nonlinear fashion as LVEF fell, with the mortality rate increasing steeply in patients with an LVEF below 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, using LVEF to estimate survival in an individual patient is of limited value. Large trials have demonstrated that patients with NYHA class II or III heart failure have a worse prognosis than those who are asymptomatic. Despite the difference in outcome, the difference in mean LVEF between asymptomatic and symptomatic patients in these trials was small &mdash; 28 to 31 percent in asymptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/33,36\">",
"     33,36",
"    </a>",
"    ] versus 25 percent in patients with moderate symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/42\">",
"     42",
"    </a>",
"    ]. Another problem is that the LVEF is of limited utility in some situations, as in the immediate postinfarction period where LV dysfunction may be caused by large areas of hibernating or stunned myocardium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/41/10905?source=see_link\">",
"     \"Evaluation of hibernating myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite these limitations, information about the LVEF, generated from echocardiography, often results in decisions about management. This was illustrated in a report of 259 patients with suspected or untreated HF who were referred for echocardiography by general practitioners; the findings resulted in a change in management in more than two-thirds of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increases in LVEF have been linked to improved prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]. Although the degree of improvement is important, it must be considered in the context of other responses that may affect mortality. An analysis of the combined data from V-HeFT I and II showed that, although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    did not increase LVEF as much as",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"      hydralazine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"      isosorbide dinitrate",
"     </a>",
"     ,",
"    </span>",
"    it was associated with a greater reduction in mortality (",
"    <a class=\"graphic graphic_figure graphicRef64938 \" href=\"UTD.htm?19/46/20205\">",
"     figure 4",
"    </a>",
"    ); these observation suggest that inhibition of the renin-angiotensin system conferred additional survival benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/43,47\">",
"     43,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The V-HeFT data also found that serial measurements of LVEF provided additional prognostic information, suggesting that there is some merit to monitoring LVEF or chamber size to assess response to therapy and altering it accordingly. However, randomized clinical trials have yet to prospectively test this hypothesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Serum markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac troponin I and T, which are released during myocyte injury, are elevated in some patients with HF, even in the absence of coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. Such enzyme elevations are associated with progressive decline in left ventricular function and more frequent cardiac events, suggesting that they are markers of ongoing myocardial damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=see_link\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surrogate markers, such as LVEF, ventricular volumes, and fractional shortening, provide a general guide to the extent of cardiac remodeling and are useful clinical predictors of outcome. However, they do not provide a clear picture of changes in the underlying pathophysiology of the heart. New developments that may be useful to assess the extent of LV remodeling include imaging techniques for the quantitative evaluation of myocardial and nonmyocardial components and the measurement of neurohormones known to be elevated in HF (such as brain natriuretic peptide) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. The latter approach, perhaps combined with echocardiography, offers the possibility of more reliable detection of asymptomatic LV dysfunction. There is also evidence that plasma BNP can be used to monitor the effect of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EFFECT OF THERAPEUTIC INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Slowing or reversing remodeling has not, until recently, been a recognized goal of therapy. The most convincing data demonstrating that chronic medical therapy (eg, ACE inhibitors and beta blockers) modify the remodeling process are based upon changes in LV end-diastolic and end-systolic volumes and LVEF [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/3-5,8,9\">",
"     3-5,8,9",
"    </a>",
"    ]. The effect of these agents on remodeling is in addition to other clinically relevant benefits that result in a reduction in morbidity and mortality in patients with HF as well as asymptomatic left ventricular dysfunction (",
"    <a class=\"graphic graphic_figure graphicRef75136 \" href=\"UTD.htm?11/15/11517\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/33,36\">",
"     33,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to these medical therapies, a number of surgical approaches have been evaluated in the treatment of heart failure, some of which affect remodeling. Their clinical role remains to be determined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35143?source=see_link\">",
"     \"Surgical management of heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Vasodilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasodilator therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/16/23814?source=see_link\">",
"     prazosin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/45/2775?source=see_link\">",
"     felodipine",
"    </a>",
"    do not reduce mortality or hospitalization rate in patients with systolic heart failure (",
"    <a class=\"graphic graphic_figure graphicRef78557 \" href=\"UTD.htm?13/24/13709\">",
"     figure 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30438?source=see_link\">",
"     \"Calcium channel blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These observations suggest that an improvement in LV emptying, which accompanies peripheral vasodilation and reduced afterload, is not sufficient to improve outcome. What may be required is an effect on remodeling.",
"   </p>",
"   <p>",
"    Consistent with this hypothesis is the observation that the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    improves survival in patients with heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/10,55\">",
"     10,55",
"    </a>",
"    ] and regresses remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/11\">",
"     11",
"    </a>",
"    ]. In the A-HeFT Trial, the addition of combined hydralazine and isosorbide dinitrate to standard HF therapy in 1050 black patients with NYHA class III to IV HF was associated with a significant reduction in mortality at a mean of 10 months (6.2 versus 10.2 percent with placebo) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/10\">",
"     10",
"    </a>",
"    ]. The mortality benefit was associated with regression of LV remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link&amp;anchor=H27821874#H27821874\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\", section on 'Hydralazine plus nitrates'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Inotropic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positive inotropic drugs may exert favorable hemodynamic effects but either have no effect on (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/12\">",
"     12",
"    </a>",
"    ], or reduce survival (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    , flosequinan, pimobendan, ibopamine and vesnarinone) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7769?source=see_link\">",
"     \"Inotropic agents in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     ACE inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitors improve survival in patients with asymptomatic LV dysfunction (",
"    <a class=\"graphic graphic_figure graphicRef75136 \" href=\"UTD.htm?11/15/11517\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/33,36\">",
"     33,36",
"    </a>",
"    ] and moderate to severe HF (",
"    <a class=\"graphic graphic_figure graphicRef70015 \" href=\"UTD.htm?10/28/10701\">",
"     figure 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/42,58,59\">",
"     42,58,59",
"    </a>",
"    ]. Furthermore, they tend to be more effective than the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    in white patients (",
"    <a class=\"graphic graphic_figure graphicRef64938 \" href=\"UTD.htm?19/46/20205\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/47\">",
"     47",
"    </a>",
"    ], but apparently not in self-designated black patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link&amp;anchor=H32#H32\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\", section on 'Hydralazine with nitrates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A survival benefit has also been shown when ACE inhibitors are started soon after myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/33,61,62\">",
"     33,61,62",
"    </a>",
"    ]. A meta-analysis concluded that early intervention within 3 to 16 days of infarction can slow the progression of cardiovascular disease and improve the survival rate (",
"    <a class=\"graphic graphic_figure graphicRef58405 \" href=\"UTD.htm?28/62/29677\">",
"     figure 7",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Mechanisms of benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits seen with ACE inhibitors cannot be entirely ascribed to vasodilation and their effect on blood pressure since, as noted above, these drugs are more effective than other vasodilators such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/16/23814?source=see_link\">",
"     prazosin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/55\">",
"     55",
"    </a>",
"    ], calcium channel blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/57\">",
"     57",
"    </a>",
"    ], and, in white patients, the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    in white patients (",
"    <a class=\"graphic graphic_figure graphicRef64938 \" href=\"UTD.htm?19/46/20205\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is evidence that ACE inhibitors and angiotensin II receptor blockers have favorable effects on certain parameters of remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/3-6,64\">",
"     3-6,64",
"    </a>",
"    ]. This effect is presumably mediated by inhibition of angiotensin II or, with ACE inhibitors, augmentation of bradykinin, which appear to play an important role in the remodeling process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19865?source=see_link&amp;anchor=H14#H14\">",
"     \"Cardiac remodeling: Basic aspects\", section on 'Role of angiotensin II'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Using serial radionuclide ventriculograms, the SOLVD prevention trial showed that, compared with placebo,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    slowed or reversed LV dilation in patients with asymptomatic LV dysfunction (LVEF &le;35 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/4\">",
"     4",
"    </a>",
"    ]. The reduction in LV volumes with enalapril treatment were less in these asymptomatic patients than in those with mild to moderately symptomatic HF [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/3\">",
"     3",
"    </a>",
"    ]. Attenuation of the progressive increase in LV dilation and hypertrophy could also be demonstrated by Doppler echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1799?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors in acute myocardial infarction: Mechanisms of action\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Combination of ACE inhibitor and angiotensin II receptor blocker",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal and clinical studies suggest that the combination of an ACE inhibitor and an angiotensin II receptor blocker is more effective than an ACE inhibitor alone for attenuating remodeling after a myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. A pilot clinical study randomly assigned 99 patients with a suspected anterior infarction to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    plus either placebo or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    ; an additional 23 patients received only losartan [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/66\">",
"     66",
"    </a>",
"    ]. After three months, patients receiving combination therapy had a significantly smaller left ventricular end systolic volume and a trend toward a higher LVEF compared to those receiving captopril or losartan alone. In the large Val-HeFT trial the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    to all other background therapy, including ACE inhibitors, resulted in a greater increase in ejection fraction compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonetheless, some trials have raised the possibility of adverse effects when high-dose angiotensin receptor blocker therapy is added to high-dose ACE inhibitor therapy, especially in the presence of background beta blocker therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/6\">",
"     6",
"    </a>",
"    ]. Furthermore, ONTARGET demonstrated no long-term benefit of adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/38/27239?source=see_link\">",
"     telmisartan",
"    </a>",
"    to ACE inhibitor therapy in patients with atherosclerosis. It is clear that dose considerations of these two classes of compounds are critical in assessing their additive effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients able to tolerate such therapy, the addition of certain beta blockers (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"     bisoprolol",
"    </a>",
"    ) to standard therapy with ACE inhibitor and diuretics can improve LV function, clinical status, and long-term survival (",
"    <a class=\"graphic graphic_figure graphicRef62633 \" href=\"UTD.htm?11/47/12029\">",
"     figure 8",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to its antiarrhythmic properties and protection against sudden death, beta blockade has beneficial effects on LV geometry and mass [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/67-69\">",
"     67-69",
"    </a>",
"    ] and consistently improves LVEF in patients with HF irrespective of etiology (",
"    <a class=\"graphic graphic_figure graphicRef65184 \" href=\"UTD.htm?25/13/25821\">",
"     figure 9",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/8,9,31,70-74\">",
"     8,9,31,70-74",
"    </a>",
"    ]. These benefits require continued therapy. This was illustrated in a study of 33 patients with severe HF in which withdrawal of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    after an average of 16 months produced deterioration in LV function in two-thirds of patients; those surviving benefited from readministration of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Beta blocker therapy can also improve parameters of remodeling other than LVEF. These include reductions in LV end-diastolic and end-systolic volume index [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/8,31,74\">",
"     8,31,74",
"    </a>",
"    ] and increased LV fractional shortening [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/76\">",
"     76",
"    </a>",
"    ]. In patients with a small anterior wall myocardial infarction, early treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    produces similar effects on preservation of left ventricular function and volumes; however, beta blockade alone is not adequate to prevent ventricular dilatation when the infarction is larger [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Beta blockers may also improve left ventricular remodeling in patients with asymptomatic left ventricular dysfunction. In the REVERT trial of 149 asymptomatic patients with an LVEF &lt;40 percent who were randomly assigned to treatment with either 200 or 50 mg of extended release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    or placebo, an increase in LVEF was observed in both beta blocker groups as compared to baseline and placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Natriuretic peptide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial natriuretic peptide (ANP) is a direct vasodilator, which lowers the systemic blood pressure, inhibits renin and endothelin secretion, and may have a direct effect on the myocardium, inhibiting myocyte hypertrophy and fibroblast collagen synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. Brain natriuretic peptide infusion had a beneficial effect on remodeling in experimental models [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These actions suggest that ANP may have a beneficial effect on remodeling. This was examined in a series of 60 patients with a first anterior wall myocardial infarction who underwent primary angioplasty; an intravenous infusion of ANP for over 24 hours resulted in the prevention of remodeling with a higher LVEF at one month when compared to an infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    (55 versus 51 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/83\">",
"     83",
"    </a>",
"    ]. However, a large clinical trial found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    (recombinant human brain natriuretic peptide, BNP 1-32) did not alter rates of death or rehospitalization at 30 days [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35701?source=see_link\">",
"     \"Nesiritide in the treatment of acute decompensated heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Revascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Revascularization can improve regional and global left ventricular function and ventricular size in patients with chronic coronary heart disease and severe left ventricular dysfunction who have viable, but hibernating myocardium. In such patients, revascularization can reduce the extent of remodeling and improve left ventricular size and shape; these changes are independent of an incremental to the improvement in left ventricular function [",
"    <a class=\"abstract\" href=\"UTD.htm?0/52/842/abstract/85\">",
"     85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/41/10905?source=see_link\">",
"     \"Evaluation of hibernating myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Cardiac resynchronization therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac resynchronization therapy (CRT) with biventricular (BiV) pacing has been employed in selected patients with heart failure to improve ventricular emptying by restoring mechanical synchrony. Long-term trial data with this form of therapy has revealed a chronic reduction in heart size and improvement in ejection fraction consistent with regression of cardiac remodeling. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10823?source=see_link&amp;anchor=H6#H6\">",
"     \"Rationale for and mechanisms of benefit of cardiac resynchronization therapy\", section on 'Reverse ventricular remodeling'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33932025\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac remodeling is manifested as changed in cardiac size, shape and function in response to cardiac injury or increased load. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Determinants of greater myocardial infarct expansion and ventricular remodeling include large infarct size, Q wave infarction, anterior location, lack of patency of the infarct vessel, elevated intraventricular pressure, and lack of use of thrombolytic agent. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Remodeling after myocardial infarction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The greater the extent of left ventricular remodeling, the poorer the prognosis. Among patients with coronary heart disease, recent myocardial infarction, or heart failure, relatively small increases in ventricular volume are associated with major increases in risk of death. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ventricular mass, cavity size, shape and systolic function can be assessed by echocardiography, cardiovascular magnetic resonance imaging or computed tomography. Radionuclide imaging provides a simple assessment of left ventricular chamber size and left ventricular systolic function. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Ventricular mass and shape'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Choice of imaging technique'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Echocardiographic is the most commonly used modality for assessing ventricular size and function but it is subject to technical limitations.",
"     </li>",
"     <li>",
"      Cardiovascular magnetic resonance imaging provides high reproducibility but is less available than echocardiography.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A depressed left ventricular ejection fraction is an adverse prognostic indicator although its predictive value in an individual patient is limited. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Use of LVEF to guide management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Consistent with the hypothesis that remodeling is pathogenetically important in HF is the observation that angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, beta blockers, the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      and nitrates, and aldosterone inhibition as well as cardiac resynchronization therapy each improve survival in patients with HF, and can slow and in some cases reverse, certain parameters of cardiac remodeling. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Effect of therapeutic interventions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/1\">",
"      Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000; 35:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/2\">",
"      Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000; 101:2981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/3\">",
"      Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation 1992; 86:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/4\">",
"      Konstam MA, Kronenberg MW, Rousseau MF, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. Circulation 1993; 88:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/5\">",
"      Greenberg B, Quinones MA, Koilpillai C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 1995; 91:2573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/6\">",
"      Wong M, Staszewsky L, Latini R, et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 2002; 40:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/7\">",
"      McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/8\">",
"      Doughty RN, Whalley GA, Gamble G, et al. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 1997; 29:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/9\">",
"      Groenning BA, Nilsson JC, Sondergaard L, et al. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 2000; 36:2072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/10\">",
"      Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/11\">",
"      Cohn JN, Tam SW, Anand IS, et al. Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. J Card Fail 2007; 13:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/12\">",
"      The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997; 336:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/13\">",
"      Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/14\">",
"      Hampton JR, van Veldhuisen DJ, Kleber FX, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet 1997; 349:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/15\">",
"      Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 1998; 339:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/16\">",
"      Lubsen J, Just H, Hjalmarsson AC, et al. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 1996; 76:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/17\">",
"      Giannuzzi P, Temporelli PL, Bosimini E, et al. Heterogeneity of left ventricular remodeling after acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-3 Echo Substudy. Am Heart J 2001; 141:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/18\">",
"      McKay RG, Pfeffer MA, Pasternak RC, et al. Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion. Circulation 1986; 74:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/19\">",
"      Popovi�� AD, Neskovi�� AN, Marinkovi�� J, Thomas JD. Acute and long-term effects of thrombolysis after anterior wall acute myocardial infarction with serial assessment of infarct expansion and late ventricular remodeling. Am J Cardiol 1996; 77:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/20\">",
"      Pirolo JS, Hutchins GM, Moore GW. Infarct expansion: pathologic analysis of 204 patients with a single myocardial infarct. J Am Coll Cardiol 1986; 7:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/21\">",
"      Rumberger JA, Behrenbeck T, Breen JR, et al. Nonparallel changes in global left ventricular chamber volume and muscle mass during the first year after transmural myocardial infarction in humans. J Am Coll Cardiol 1993; 21:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/22\">",
"      Leung WH, Lau CP. Effects of severity of the residual stenosis of the infarct-related coronary artery on left ventricular dilation and function after acute myocardial infarction. J Am Coll Cardiol 1992; 20:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/23\">",
"      Bosimini E, Giannuzzi P, Temporelli PL, et al. Electrocardiographic evolutionary changes and left ventricular remodeling after acute myocardial infarction: results of the GISSI-3 Echo substudy. J Am Coll Cardiol 2000; 35:127.",
"     </a>",
"    </li>",
"    <li>",
"     White, HD, Norris, RM, Brown, MA, et al. Left ventricular end-systolic volume as the major.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/25\">",
"      Hammermeister KE, DeRouen TA, Dodge HT. Variables predictive of survival in patients with coronary disease. Selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations. Circulation 1979; 59:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/26\">",
"      Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990; 81:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/27\">",
"      Devereux RB. Is the electrocardiogram still useful for detection of left ventricular hypertrophy? Circulation 1990; 81:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/28\">",
"      Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/29\">",
"      Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/30\">",
"      Gaudron P, Eilles C, Kugler I, Ertl G. Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors. Circulation 1993; 87:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/31\">",
"      Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet 1997; 349:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/32\">",
"      Qui&ntilde;ones MA, Greenberg BH, Kopelen HA, et al. Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 2000; 35:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/33\">",
"      Pfeffer MA, Braunwald E, Moy&eacute; LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/34\">",
"      Guidelines for the diagnosis of heart failure. The Task Force on Heart Failure of the European Society of Cardiology. Eur Heart J 1995; 16:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/35\">",
"      McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997; 350:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/36\">",
"      Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 1992; 327:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/37\">",
"      McMurray JV, McDonagh TA, Davie AP, et al. Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure? Eur Heart J 1998; 19:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/38\">",
"      Gottdiener JS. Left ventricular mass, diastolic dysfunction, and hypertension. Adv Intern Med 1993; 38:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/39\">",
"      Francis CM, Caruana L, Kearney P, et al. Open access echocardiography in management of heart failure in the community. BMJ 1995; 310:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/40\">",
"      Thomson HL, Basmadjian AJ, Rainbird AJ, et al. Contrast echocardiography improves the accuracy and reproducibility of left ventricular remodeling measurements: a prospective, randomly assigned, blinded study. J Am Coll Cardiol 2001; 38:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/41\">",
"      Cohn JN, Johnson GR, Shabetai R, et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87:VI5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/42\">",
"      Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/43\">",
"      Cintron G, Johnson G, Francis G, et al. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87:VI17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/44\">",
"      Gradman A, Deedwania P, Cody R, et al. Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group. J Am Coll Cardiol 1989; 14:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/45\">",
"      Parameshwar J, Keegan J, Sparrow J, et al. Predictors of prognosis in severe chronic heart failure. Am Heart J 1992; 123:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/46\">",
"      Likoff MJ, Chandler SL, Kay HR. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 1987; 59:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/47\">",
"      Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/48\">",
"      Sato Y, Yamada T, Taniguchi R, et al. Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation 2001; 103:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/49\">",
"      Del Carlo CH, O'Connor CM. Cardiac troponins in congestive heart failure. Am Heart J 1999; 138:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/50\">",
"      La Vecchia L, Mezzena G, Zanolla L, et al. Cardiac troponin I as diagnostic and prognostic marker in severe heart failure. J Heart Lung Transplant 2000; 19:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/51\">",
"      Vantrimpont P, Rouleau JL, Ciampi A, et al. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J 1998; 19:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/52\">",
"      Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/53\">",
"      Ferrari R, Ceconi C. Neuroendocrine activation in left ventricular dysfunction. Eur Heart J 1998; 19:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/54\">",
"      Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/55\">",
"      Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/56\">",
"      Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation 1991; 83:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/57\">",
"      Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 1997; 96:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/58\">",
"      Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/59\">",
"      Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/60\">",
"      Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 1999; 5:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/61\">",
"      K&oslash;ber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/62\">",
"      Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. Lancet 1997; 349:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/63\">",
"      Flather MD, Yusuf S, K&oslash;ber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/64\">",
"      Pfeffer MA, Lamas GA, Vaughan DE, et al. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 1988; 319:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/65\">",
"      Mankad S, d'Amato TA, Reichek N, et al. Combined angiotensin II receptor antagonism and angiotensin-converting enzyme inhibition further attenuates postinfarction left ventricular remodeling. Circulation 2001; 103:2845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/66\">",
"      Di Pasquale P, Bucca V, Scalzo S, et al. Does the addition of losartan improve the beneficial effects of ACE inhibitors in patients with anterior myocardial infarction? A pilot study. Heart 1999; 81:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/67\">",
"      Lowes BD, Gill EA, Abraham WT, et al. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol 1999; 83:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/68\">",
"      Hall SA, Cigarroa CG, Marcoux L, et al. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 1995; 25:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/69\">",
"      Ghio S, Magrini G, Serio A, et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur Heart J 2006; 27:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/70\">",
"      Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996; 94:2807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/71\">",
"      Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996; 94:2793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/72\">",
"      A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation 1994; 90:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/73\">",
"      Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy : the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation 2000; 101:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/74\">",
"      Doughty RN, Whalley GA, Walsh HA, et al. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation 2004; 109:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/75\">",
"      Waagstein F, Caidahl K, Wallentin I, et al. Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989; 80:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/76\">",
"      Lechat P, Escolano S, Golmard JL, et al. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). Circulation 1997; 96:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/77\">",
"      Galcer&aacute;-Tom&aacute;s J, Castillo-Soria FJ, Villegas-Garc&iacute;a MM, et al. Effects of early use of atenolol or captopril on infarct size and ventricular volume: A double-blind comparison in patients with anterior acute myocardial infarction. Circulation 2001; 103:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/78\">",
"      Colucci WS, Kolias TJ, Adams KF, et al. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. Circulation 2007; 116:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/79\">",
"      Horio T, Nishikimi T, Yoshihara F, et al. Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. Hypertension 2000; 35:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/80\">",
"      Redondo J, Bishop JE, Wilkins MR. Effect of atrial natriuretic peptide and cyclic GMP phosphodiesterase inhibition on collagen synthesis by adult cardiac fibroblasts. Br J Pharmacol 1998; 124:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/81\">",
"      George I, Xydas S, Klotz S, et al. Long-term effects of B-type natriuretic peptide infusion after acute myocardial infarction in a rat model. J Cardiovasc Pharmacol 2010; 55:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/82\">",
"      George I, Morrow B, Xu K, et al. Prolonged effects of B-type natriuretic peptide infusion on cardiac remodeling after sustained myocardial injury. Am J Physiol Heart Circ Physiol 2009; 297:H708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/83\">",
"      Hayashi M, Tsutamoto T, Wada A, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2001; 37:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/84\">",
"      O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/52/842/abstract/85\">",
"      Senior R, Lahiri A, Kaul S. Effect of revascularization on left ventricular remodeling in patients with heart failure from severe chronic ischemic left ventricular dysfunction. Am J Cardiol 2001; 88:624.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3476 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.65.66-4367187BB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_52_842=[""].join("\n");
var outline_f0_52_842=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33932025\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      REMODELING AFTER MYOCARDIAL INFARCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Measures of remodeling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Ventricular mass and shape",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Left ventricular volume and systolic function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Choice of imaging technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Use of LVEF to guide management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Serum markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EFFECT OF THERAPEUTIC INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Vasodilators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Inotropic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ACE inhibition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Mechanisms of benefit",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Combination of ACE inhibitor and angiotensin II receptor blocker",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Natriuretic peptide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Revascularization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Cardiac resynchronization therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33932025\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3476\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3476|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/34/39458\" title=\"figure 1\">",
"      Cardiac remodeling after anterior MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/30/28141\" title=\"figure 2\">",
"      LVEF survival LV dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/15/11517\" title=\"figure 3\">",
"      ACE inhibitor in LV dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/46/20205\" title=\"figure 4\">",
"      ACEI vs hydralazine in HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/24/13709\" title=\"figure 5\">",
"      Felodipine in HF V HeFT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/28/10701\" title=\"figure 6\">",
"      ACE inhibitor moderate HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/62/29677\" title=\"figure 7\">",
"      ACE inhibitors improve outcome after MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/47/12029\" title=\"figure 8\">",
"      Carvedilol in HF I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/13/25821\" title=\"figure 9\">",
"      Carvedilol and LVEF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1799?source=related_link\">",
"      Angiotensin converting enzyme inhibitors in acute myocardial infarction: Mechanisms of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30438?source=related_link\">",
"      Calcium channel blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19865?source=related_link\">",
"      Cardiac remodeling: Basic aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=related_link\">",
"      Clinical implications and treatment of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13145?source=related_link\">",
"      Contrast echocardiography: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=related_link\">",
"      Electrocardiographic diagnosis of left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/41/10905?source=related_link\">",
"      Evaluation of hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7769?source=related_link\">",
"      Inotropic agents in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35701?source=related_link\">",
"      Nesiritide in the treatment of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=related_link\">",
"      Noninvasive methods for measurement of left ventricular systolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=related_link\">",
"      Predictors of survival in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4058?source=related_link\">",
"      Prognosis of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10823?source=related_link\">",
"      Rationale for and mechanisms of benefit of cardiac resynchronization therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35658?source=related_link\">",
"      Risk stratification for cardiac events after acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35143?source=related_link\">",
"      Surgical management of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=related_link\">",
"      Use of digoxin in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_52_843="NSAIDs renal failure";
var content_f0_52_843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F69369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F69369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions associated with nonsteroidal anti-inflammatory drug-induced, hemodynamically-mediated acute renal failure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        True volume depletion - vomiting, diarrhea, diuretic therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cirrhosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glomerular diseases, including nephrotic syndrome and lupus nephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypercalcemia, which directly induced renal vasoconstriction",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_52_843=[""].join("\n");
var outline_f0_52_843=null;
var title_f0_52_844="Behaviors that enhance outcome";
var content_f0_52_844=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F54037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F54037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical behaviors that enhance the outcomes of medical care",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cognitive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Negotiating priorities and expectations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Giving an explanation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bringing a patient to a crossroads",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Making suggestions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Educating the patient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Giving a prognosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Affective",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Conveying empathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encouraging emotional expression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Giving encouragement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Offering hope",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Touching",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Facilitating self-forgiveness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Giving reassurance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Behavioral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Emphasizing patient's active role",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Praising desired behaviors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suggesting alternative behaviors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Attending to compliance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Social",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Using family and social supports",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Using community",
"agencies and other health care providers",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Lipkin M, Putnam S, Lazare A. The Medical Interview. Springer-Verlag, New York 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_52_844=[""].join("\n");
var outline_f0_52_844=null;
var title_f0_52_845="NCDB no surg surv panc";
var content_f0_52_845=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Five-year overall survival for pancreatic adenocarcinoma from the National Cancer Data Base: nonresected",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"3\">",
"       Nonsurgical patients",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"5\">",
"       Observed survival",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Median survival, months",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Stage",
"      </td>",
"      <td class=\"subtitle2\">",
"       Number of patients",
"      </td>",
"      <td class=\"subtitle2\">",
"       Percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       1-year, percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       2-year, percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       3-year, percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       4-year, percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       5-year, percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IA",
"      </td>",
"      <td>",
"       3412",
"      </td>",
"      <td>",
"       4.4",
"      </td>",
"      <td>",
"       29.2",
"      </td>",
"      <td>",
"       10.5",
"      </td>",
"      <td>",
"       6.2",
"      </td>",
"      <td>",
"       4.6",
"      </td>",
"      <td>",
"       3.8",
"      </td>",
"      <td>",
"       6.8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IB",
"      </td>",
"      <td>",
"       4298",
"      </td>",
"      <td>",
"       5.4",
"      </td>",
"      <td>",
"       26.0",
"      </td>",
"      <td>",
"       9.4",
"      </td>",
"      <td>",
"       5.7",
"      </td>",
"      <td>",
"       4.0",
"      </td>",
"      <td>",
"       3.4",
"      </td>",
"      <td>",
"       6.1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IIA",
"      </td>",
"      <td>",
"       8486",
"      </td>",
"      <td>",
"       10.1",
"      </td>",
"      <td>",
"       25.0",
"      </td>",
"      <td>",
"       7.7",
"      </td>",
"      <td>",
"       4.1",
"      </td>",
"      <td>",
"       2.8",
"      </td>",
"      <td>",
"       2.4",
"      </td>",
"      <td>",
"       6.2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IIB",
"      </td>",
"      <td>",
"       6570",
"      </td>",
"      <td>",
"       11.8",
"      </td>",
"      <td>",
"       26.9",
"      </td>",
"      <td>",
"       7.7",
"      </td>",
"      <td>",
"       3.8",
"      </td>",
"      <td>",
"       2.6",
"      </td>",
"      <td>",
"       2.0",
"      </td>",
"      <td>",
"       6.7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       III",
"      </td>",
"      <td>",
"       12,981",
"      </td>",
"      <td>",
"       13.0",
"      </td>",
"      <td>",
"       27.0",
"      </td>",
"      <td>",
"       7.3",
"      </td>",
"      <td>",
"       3.4",
"      </td>",
"      <td>",
"       2.4",
"      </td>",
"      <td>",
"       1.8",
"      </td>",
"      <td>",
"       7.2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IV",
"      </td>",
"      <td>",
"       64,454",
"      </td>",
"      <td>",
"       55.2",
"      </td>",
"      <td>",
"       8.3",
"      </td>",
"      <td>",
"       2.3",
"      </td>",
"      <td>",
"       1.2",
"      </td>",
"      <td>",
"       0.8",
"      </td>",
"      <td>",
"       0.6",
"      </td>",
"      <td>",
"       2.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Total",
"       </strong>",
"      </td>",
"      <td>",
"       <strong>",
"        100,201",
"       </strong>",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       <strong>",
"        3.5",
"       </strong>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reference:",
"     <br>",
"      <ol>",
"       <li>",
"        Bilimoria KY, Bentrem DJ, Ko Cy, et al. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer. 2007; 110(4):738-44, with permission of Wiley.",
"       </li>",
"      </ol>",
"      Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_52_845=[""].join("\n");
var outline_f0_52_845=null;
var title_f0_52_846="Osteoporosis screening recs";
var content_f0_52_846=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F62866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F62866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Osteoporosis screening recommendations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td rowspan=\"14\">",
"        National Osteoporosis Foundation (NOF) and International Society for Clinical Densitometry (ISCD)",
"       </td>",
"       <td class=\"sublist1_start\">",
"        The NOF and ISCD recommend measurement of BMD (DXA of the hip and spine) in",
"        <sup>",
"         [1-3]",
"        </sup>",
"        :",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; All women 65 years and older and men 70 and older regardless of risk factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Postmenopausal women and men 50 to 70 years when risk factors are present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Adults who have a fracture after age 50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Adults with a condition or taking a medication associated with low bone mass or bone loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Anyone being considered for pharmacologic therapy for osteoporosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Anyone being treated for osteoporosis to monitor response to therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Anyone not receiving therapy when evidence of bone loss would lead to treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Women in the menopausal transition if there is a specific risk factor associated with increased fracture, such as low body weight, prior low-trauma fracture, or high risk medication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Postmenopausal women discontinuing estrogen should be considered for bone density testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; The 33 percent forearm (1/3 radius) site is recommended in the following cases:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - If hip and/or spine cannot be measured or interpreted",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - Hyperparathyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - Severe obesity (over the weight limit of DXA table)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        Association of Clinical Endocrinologists (AACE)",
"       </td>",
"       <td class=\"sublist1_start\">",
"        AACE recommends measurement of BMD (DXA) in",
"        <sup>",
"         [4]",
"        </sup>",
"        :",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; All women 65 years and older",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Any adult with a history of fracture not caused by severe trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Younger postmenopausal women with clinical risk factors for fracture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; The lumbar spine (PA) and proximal femur are recommended sites of measurement",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        United States Preventive Services Task Force (USPSTF)",
"       </td>",
"       <td class=\"sublist1_start\">",
"        USPSTF recommends measurements of BMD in",
"        <sup>",
"         [5]",
"        </sup>",
"        :",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; All women ages 65 and older",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; In addition, they recommend screening in younger women whose fracture risk is equal to or greater than that of a 65-year-old white woman who has no additional risk factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; The best site to screen is not mentioned, although the report agrees that DXA of the hip is the best predictor of hip fracture",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        American Academy of Family Physicians",
"       </td>",
"       <td class=\"sublist1_start\">",
"        The American Academy of Family Physicians recommends measurement of BMD in",
"        <sup>",
"         [6]",
"        </sup>",
"        :",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Women ages 65 and older",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Women 60 and older at increased risk for osteoporotic fracture",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        National Institutes of Health",
"       </td>",
"       <td class=\"sublist1_start\">",
"        The NIH recommends",
"        <sup>",
"         [7]",
"        </sup>",
"        :",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; BMD measurements for individuals at high risk for osteoporosis. They do not recommend universal screening.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        UK National Osteoporosis Guideline Group (NOGG)",
"       </td>",
"       <td>",
"        The UK National Osteoporosis Guideline Group (NOGG) does not recommend population screening. They are in favor of performing BMD measurements using a case finding strategy based upon age-specific fracture probability thresholds",
"        <sup>",
"         [8]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Canadian Osteoporosis Society",
"       </td>",
"       <td class=\"sublist1_start\">",
"        The Canadian Osteoporosis Society recommends BMD measurement in",
"        <sup>",
"         [9]",
"        </sup>",
"        :",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Postmenopausal women &ge;65 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Men &ge;65 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Younger men and women with additional clinical risk factors for fracture",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Fulton JP. New guidelines for the prevention and treatment of osteoporosis. National Osteoporosis Foundation. Med Health R I 1999; 82:110.",
"       </li>",
"       <li>",
"        NOF's New Clinician's Guide to Prevention and Treatment of Osteoporosis. file://www.nof.org/sites/default/files/pdfs/NOF_ClinicianGuide2009_v7.pdf (Accessed on January 10, 2011).",
"       </li>",
"       <li>",
"        The Internationals Society for Clinical Densitometry Official Positions. www.iscd.org/Visitors/positions/OfficialPositionsText.cfm (Accessed on January 10, 2011).",
"       </li>",
"       <li>",
"        American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Postmenopausal Osteoporosis. file://www.aace.com/pub/pdf/guidelines/OsteoGuidelines2010.pdf (Accessed on January 10, 2011).",
"       </li>",
"       <li>",
"        U.S. Preventive Services Task Force. Screening for Osteoporosis Recommendation Statement. file://www.uspreventiveservicestaskforce.org/uspstf10/osteoporosis/osteors.htm (Accessed on February 10, 2011).",
"       </li>",
"       <li>",
"        American Academy of Family Physicians. Recommendations for clinical preventative services. file://www.aafp.org/exam.xml (Accessed on January 10, 2011).",
"       </li>",
"       <li>",
"        www.consensus.nih.gov (Accessed on January 10, 2011).",
"       </li>",
"       <li>",
"        National Osteoporosis Guideline Group (NOGG). file://www.shef.ac.uk/NOGG/index.html (Accessed on June 29, 2011).",
"       </li>",
"       <li>",
"        Papaioannou A, Morin S, Cheung AM, et al. 2010 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: Summary. CMAJ 2010; 182:1864.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_52_846=[""].join("\n");
var outline_f0_52_846=null;
var title_f0_52_847="Pediatric oropharyngeal trauma algorithm";
var content_f0_52_847=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 471px\">",
"   <div class=\"ttl\">",
"    Evaluation and management of oropharyngeal trauma in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 451px; height: 378px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CTA: computed tomography angiography.",
"     <br>",
"      * Internal carotid artery abnormality, tissue disruption or air near carotid sheath.",
"      <br>",
"       &bull; Admission is warranted if social concerns prevent home observation.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_52_847=[""].join("\n");
var outline_f0_52_847=null;
